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3Abstract
Background: In high-income countries an increasing proportion of all tuberculosis cases
are detected in migrants. Understanding the epidemiology of tuberculosis in migrants to
inform evidence-based screening policies is a priority.
Methods: A systematic review and meta-analysis of pre-entry screening for tuberculosis
was undertaken (chapter 2). Data from a pilot pre-entry programme in migrants to the
UK was described, and risk factors for prevalent cases examined (chapter 3). The
accuracy of a novel method for identifying individuals between two datasets was
studied (chapter 4). This linkage method was used to combine data from migrants
screened pre-entry to the UK tuberculosis register including molecular strain typing
data. The linked datasets enabled estimates of the incidence of tuberculosis to be
calculated, and risk factors were identified (chapters 5 and 6).
Results: The systematic review identified 15 studies and found that culture confirmation
increased with WHO prevalence in the country of origin. The crude prevalence of
bacteriologically confirmed tuberculosis identified by UK pre-entry screening was 92
per 100,000 population screened. Migrants reporting a history of contact with a case of
tuberculosis, and those from higher prevalence countries were at greatest risk.
Compared to a gold standard of NHS number, probabilistic linkage identified
individuals in two datasets with high sensitivity and specificity. The estimated incidence
of tuberculosis notified in the UK in migrants screened pre-entry was 194 per 100,000
person years at risk. Migrants with a chest radiograph classified as suspected
tuberculosis and those from higher prevalence countries had a higher risk post-
migration. Compared to other non-UK born individuals, migrants screened pre-entry
were less likely to be the first case in a cluster of tuberculosis.
Conclusions: This thesis generated new knowledge that improves our understanding of
the epidemiology of tuberculosis in migrants to the UK. Based on these findings,
evidence-based screening recommendations were made.
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CHAPTER 1
Tuberculosis, migration and UK immigration
screening policy: an introduction
1.1 Abstract
Tuberculosis is a major global cause of morbidity and mortality. In 2013, tuberculosis
was estimated to have resulted in 1.3 million deaths, and there were 9 million cases of
tuberculosis across the globe in 2014. Tuberculosis is therefore a major population
health challenge requiring a coordinated international effort, particularly given the
increasing movement of people across countries and regions. For over a century,
immigration medical screening has targeted people moving from high to low
tuberculosis burden countries, and this screening has taken several forms. Investigating
the epidemiology of tuberculosis in screened migrants would enable a better
understanding of those at greatest risk, and would facilitate the development of
evidence-based medical screening interventions to improve the health of this
population.
1.2 Natural history, detection and treatment of tuberculosis
Mycobacterium tuberculosis was first described as the cause of tuberculosis by the
German physician and scientist Robert Koch in 1882.(1) At the time of this discovery,
tuberculosis was a major cause of morbidity and mortality, with one in seven people
dying from the disease - a statistic Koch highlighted when he reported his discovery for
the first time.(2) When Koch identified the aetiological agent of tuberculosis (TB), little
was known about its natural history.(3) Understanding the natural history of
tuberculosis is important, particularly when aiming to improve evidence-based
screening in migrant populations, as it helps illustrate when and where screening
17
interventions could be targeted. This chapter begins with a brief overview of the natural
history of tuberculosis and focuses on the distinction between active disease and latent
infection, as understanding these two entities clarifies the potential opportunities for
public health interventions aimed at ultimately reducing the burden of tuberculosis in
migrants.
Image 1. Natural history of M.tuberculosis: from latent infection to active disease.
Source: Tuberculosis vaccines - a new kid on the block. Kaufmann.(4) Reproduced
with permission Copyright © 2014 Nature Publishing Group.
Latent infection and active disease are both caused by M.tuberculosis, which is spread
primarily through air droplets, although transmission can occur through ingestion, for
example, by drinking unpasteurised milk. The immune system response to infection
includes the involvement of T lymphocytes which cause the formation of granulomas,
where this initial infection is kept under control by macrophages (Image 1).(4) An
individual that has been infected with M.tuberculosis has no clinical symptoms during
this period of latent infection, and they are not infectious to others as they do not
produce the air droplets containingM.tuberculosis.
1.2.1 Latent tuberculosis infection
The WHO defines latent tuberculosis infection as: “a state of persistent immune
response to stimulation by M.tuberculosis antigens without evidence of clinically
manifested active tuberculosis.”(5) The US Centers for Disease Control has outlined a
series of criteria that help define the characteristics of a person with latent infection
(Box 1).
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Box 1. CDC defined characteristics of a person with latent tuberculosis infection.(6)
A person with latent tuberculosis infection:
• Usually has a skin test or blood test result indicating TB infection
• Has a normal chest x-ray and a negative sputum test
• Has TB bacteria in his/her body that are alive, but inactive
• Does not feel sick
• Cannot spread TB bacteria to others
• Needs treatment for latent TB infection to prevent TB disease; however, if
exposed and infected by a person with multidrug-resistant TB (MDR TB) or
extensively drug-resistant TB (XDR TB), preventive treatment may not be an option
Whilst the CDC criteria for latent tuberculosis set out in Box 1 indicate that an
individual with latent tuberculosis “has a normal chest x-ray and negative sputum”, the
UK tuberculosis technical instructions for classifying chest radiographs, which is based
on the Canadian immigration system, has a category for minor findings on chest
radiographs that are occasionally associated with tuberculosis infection.(7,8)
There are several tests for detecting latent infection including the Tuberculin Skin Test
(TST), and Interferon Gamma Release Assays (IGRAs) blood tests.(9) IGRA tests
require only a single contact with the patient compared to TST, which needs two visits
to a health worker - one to carry out the test and another between 48 and 72 hours later
to read it.(10) IGRA tests have comparable sensitivity and specificity to TST, are
unaffected by BCG vaccination (unlike TST), may have less false positives in people
exposed to environmental mycobacteria, but are more costly and the predictive validity
for the development of active tuberculosis (see Box 2) in migrants is currently
unknown.(11,12)
Based on a systematic review of the scientific literature published before the availability
of anti-tuberculosis therapy (and therefore also HIV), the mean time between onset of
tuberculosis disease and cure or death was three years. It is estimated that individuals
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with latent infection who do not undergo treatment have a life time risk of progressing
to active tuberculosis of approximately 10%, and whilst this often quoted historical
figure has a high degree of uncertainty, those co-infected with HIV have a 30% lifetime
risk which is almost certainly higher.(13,14) The progression from latent infection to
active tuberculosis disease occurs when the immune system is no longer able to control
the infection, therefore explaining the increased rates of progression in those co-infected
with HIV, which impairs the ability of the immune system.(13,15,16) Tuberculosis
disease most commonly affects the lung, but it can cause disease in any organ and can
be exclusively extra-pulmonary i.e. have no lung involvement at the time of clinical
presentation.(17)
Effective treatments for latent tuberculosis infection exist for both HIV positive and
negative individuals. Systematic reviews estimate that treatment for latent infection can
reduce the risk of progression to active disease in HIV positive individuals with a
positive tuberculin skin test (relative risk in treated vs. untreated patients 0.38; 95% CIs:
0.25, 0.57), and in HIV negative individuals (relative risk in treated vs. untreated
patients 0.40; 95% CIs: 0.31, 0.52).(14,18)
Treatment for latent infection has side effects in some individuals, including serious
events such as liver failure.(19) Therefore not everyone identified with latent infection
will take up the offer of treatment based on personal preferences and values around risk
versus benefit of treatment. There are other reasons why not everyone with latent
infection is treated, including the fact that as latent infection is an asymptomatic state, it
is only through screening that eligible patients are identified and offered treatment, and
such screening programmes are not universally available in most countries. Despite
these issues, treatment for tuberculosis infection is widely available in many high-
income countries, and if cases of infection are correctly identified and appropriately
treated, there is a potential to reduce the burden of morbidity and mortality from
tuberculosis.(20)
In 1985 Karel Styblo, a medical advisor to the Royal Netherlands Tuberculosis
Association, described the relationship between tuberculosis infection and the risk of
developing infectious tuberculosis (i.e. disease that can spread to others).(21) Styblo’s
relationship can be summarised as follows: two people will develop active tuberculosis
disease for every 20 cases of latent infection, and one of these cases of active disease
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will become an infectious case capable of spreading the disease to others. This “rule of
thumb” was based upon tuberculosis surveillance data from the Netherlands and USA,
as well as prevalence surveys from 12 low-income countries. This rule does not
necessarily apply in all contexts(22), and can be modified with additional data, but it
illustrates the relationship between infection, disease and transmission, and the potential
opportunities at each stage and associated benefits with regard to prevention of future
cases.
1.2.2 Active tuberculosis disease
An individual infected with M.tuberculosis who develops active disease with symptoms
such as fever, cough and weight loss has the ability to transmit tuberculosis to others –
the onset of these symptoms are characteristic of the development of active disease
(Box 2).
Box 2. CDC defined characteristics of a person with active tuberculosis disease.(6)
A person with TB disease:
• Usually has a skin test or blood test result indicating TB infection
• May have an abnormal chest x-ray, or positive sputum smear or culture
• Has active TB bacteria in his/her body
• Usually feels sick and may have symptoms such as coughing, fever, and
weight loss
• May spread TB bacteria to others
• Needs treatment to treat TB disease
Tuberculosis disease can be detected in a variety of ways. Guidelines by the National
Institute for Health and Care Excellence (NICE) suggest that individuals with suspected
tuberculosis of the lungs should first have a chest radiograph, and if this has any of the
characteristic appearances of tuberculosis lesions then multiple sputum samples should
be taken.(23) These multiple sputum samples can be tested in a variety of ways, but
historically two forms of testing have been performed: sputum smear microscopy; and
mycobacterial culture testing.(17) Smear microscopy formed the basis of tuberculosis
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disease detection for many years because, compared to culture methods, it required less
complex equipment, training of technicians was simpler, it correlated with the
infectiousness of a case, and results were available more rapidly.(24) Despite these
advantages, smear microscopy has several limitations including the rates of false
positives, false negatives, inter-observer reliability and problems with reproducibility in
the preparation of sputum samples.(24,25)
The probability of a positive smear microscopy result is proportional to how many
bacilli are present in a sputum sample produced by an individual with disease. When
concentrations of the organism in a sample from an individual with M.tuberculosis
disease are below 1,000 per ml, the probability of a positive test becomes less than
10%.(24) This is in contrast to a sputum tested by culture, that can detect smaller
numbers of bacilli, with a limit of around 100 organisms per ml.(24) Smear microscopy
also has higher false negative rates for detecting tuberculosis disease in HIV positive
individuals.(25,26) Individuals with culture positive, but smear negative disease are less
likely to be infectious, as well as more likely to have a positive outcome without
treatment compared to smear positive cases.(27,28) For these reasons, NICE
recommends that microscopy and culture are both used: “multiple sputum samples (at
least three, with one early morning sample) should be sent for tuberculosis microscopy
and culture for suspected respiratory tuberculosis before starting treatment if possible
or, failing that, within 7 days of starting”.(23) Once a case of active tuberculosis is
detected, the World Health Organisation (WHO) and NICE both recommend a standard
regimen of six months of treatment of active respiratory disease using four initial drugs
(6 months of isoniazid and rifampicin supplemented in the first 2 months with
pyrazinamide and ethambutol).(23,29) More complicated treatment recommendations,
such as those for drug resistant cases of tuberculosis, or disease that affects the bones or
central nervous system, are not discussed in this chapter as these are rarely detected at
pre-entry screening.(23)
1.3 Global tuberculosis epidemiology
Globally, there were an estimated 9 million cases of tuberculosis in 2014(30) and in
2010 it ranked as the 13th largest cause of disability-adjusted life years.(31) The largest
burden of disease occurs in the WHO regions of South-East Asia and Western Pacific,
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which account for over half of all cases. Although the largest number of cases occurs in
these regions, prevalence rates are highest in the African region. The WHO African
region has approximately a quarter of all cases globally, and has seen a slower decline
in prevalence rates compared to most other regions since 1990 (Figure 1). Mortality
rates in the African region are also higher than others, and it has the highest death rates
(Figure 2). With the exception of Europe (which saw an increase in rates through the
1990s followed by a decline), there has been a gradual decline since 1990 in the
prevalence of tuberculosis in all WHO regions. There is disagreement about the actual
rates of change, particularly when comparing different methodologies and rates for
adults and children, but general agreement in the overall direction of change towards a
decline. (30,32–34)
Figure 1. Trends in estimated TB prevalence rates 1990–2013 and forecast TB
prevalence rates 2014–2015, by WHO region.
Source: World Health Organisation. Global tuberculosis report 2014.(30)
Reproduced in accordance with WHO guidelines.
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Figure 2. Trends in estimated TB mortality rates 1990–2013 and forecast TB mortality
rates 2014–2015, by WHO region.
Source: World Health Organisation. Global tuberculosis report 2014.(30)
Reproduced in accordance with WHO guidelines.
The total number of cases is higher in men, who account for approximately 60% of all
reported disease internationally.(30) Incidence rates in HIV-negative men and women
peak in the 25-29 year age groups and gradually decline after this point, with men
having a higher incidence compared to women in all age groups except those aged 5-19
years (Figure 3).(32) The total number of deaths is higher in men than women in all age
groups except in those aged 5-19. Total number of deaths, as presented in Figure 3,
should be considered in the context of the population age structure, as age-specific rates
increase with age up to 70 years in men.(32) Despite increasing death rates with age,
83% of cases and 59% of all global deaths were in individuals younger than 60 years in
2013 as a result of the young age-structure in countries with substantial burden of
tuberculosis in individuals who are HIV-negative.
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Figure 3. Global age-sex distribution of tuberculosis incidence (A) and deaths (B) in
HIV-negative individuals in 2013.
Source: Murray CJL, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA,
et al. Global, regional, and national incidence and mortality for HIV, tuberculosis,
and malaria during 1990–2013: a systematic analysis for the Global Burden of
Disease Study 2013. The Lancet. 2014 Sep;384(9947):1005–70.(32).(4)
Reproduced with permission Copyright © 2014 Elsevier Ltd.
1.4 Tuberculosis epidemiology in the UK
In the UK, a total of 7,892 tuberculosis cases were notified during 2013, representing a
slight decline of the annual number of cases compared to 2012, and a reversal of the
increasing number of notifications that had generally been going up since 1987 and
peaked in 2011.(35) During this period of time, the rate of tuberculosis in UK born
individuals has remained constant at around 4.1 per 100,000 population (Figure 4). The
total number of cases in non-UK born individuals was 5,529 (70%) in 2013, which was
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more than double the 2,103 (27%) cases in the UK born population.a The rates of
tuberculosis were nearly 18 times higher in the non-UK born population at 70 per
100,000 population and approximately 80% of all cases in individuals born outside the
UK had lived in the country for two or more years. The non-UK born rate has been
declining annually from a peak of 98 per 100,000 in 2005.(35)
Men accounted for over half of all cases in 2013 (58%, 4,560/7,892). In the UK born,
the highest rates of tuberculosis are found in those aged over 80, which is likely to
reflect historical exposure to tuberculosis and waning immunity in the elderly.(36–39)
In the non-UK born population, the highest number of cases is found in those aged 30-
34, but the highest rates are in those aged 20-29.(35)
Figure 4. Tuberculosis case reports and rates by place of birth, UK, 2000-2013.
Data source: Public Health England. Tuberculosis in the UK: annual report -
2014.(35)
The burden of tuberculosis in individuals not born in the UK is therefore substantial and
despite encouraging declines in both the total number of cases and rates of disease,
further work is required to better understand who is at highest risk and the potential
opportunities for health improvement interventions if we are to fully tackle and
eliminate tuberculosis as a public health problem in the UK. This is particularly
important as England has some of the highest rates of disease in Europe, particularly in
a percentages do not add up to 100 because of missing data on country of birth.
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urban areas like London and Birmingham which have a larger number of cases and
much higher rates than all other big European cities.(40,41)
Tuberculosis cases in England, Wales and Northern Ireland are notified to the Enhanced
Tuberculosis Surveillance system (ETS). In Scotland, cases are notified to the Enhanced
Surveillance of Mycobacterial Infections (ESMI), and data from ETS and ESMI are
combined for the purpose of UK reporting. Using case notification data in their current
configuration has several important limitations for the understanding of the burden of
disease in migrant populations. Firstly, it has only been possible to estimate the
incidence of active tuberculosis in non-UK born populations based on country of birth
and not country of migration, which is more likely to represent risk of disease,
particularly where these two countries may have very different population levels of
tuberculosis. Secondly, there is a lack of reliable population denominator data for the
UK based on country of birth, and therefore these estimates are generally presented by
ethnicity, which has limitations for informing public health practice, as these groups are
extremely heterogeneous. Thirdly, incidence estimates in non-UK born individuals
includes prevalent cases in migrants who arrive in the UK with active disease – these
are therefore not truly incident cases. Fourthly, limited risk factor data on non-UK born
individuals are available, and very little of these data relate to migrant history prior to
arrival in the UK, which could be extremely informative for improving our
understanding of the disease in this group. Finally, the follow-up of migrants for
epidemiological and public health purposes after entering the UK has not previously
been possible as no dataset existed to facilitate this process. Therefore there is an urgent
need for an improved dataset that would overcome these limitations in existing
surveillance data.
1.5 Migration and tuberculosis
In recent decades, migration patterns have led to a change in the epidemiological profile
of tuberculosis in many low-incidence countries.(42) In the United States, the total
number of tuberculosis cases has been decreasing, but notifications in foreign born
individuals are 11.5 times higher than those born in the country.(43) In Europe, the
overall proportion of tuberculosis cases in individuals of foreign origin is 25.8%, but
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many countries have much higher proportions, such as Sweden (89.4%), Norway
(87.8%), and United Kingdom (70%).(44,45)
Internationally, the number of people residing outside their country of birth is
considerable. The United Nations Population Division estimated that globally this
population consisted of a total of 232 million people in 2013.(46,47) Between 1990 and
2013, North America accepted the largest gross inflow of migrants at 25 million, and
Europe had the second largest at 23 million. Every year a substantial number of
migrants move from high-incidence countries to those with a low-incidence. Reasons
for international migration include economics (to work in the receiving country or move
away from financial crises in the country of origin), education, political instability or
war, natural disasters, and reunion (joining family members in the receiving country).
(48,49)
In the UK, migration is a topic of great political and public interest, and there is a
disconnect between public perception of migration numbers and the actual number of
individuals arriving and leaving each year.(50–52) The Office for National Statistics
(ONS) publishes regular statistics on net migration, which is defined as “the difference
between the number of long-term immigrants coming to the UK and the number of
long-term emigrants leaving the UK”.(50) Between 1980 and 1997, net migration was
fairly stable, varying between a reduction of 79,000 and an increase of 76,000 per
annum (Figure 5). After 1997 net migration increased annually to a peak of 273,000 in
2007 and has seen a gradual decline since, although it remains substantially higher than
it was between 1980 and 1997.
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Figure 5. Long-term international net migration the UK and by citizenship, 1980 to
2013.
Data source: Office for National Statistics. Migration Statistics Quarterly
Report.(50)
Net migration of Non-EU citizens has also been higher than EU citizens since 1980, and
net migration of British citizens has been negative during this whole period (i.e. more
British citizens have been leaving than returning; Figure 5). Consistent with
international data on the reasons for migration, the two main reasons for immigration to
the UK were for work or formal study, with a smaller number of individuals
accompanying or joining family members.(50,53)
1.6 Medical screening of international migrants
As described in previous sections, globally and in the UK there are high levels of
migration, and in countries with low tuberculosis incidence, there has been a changing
epidemiological situation with an increasing proportion of cases detected in migrants.
Medical screening of migrants for tuberculosis has been a focus of immigration health
for over a century(54), but this recent change in the epidemiological profile of cases has
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meant that there has been increased political and public scrutiny of such programmes.
As a result, many low incidence countries have been re-examining their policies and
interventions to tackle the burden of tuberculosis in migrant populations.
Tuberculosis screening in migrants can occur at three points in time: 1) prior to entering
the country (pre-entry screening); 2) at the point of entry (upon entry or port of entry);
3) or post-arrival. Many European countries have implemented post-arrival screening
programmes.(55,56) Whilst there are differences in the screening approach
implemented, the characteristics of such post-arrival programmes are well
documented.(55) Canada, USA, Australia, New Zealand and Israel all have pre-entry
screening programmes for tuberculosis. Before the work undertaken in this thesis, no
systematic review of the published literature on existing pre-entry programmes had been
performed. The lack of such a review limited the ability to draw conclusions about the
international effectiveness of pre-entry screening, and the potential strengths and
weaknesses of the different approaches taken by each country.
The UK historically used a combination of upon- and post-entry screening.(57,58) In
2005 the UK Border Agency (UKBA) and Foreign and Commonwealth Office (FCO)
funded the set up costs for a trial of pre-entry screening for active tuberculosis disease
in migrants to the UK.(59) The pilot programme was run in partnership with the
International Organization for Migration (IOM), an inter-governmental organisation that
works with migrants, governments and the international community.(60) The pilot was
launched in 2005 by IOM in Kenya and was rolled out to seven other locations
screening migrants from a total of 15 countries. Local IOM clinics ran the programme
with oversight from an epidemiological unit based in Manila, Philippines. The UK
technical instructions describe the pre-entry screening programme in detail and involve
a combination of symptom screening, clinical examination, chest radiography and
sputum sampling (reviewed in detail in Chapter 3).(7) In May 2012 it was announced
that the UK would close its existing upon entry screening programme for migrants and
move fully to a pre-entry system, expanding it from the 15 pilot locations to 101
countries with a WHO estimated incidence of greater than 40 per 100,000 population.
This transition from upon to pre-entry screening was conducted in four phases and was
completed on 31st March 2014 (Figure 6).
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Figure 6. Location of pre-entry screening sites globally (includes IOM and non-IOM
sites).
Note: Pre-entry pilot scheme countries were Bangladesh, Burkina Faso, Cambodia,
Cote D'Ivoire, Eritrea, Ghana, Kenya, Laos, Niger, Pakistan, Somalia, Sudan,
Tanzania, Thailand, and Togo.
In addition to pre-entry screening for active disease, NICE guidelines recommend post-
migration screening for latent tuberculosis infection in individuals aged 16–35 years
who enter the UK from high-incidence countries.(23) At present, the implementation
levels of these post-entry screening recommendations for latent tuberculosis vary across
the country and are dependent on local policies and funding, and there is evidence that
levels of screening do not reflect the local burden of disease.(61–63) There is also a
great deal of variation internationally in the application of such screening programmes,
including a lack of evidence regarding the cost effectiveness of the different
approaches.(56) A national collaborative tuberculosis strategy formulated by Public
Health England in 2015 called for new entrant latent tuberculosis screening to be
systematically implemented across England.(64)
1.6.1 Informing evidence-based screening programme for migrants to the UK.
As described in previous sections, the benefits of screening for latent infection and
active disease relate to the natural history of tuberculosis. The current pre-entry
tuberculosis screening programme detects active pulmonary tuberculosis using a
combination of chest radiographs and sputum smear and culture tests. Several novel
diagnostic tools have been developed that may offer substantial improvements to the
existing migrant screening pathway and are outlined in Figure 7.(65,66) Active
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tuberculosis can be confirmed with the Xpert® MTB/RIF assay, which uses molecular
techniques and has increased the sensitivity of non-culture based tests and allows rapid
detection of resistance (67,68). Despite these advantages, Xpert® is expensive and
limited by its throughput capacity, which given the large number of migrants attending
pre-entry screening clinics could be problematic operationally, as well as its lower
accuracy for detecting extra-pulmonary disease compared to traditional culture
methods.(69) Screening for latent tuberculosis can be performed using new IGRA tests,
which require only a single contact with the patient and have comparable sensitivity and
specificity to TST testing(11,12). However, IGRAs are costly and the ability of this test
to predict development of active tuberculosis in migrants is uncertain at present (9,70–
72).
Figure 7. Screening options for TB in UK migrants.
The exact combination of tests for latent and active disease that would be most effective
could be informed by a better understanding of the epidemiology of tuberculosis in
migrants to the UK. As described earlier in this chapter, approximately 80% of
tuberculosis disease notified in non-UK born individuals have lived in the country for
two or more years.(35) This suggests that many cases do not enter with active disease,
and despite various cross-sectional studies in UK migrants, it is uncertain what
proportion of all individuals enter the country with latent tuberculosis, and who would
therefore be amenable to intervention through a pre-entry screening programme for
latent infection.(73) Similarly, few data exist to estimate the number of migrants who
become infected on trips back to their country of origin, or acquire tuberculosis in the
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UK due to other risk factors that are prevalent in new entrants such as poor housing,
behavioural and lifestyle factors or immunosuppression due to HIV.(74–76,76)
Therefore, despite the high number of cases in individuals not born in the UK, it has not
been feasible to calculate the incidence rates of active tuberculosis in migrants, or the
number of these cases that were due to reactivation of disease acquired prior to entry
and therefore potentially amenable to intervention if detected after arrival in the UK.
Probabilistic matching algorithms developed by Public Health England are able to
identify individuals across datasets without unique identifiers such as an NHS number,
whilst also allowing for missing data and errors such as misspelling of names, and
switching of day and month for dates of birth in record entries. Probabilistic matching
therefore has the potential to identify incident cases of disease notified in the UK among
individuals screened by the pre-entry programme by linking data from the UK
tuberculosis register with that from migrants screened pre-entry. Such a dataset would
enable estimates of the incidence of tuberculosis in migrants to be calculated, as well as
the risk factors associated with these cases. Analysis of strain typing data, also
contained within the UK tuberculosis register, would also facilitate estimates of the
proportion of incident cases among migrants screened via the pre-entry programme that
were due to reactivation. By combining these new epidemiological data about prevalent
and incident tuberculosis in migrants to the UK, and using existing mathematical
models, it would be possible to establish the best combination of tests to reduce the
burden of infection and disease in this vulnerable group. This information could also be
used to examine the cost effectiveness of new diagnostic tests for latent and active
tuberculosis in migrants undergoing pre-entry screening.
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1.7 Aims and objectives of the PhD thesis
This PhD aimed to inform the development of evidence-based migrant screening by
examining the epidemiology of tuberculosis in migrants screened by a pre-entry
programme.
Specific research objectives were:
1. To systematically review the published literature on pre-entry screening for
tuberculosis in migrants to low incidence countries (Chapter 2).
2. To estimate the prevalence and risk factors for tuberculosis in migrants from
high incidence countries screened prior to entering the UK (Chapter 3).
3. To establish the accuracy of probabilistic linkage for identifying individuals
across datasets where no standard unique identifier or address data exist
(Chapter 4).
4. To estimate the incidence and risk factors for tuberculosis cases notified in the
UK among migrants screened by a pre-entry programme (Chapter 5).
5. To use molecular strain typing data to infer whether migrants screened pre-entry
are less likely than non-UK born individuals to transmit tuberculosis (using the
proxy marker of being the first case in a cluster of tuberculosis cases) and
describe the incidence and risk factors of first in cluster cases in pre-entry
screened migrants Chapter 6).
6. To use molecular strain typing data to infer the incidence of disease in pre-entry
screened migrants that is potentially preventable through additional screening
for latent tuberculosis infection by measuring the post-migration incidence of
tuberculosis cases with unique molecular strain typing fingerprints (suggestive
of disease reactivation rather than local transmission Chapter 6)
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CHAPTER 2
Pre-entry screening for tuberculosis in migrants to low-
incidence countries: a systematic review and meta-analysis
2.1 Abstract
Background: Several high income countries have pre-entry screening programmes for
tuberculosis. This chapter aims to describe the existing literature on pre-entry screening
programmes in order to inform evidence-based policy for migrant health screening.
Methods: Six bibliographic databases were searched for experimental or observational
studies and systematic reviews, which reported data on migrant screening for active or
latent tuberculosis by any method before migration to a low-incidence country. Primary
outcomes were principal reported screening prevalence of active tuberculosis;
prevalence of culture confirmed cases; and prevalence of sputum smear for acid-fast
bacilli cases. Where appropriate, fixed effects models were used to summarise the
prevalence of pre-entry screening across included studies.
Results: A total of 15 unique studies with data on 3,739,266 migrants screened pre-entry
for tuberculosis between 1982 and 2010 were identified. Heterogeneity was high for all
primary outcomes. After stratifying by prevalence in country of origin heterogeneity
was reduced for culture and smear confirmed cases. Culture confirmed prevalence
increased with prevalence in the country of origin, and summary estimates ranged from
20 (95%CIs: 10, 32) to 336 per 100,000 individuals screened (95%CIs: 283, 393) in
countries with a prevalence of 50-149 and greater than 350 per 100,000 population
respectively.
Conclusion: Targeting high-prevalence countries is likely to result in the highest levels
of prevalent active disease to be identified.
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2.2 Introduction
Several high income countries (Australia, Austria, Canada, France, Israel, Jordan, New
Zealand and USA) have pre-entry screening programmes for tuberculosis.(56) The UK
has used a combination of upon- and post-entry screening for several decades, but fully
transitioned to pre-entry screening on 1st April 2014.(7)
Because of the high burden of tuberculosis in migrants, many governments in low-
incidence settings have implemented screening programmes. Tuberculosis screening
programmes for migrants can occur at three points in time: 1) pre-entry (prior to
entering the country); 2) upon-entry; 3) or post-entry. Many European countries have
implemented post-entry screening and, whilst there are differences in the screening
approach, the characteristics of such programmes are well documented.(55)
The prevalence of pre-entry screening programmes for tuberculosis may differ from
upon- and post-entry programmes. With some exceptions, upon- and post-entry
screening tends not to be a compulsory part of visa applications; therefore, individuals
undergoing screening may not be representative of the wider migrant population.
Attendance for post-entry screening may be determined by patient health seeking
behaviour or the opinion of immigration staff in upon-entry settings. Conversely, pre-
entry screening programmes are typically a compulsory part of the visa application
process and as a result coverage is higher, if not complete, and such studies should be
fully representative of the populations screened and intending to migrate.
The characteristics of post- and upon-entry screening programmes have been well
documented previously, but pre-entry screening programmes have not been
systematically reviewed.(55,77,78) The aim of this systematic review was therefore to
establish the ability of pre-entry screening programmes to detect prevalent cases of





The following study types were eligible for inclusion in this review: experimental
studies (randomized controlled trials as well as quasi-randomized controlled trials,
including before and after studies); observational studies (including retrospective and
prospective cohort studies, case-control studies, cross-sectional and case series); and
systematic reviews. Additional inclusion criteria were that a study needed to be
published with an abstract in English; to report the total number of individuals screened
who plan to migrate as well as the number of cases of tuberculosis infection or disease
identified; and screening was required to have taken place prior to the migrant entering
a low-incidence country. Eligible studies could screen for tuberculosis by any method
including radiographic, microbiological and a clinician’s recommendation to treat an
individual on the basis of clinical and/or radiological signs and/or symptoms compatible
with tuberculosis.
2.3.2 Important definitions used in this systematic review and meta-analysis
We used the definition of migrants developed by Rieder et al. and used in a recent
systematic review of screening in the EU.(55,79) This review classifies migrants into
the following groups: Migrant (a foreigner legally admitted and expected to settle in a
host country); Asylum seeker (a person wishing to be admitted to a country as a refugee
and awaiting decision on their application for refugee status under relevant international
instruments); Foreign-born citizen (a person who is a national of the state in which they
are present but who was born in another country); Undocumented foreigner/migrant
(formerly classified as ‘illegal’, describing an individual who enters, stays or works in a
host country without an appropriate residence permit or visa).
There is no universally accepted definition of a low-incidence tuberculosis country. For
the purpose of this analysis we used the European Centre for Disease Prevention and
Control (ECDC) definition of a low-incidence country as one with a notification rate
below 20 cases per 100,000 in the general population.(80)
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2.3.3 Primary and secondary outcomes
Three primary outcomes were considered: 1) the principal prevalence of pre-entry
screening for active tuberculosis reported for each study (detected by any method); 2)
prevalence of active tuberculosis cases confirmed by culture; 3) prevalence of active
tuberculosis cases confirmed by smear for acid-fast bacilli (AFB). Secondary outcomes
included: 1) prevalence of active cases detected by radiography; 2) prevalence of drug
resistant active disease; 3) prevalence of latent tuberculosis (diagnosed by any method);
4) costs associated with screening individual migrants, and; 5) costs of treatment for
individuals screened and found to have tuberculosis. PRISMA reporting guidelines were
followed.(81)
2.3.4 Search strategy
The following sources were searched to identify published literature: Medline,
EMBASE, LILACS; Cochrane Infectious Diseases Group Specialized Register;
Cochrane Library; Conference Proceedings Citation Index- Science; Conference
Proceedings Citation Index- Social Science & Humanities. Reference lists of included
studies were hand-searched in order to identify further relevant work. Only studies
published after 1980 were included.
Detailed search terms for the bibliographic databases are presented in Appendix 1. In
summary, terms covered the populations of interest (migrants, refugees, asylum seekers,
new entrants, and undocumented migrants), the intervention (pre-entry screening) and
standard terms for tuberculosis.
Initial search results were imported into EPPI-Reviewer 4 where duplicates were
identified and removed. An updated search carried out on 1st April 2014 was performed
in Zotero.(82,83) Three researchers (Robert Aldridge, Tom Yates, and Dominik Zenner)
screened titles, abstracts and full text publications. Disagreements were resolved by
discussion and remaining issues were assessed in conjunction with a fourth reviewer
(Andrew Hayward – primary supervisor of this PhD thesis). Data from included studies
were extracted in duplicate to an Excel spread sheet.
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2.3.5 Methods for the meta-analysis
Fixed effects models with Freeman-Tukey transformation of data were used to estimate
the summary prevalence of pre-entry screening across studies and subgroups where
appropriate.(84,85) The I-squared transformation was used to describe the proportion of
total variation in study estimates that is due to heterogeneity.(86) Where overlapping
data on an individual screening programme were identified, the publication with the
largest amount of data (by time period or number of individuals screened) was included
in this review. Economic components of the studies identified were presented in a
narrative format where identified.
Subgroup analysis was carried out for the primary outcomes to examine the impact of:
prevalence in the country of origin; the screening method used (e.g. radiographic,
microbiological, and clinical); receiving country; and type of migrants screened. As
there are no universally accepted categories to classify prevalence of tuberculosis at the
country level, we chose to use the following groups: 20-49; 50–149; 150–249; 250–349,
and ≥350/100 000 cases per 100,000 population. We used WHO prevalence estimates 
for the middle year in which screening was performed.(42) Where possible, data for
primary outcomes were extracted for each of the subgroups (e.g. different countries of
origin) and then included in the subgroup analysis.
2.3.6 Assessment of the risk of bias of included studies
The risk of bias for included studies was assessed using the GRADE approach, and was
carried out independently by two reviewers (Robert Aldridge and Tom Yates).(87) Any
disagreements were discussed and resolved with the help of a third reviewer (Andrew
Hayward) where necessary.
2.4 Results
A search of all bibliographic databases was performed on 5th April 2013 and updated on
1st April 2014. A total of 1,887 studies were found (Figure 8). A further 15 publications
were identified through other sources including reviewing references of included
studies. A total of 157 full text articles were retrieved and assessed for eligibility and 19
manuscripts met the inclusion criteria after double screening and review.(88–106) After
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further review and extraction of data, four studies were excluded from the final analysis
as they contained overlapping data for the primary outcomes.(103–106)
Figure 8. Study ﬂow diagram. 
The 15 studies included in the final analysis reported data on 3,739,266 individual
migrants screened between 1982 and 2010 (Table 1).(88–102) Data were published on
migrants to four low-incidence countries (Figure 9). The smallest study reported data on
873 migrants and the largest 3,092,729 migrants. Screening protocols varied between
studies, but many involved an initial chest radiograph, clinical examination and testing
of sputum smear and culture in selected individuals. The principal outcome for 10
studies reporting data on active tuberculosis included a combination of smear, culture or
intention to treat on the basis of clinical findings as part of their case definition (Figure
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10). Meta-analyses of prevalence for all three primary outcomes demonstrated high
levels of heterogeneity (I-squared greater than 90%) and therefore summary effect
estimates across studies were not calculated.
Figure 9. Map of countries conducting pre-entry screening of migrants (receiving
countries) and the prevalence of culture confirmed cases for migrants by
country of origin.
Note: For countries with yield for culture confirmed cases in more than one study,
data from the most recent study is presented.
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Figure 10. Forrest plot of pre-entry screening programme prevalence for principal
outcome of active tuberculosis cases found by each study (case definition
varies between studies, sorted by year of publication).
No studies reported the number of individuals tested by sputum culture or smear and
therefore it was only possible to calculate prevalence based on the total number of
individuals screened, and not by total number of microbiological tests performed (Table
2). Six studies presented data on a total of 755 cases that were culture confirmed among
452,971 individuals initially screened. (90,91,94–98) Six studies presented data on
smear positive cases of tuberculosis, with a total of 987 cases found in the 569,210
individuals initially screened.(88,89,91,95,97,99) The majority of studies performed
sputum smears on three samples for those individuals with a chest radiograph or clinical
symptoms suggestive of tuberculosis (Full details in Appendix 2). There was some
variation in the number of positive samples required to classify individuals with smear
positive disease.
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2.4.1 Stratifying by prevalence in the country of origin, population, screening
method and receiving country.
After stratifying results by prevalence of tuberculosis in the country of origin,
heterogeneity was reduced for culture and smear confirmed cases, but not principal
outcome - active tuberculosis cases (Figure 11 and Appendix 3, Figures 39-41).
Increasing prevalence of culture and smear positive cases were seen with increasing
prevalence in the country of origin. Summary estimates of prevalence of culture positive
cases ranged from 20 (95%CIs 10, 32) to 336 per 100,000 individuals screened
(95%CIs: 283, 393) in countries with an incidence of 50-149 or greater than 350 per
100,000 population respectively (Figure 11). The results of the meta-analyses are
dominated by one large study, which acknowledged limitations with data for smear and
culture testing as this was not uniformly performed across all sites and for all cases.(91)
Across all included studies, prevalence of culture confirmed cases was highest in
migrants to USA from Vietnam with 1298 cases per 100,000 individuals screened
(95%CIs: 1118, 1492; Figure 40 in Appendix 3).
Figure 11. Forrest plot of pre-entry screening programme prevalence of culture positive
cases of tuberculosis, stratified by WHO prevalence of tuberculosis in country
of origin (sorted by prevalence in country of origin).
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With the exception of culture confirmed cases in refugees (I-squared 0%, p= 0.85),
heterogeneity remained high for all three primary outcomes (I-squared greater than
90%) after stratifying by population, screening method and receiving country (full
results presented in the Appendix 3, Figures 39-53).
2.4.2 Secondary outcomes
Among studies reporting data on culture confirmed cases, three described prevalence of
Multi-drug resistant (MDR) tuberculosis. A total of 33 cases in 183 individuals with
culture confirmed disease were found in these three studies.(91,95,97) Whilst the
majority of studies performed radiographic screening as a first line test, numerator and
denominator data for this specific outcome were only presented in five
studies.(90,93,95,96,101) A total 34,495 positive cases by chest radiograph were
reported among the 3,154,873 individuals screened. This is likely to include both active
and signs of previous tuberculosis infection or disease that has been treated or cleared
spontaneously. Not all studies provided details as to how chest radiographs were
analysed and classified which is likely to explain some of the variation in findings
between studies.
Three studies reported data on latent tuberculosis infection, with a total of 1,884 latent
tuberculosis infections found among 20,587 (9.2%) individuals screened (varying tests
and cut offs were used – see Appendix 2 for full details).(92,97,102) One study tested
for latent tuberculosis on a sample of migrants on the basis of chest radiograph results
(testing 1,000 applicants with radiographic findings consistent with active tuberculosis
and 500 applicants with a normal radiograph). Therefore the prevalence of latent
tuberculosis from this study does not represent population prevalence of LTBI and the
results were not included in this secondary analysis.(98)
Cost effectiveness was examined by one study using data from the Canadian pre-entry
migrant screening programme from June 1996 to June 1997.(90) Compared to passive
detection of cases after arrival in Canada, this study estimated the incremental cost
(savings) to treat each case of prevalent active tuberculosis detected pre-entry as
$39,409.(90) A further study, using data presented in this systematic review(96),
estimated the cost of running a health station for an active tuberculosis screening
programme in Ethiopia at $60,100 for approximately 3,500 individuals screened per
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annum.(107) No data were found on costs of treatment for individuals screened and
found to have tuberculosis.
2.4.3 Risk of bias of included studies
GRADE criteria were used to assess the risk of bias of included studies (Table 3). All
included studies were observational in nature and therefore the evidence for each
outcome was initially determined as low as per the GRADE methodology. This
systematic review focused on describing prevalence of existing screening programmes
in operational settings and therefore observational studies are an appropriate study
design. The majority of studies were at risk of bias as a result of the eligibility criteria
applied, and the reporting and measurement of exposure and outcome data. Substantial
heterogeneity existed for primary outcomes, with confidence intervals across studies
showing minimal or no overlap with the exception of culture and smear confirmed
disease when stratified by prevalence in country of origin. As a result of these
limitations, the quality of evidence for all outcomes was downgraded to very low as per
the GRADE methodology.
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Table 1. Summary descriptive information for each study included in review.
Study Year of
publication






















Bollini 1998 X-ray. If compatible with
TB, sputum smear samples









Dasgupta 2000 X-ray, If compatible with
TB, sputum smear samples







12898 17 132 Migrants Multiple Canada Multiple 1996-97
Gorbacheva 2010 X-ray, clinical examination,
history and TST. Three
sputum specimens in those



















one or more positive
sample by sputum
smear and/or culture
378939 519 137 Migrants Multiple Australia Multiple 2009-10




873 9 1031 Adoptees South
Korea
USA South Korea 1985-88
Liu 2009 X-ray. If compatible with
TB, sputum smear samples







3092729 29,998 970 Mixed Multiple USA Multiple 1999-05
Malone 1994 X-ray and physical
examination. If compatible
with TB, sputum smear and









Maloney 2006 X-ray. If compatible with
TB, sputum smear and




14098 183 582 Migrants Vietnam USA Vietnam 1998-99
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consecutive samples
Mor 2012 X-ray, clinical examination,
history and TST. Three
sputum specimens in those




13379 57 426 Migrants Ethiopia Israel Ethiopia 2001-05
Oeltman 2008 X-ray, clinical examination,
history. Three sputum
specimens in those with










Painter 2013 X-ray, clinical examination,
history and sputum testing







1475 859 -** Migrants Vietnam USA Vietnam 2008-10
Plant 2004 X-ray, clinical examination,
history. Three sputum
specimens in those with




6018 36 598 Migrants Vietnam Australia Vietnam 1997-01
Wang 1991 X-ray followed by three
sputum cultures in those with
findings suggestive of TB
Inactive
tuberculosis***
21956 1173 5343 Migrants Multiple Canada Multiple 1982-85
Watkins 2005 X-ray X-ray positive cases 1669 170 10186 Migrants Vietnam Australia Vietnam Not stated
Yanni 2013 X-ray, clinical examination,
history and sputum testing







14077 1 7 Refugees Iraq USA Jordan 2007-09
* Limitations in sputum smear and culture methods reported by study authors.
† Full definition of presumptive active TB not provided and unable to contact corresponding author to confirm what this encompasses.
‡ Active pulmonary TB defined as a symptomatic patient with pulmonary disease and confirmed M.tuberculosis complex culture.
§ Following the results of chest X-ray, applicants were invited to participate in a study of TST and QFT for which they would be provided the results, but the result of
which would not affect their visa application. Varying size of TST was used as cut off
**Prevalence for latent tuberculosis for this study is not presented as the primary aim of the study was to compare the sensitivity of QuantiFERON ®-TB Gold In-Tube
Assay (QFT) and TST for culture- positive pulmonary. It was therefore performed on a sample of migrants with and without abnormal X-ray results, and therefore
prevalence of latent tuberculosis will not be representative.
*** Inactive tuberculosis defined by authors as: “radiograph shows evidence of tuberculosis, it is repeated at a minimum interval of 3 months to confirm stability of the
lesion. In addition, 3 sputum cultures, incubated for 7-8 weeks, taken at least 24h apart, are required to be negative.”
‡ Whilst the abstract mentions these countries, it was unclear whether refugees went to anywhere other than USA and Canada and authors were uncontactable to confirm.
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Bollini 131241 729 (0.6) 729 (0.6) Migrants Vietnam US,
Australia,
Canada
Dasgupta 12898 17 (0.1) 722 (5.6) 353 (2.7) Migrants Multiple Canada







King† 12795 113 (0.9) 4 (0.0) 43 (0.3) Migrants Philippines Australia
King† 59666 87 (0.1) 2 (0.0) 24 (0.0) Migrants India Australia
King† 13621 84 (0.6) 6 (0.0) 43 (0.3) Migrants Vietnam Australia
King† 71600 43 (0.1) 1 (0.0) 14 (0.0) Migrants China Australia
King† 42503 24 (0.1) 2 (0.0) 8 (0.0) Migrants South Korea Australia
King† 12859 20 (0.2) 0 (0.0) 8 (0.1) Migrants Malaysia Australia
King† 9192 15 (0.2) 1 (0.0) 0 (0.0) Migrants Indonesia Australia
King† 1512 14 (0.9) 1 (0.1) 10 (0.7) Migrants Cambodia Australia
King† 10608 13 (0.1) 0 (0.0) 2 (0.0) Migrants Thailand Australia
King† 2861 12 (0.4 0 (0.0) 5 (0.2) Migrants Nepal Australia
Lange 873 9 (1.0) 9 (1.0) Adoptees South Korea USA
Lui 2714223 26075 (1.0) 26075 (1.0) Migrants Multiple USA
Lui 378506 3923 (1.0) 3923 (1.0) Refugees Multiple USA
Malone 11000 340 (3.1) 37 (0.3) Migrants Haiti USA
Maloney 14098 82 (0.6) 82 (0.6) 183 (1.3) 5 (0.0) 1331 (9.4) Migrants Vietnam USA
Mor 13379 57 (0.4) 37 (0.3) 150 (1.1) Migrants Ethiopia Israel









Painter 20100 211 (1.0) 211 (1.0) 2087 (10.4) Migrants Vietnam USA
Plant 5108 25 (0.5) 15 (0.3) Migrants Vietnam Australia
Plant 910 11 (1.2) 6 (0.7) Migrants Cambodia Australia
Wang 21956 1173 (5.3) Migrants Multiple Canada
Watkins 1669 170 (10.2) 170 (10.2) Migrants Vietnam Australia
Yanni 14077 1 (0.0) 251 (1.8) Refugees Iraq USA
† Study reports that overall 230 cases were culture confirmed and 67 were smear positive, but not all of these data are included as the data on number of migrants
screened was not presented for all countries.
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Table 3. GRADE summary of findings and quality of evidence for the primary and secondary outcomes



















Sputum Culture 6 Observational
studies*








Sputum Smear 6 Observational
studies*





Chest radiograph 5 Observational
studies*






























†Most studies were at some risk of bias for failure to develop and apply appropriate eligibility criteria and measurements of outcome that had limitations.
‡Largest study for analysis by subgroup(91) stated that “smear and culture testing may be offered but of variable quality”. Several studies only look back at results of individuals who
arrived in the low-incidence country—a potential bias if there was a difference in the proportion who travelled by test result, which is likely to be the case.
§Substantial heterogeneity existed among studies with CIs that minimally overlapped. The proportion of the variation in point estimates due to among-study differences was large and
exploration of a-priori subgroup analyses did not substantially explain this.
¶Populations across studies varied; however, the evidence summaries are highly relevant to policy makers and those interpreting the studies, and outcomes (such as active tuberculosis)
are likely to be of interest and important to migrants.
‖Interventions and outcomes varied greatly, particularly as smear and culture testing was offered but of variable quality in the largest included study for analysis by subgroup(91) and as 
many studies included radiographic diagnoses with substantial variation in the radiographic case definition used. Additionally, studies with high detection rates(101) seem likely to have
included inactive and old tuberculosis scars in addition to active disease.
**Data for all years from countries conducting pre-entry screening were not available in the published literature.
††Some evidence to suggest that higher tuberculosis prevalence in country conducting pre-entry screening was associated with a higher yield of cases.
‡‡There was the potential for outbreak bias in one study(97) because it was initiated as a result of an unusually high number of cases.
§§Substantial heterogeneity among studies with CIs that showed minimal or no overlap. The proportion of the variation in point estimates due to between-study differences was large.
Exploration of a-priori subgroups reduced heterogeneity.
¶¶Interventions and outcomes for multidrug-resistant cases are likely to be less variable due to procedures involved in laboratory testing being somewhat uniform across sites, although
the consistency with which these were applied across studies might cause some issues in relation to indirectness.
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2.5 Discussion
This systematic review found 15 unique studies with data on 3,739,266 individuals
screened by pre-entry tuberculosis programmes. Heterogeneity was high for all primary
outcomes examined, but reduced after stratification by prevalence of tuberculosis in the
country of origin for culture and smear confirmed cases, and culture confirmed cases in
refugees, but not principal outcome (of active tuberculosis) reported by each study.
Culture and smear confirmed prevalence increased with prevalence in the country of
origin. Summary estimates of culture confirmed cases ranged from 20 (95%CIs 10, 32)
to 336 per 100,000 individuals screened (95%CIs: 283, 393) in countries with an
incidence of 50-149 or greater than 350 per 100,000 population respectively.
2.5.1 Strengths and weaknesses of the systematic review
As far as it has been possible to identify, this is the first systematic review and meta-
analysis of pre-entry screening programme data for tuberculosis. Established systematic
review procedures were used including double screening review, and PRISMA
reporting guidelines for systematic reviews and meta-analyses.(81) Attempts were made
to reduce bias in the review process by following empirically based systematic review
and meta-analysis guidelines.(87)
There was substantial heterogeneity between studies, limiting the ability to synthesise
results across settings and outcomes. With the exception of prevalence of culture and
smear confirmed cases, when stratified by prevalence of tuberculosis in country of
origin, and culture confirmed cases in refugees, heterogeneity in the primary and
secondary outcomes remained high after exploring potential a priori explanatory
variables. Data on the age of those screened was not provided consistently, which might
be particularly important for latent tuberculosis and studies that included old
tuberculosis detected by chest radiograph. The top five countries of origin for migrants
from developing to developed countries in 2010 were Mexico, India, China,
Philippines, and Turkey.(49) Although data were presented for India, China, and the
Philippines, the migrants were not entirely representative of migrant flow between
developing and developed countries. It was not clear from most studies whether there
was uniform drug susceptibility testing or whether only retreatment cases were tested.
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There was a risk of misclassification in the principal outcomes reported by many
studies, particularly for those that included clinically identified cases (with an intention
to treat) as part of the case definition.
3.5.2 Strengths and weaknesses in relation to other studies
A previously published systematic review focused on all types of migrant screening
programmes for tuberculosis in the EU/EEA, independent of where the screening took
place.(55) This review found no studies of pre-entry screening in Europe, but data were
separately reported from three pre-entry screening programmes conducted outside
EU/EEA, all of which were included in this systematic review. A total of 14 studies
reported data from upon-entry screening programmes in EU/EEA with a median active
tuberculosis prevalence of 360 cases per 100,000 people screened (interquartile range
100–520). Five studies reported data on community post-entry screening with a
summary active tuberculosis prevalence of 220 cases per 100,000 people invited to
screening (interquartile range 100–380). Direct comparisons with upon- and post- entry
screening programmes are difficult to make due to lack of comparability between study
designs, secular trends and populations considered. Pre-entry screening, when
conducted in countries with a prevalence of tuberculosis greater than 350 per 100,000
population appears to be within a similar range as these upon- and post-entry
programmes.
2.6 Conclusion
Pre-entry screening programmes aim to identify cases of active tuberculosis before
arrival of the migrant in the host country. This review provides evidence that pre-entry
screening programmes have varying prevalence that increases with prevalence in the
country of origin. Screening in countries with prevalence <150 per 100,000 is likely to
result in a low prevalence of culture and smear confirmed cases detected. The full
public health implications of this analysis, recommendations, and directions of future
research are discussed in the final chapter of the thesis.
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2.7 Publications and presentations arising from this chapter
1. Aldridge RW, Yates TA, Zenner D, White PJ, Abubakar I, Hayward AC. Pre-entry
screening programmes for tuberculosis in migrants to low-incidence countries: a
systematic review and meta-analysis. Lancet Infect Dis. 2014 Dec;14(12):1240–9.
2. Aldridge RW, Yates TA, Zenner D, White PJ, Abubakar I, Hayward AC. Pre-entry
tuberculosis screening of migrants to low incidence countries: a systematic review. 44th
Union World Conference in Paris. 3 November 2013.
3. Aldridge RW. Investigating the epidemiology of tuberculosis in migrants to the UK and
the cost effectiveness of pre-entry screening. World TB Day 2014: Reaching the 3
Million. 24 March 2014. LSHTM
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CHAPTER 3
Prevalence and risk factors for active tuberculosis in migrants
to the UK screened pre-entry.
3.1 Abstract
Background: A pilot pre-entry screening programme was set up for migrants to the UK
from 15 countries in 2005. This study aimed to investigate the prevalence and risk
factors for tuberculosis in migrants screened prior to entering the UK from the 15 pilot
high-burden countries.
Methods: A cross-sectional study was performed on pre-entry screening data collected
between 1st October 2005 and 31st December 2013. The primary outcome was the
prevalence of bacteriologically confirmed tuberculosis. Poisson regression was used to
estimate crude prevalence and a multivariable logistic regression model was created to
identify risk factors for the primary outcome.
Results: A total of 476,455 visa applications were screened for tuberculosis at sites
where sputum samples were tested by culture. Crude prevalence was 92 per 100,000
population screened (95%CIs: 84, 101). After adjusting for age, sex and clustering by
individual, there was evidence that having contact with a case of tuberculosis (OR 11.6;
95%CIs: 7.0, 19.3; p-value <0.001) was associated with an increased risk of
bacteriologically confirmed tuberculosis at pre-entry screening.
Conclusion: The results of this study provide a comprehensive analysis of the historical
data from a pilot pre-entry screening programme that has been running since 2005. The
study identified issues that could inform evidence-based migrant screening policies, and
groups of migrants that would benefit from increased health improvement interventions.
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3.2 Introduction
In 2005 the UK Border Agency (UKBA) and Foreign and Commonwealth Office
(FCO) funded the set up costs for a trial of pre-entry screening of migrants to the UK in
conjunction with the International Organization for Migration (IOM).(59,60) The pilot
was launched in November 2005 in Kenya, Sudan and Thailand, and was subsequently
rolled out to eight locations screening migrants from a total of 15 countries (Table 4).
Local IOM clinics ran the programme with oversight from an epidemiological unit
based in Manila, Philippines.






Start of screening UKTB Global
Software Start
Thailand Laos November 2005 July 2008
Bangladesh January 2006 October 2008
Cambodia February 2006 October 2008





February 2007 December 2009
Tanzania October 2005 December 2009
Sudan Eritrea November 2005 December 2009
Kenya Somalia November 2005 August 2010
From 2005 to 2012 the pre-entry pilot scheme required migrants from 15 countries
intending to stay in the UK for longer than six months to be certified free of pulmonary
tuberculosis as part of the visa application process. IOM clinics carrying out pre-entry
screening for the UK government used a set of technical instructions that specified how
screening should be conducted, and included:(7)
x A symptom screen (asking for details of cough, haemoptysis, weight loss, night
sweats, history of previous tuberculosis).
x A clinical history including details of any recent contact with a case of active
pulmonary tuberculosis.
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x A physical examination if considered necessary by the certifying physician.
x A chest radiograph (CXR) in all applicants except pregnant women and children
under the age of 11 years.
x All applicants with radiological findings classified as “major findings sometimes
seen in active tuberculosis” (see Table 5 for further details) are required to
undergo sputum testing for tuberculosis with three sputum samples tested by
microscopy for acid fast bacilli (AFB).
In May 2012 it was announced that the pre-entry system would be expanded from the
15 pilot locations to 101 countries with a WHO incidence of greater than 40 per
100,000 population. As a result many more migrants to the UK were required to be
certified free from active tuberculosis before a visa could be issued. Analysis of the
historical data from the 15 pilot countries can be used to inform and improve the
expanded pre-entry screening programme, identifying its strengths, weaknesses and
quality assurance opportunities, as well as suggesting potential opportunities to
intervene and improve the health of migrants. Using data from the 15 pilot countries,
this study aimed to investigate the prevalence and risk factors for tuberculosis in
migrants from high incidence countries screened prior to entering the UK, and put these
data in the context of previously published literature.
3.2.1 Research questions:
The analysis presented in this chapter aims to answer the following research questions:
1. What is the prevalence of bacteriologically confirmed tuberculosis in migrants at
the time of pre-entry screening?
2. What are the risk factors for bacteriologically confirmed tuberculosis in
migrants at the time of pre-entry screening?
3.3 Methods
3.3.1 Study design and setting
This was a cross-sectional study of migrants applying for visas to stay in the UK for
more than six months, screened for tuberculosis in 15 countries taking part in a pre-
56
entry screening pilot programme. The data included in this analysis were collected
between 1st October 2005 and 31st December 2013.
3.3.2 Chest radiography
The UK technical instructions set out how tuberculosis screening was performed by
IOM from 2005.(7) All applicants completed an informed consent form in a language
they were able to understand, or steps were taken to ensure they understood the form if
they were unable to read it (See Appendix 4 for a copy of the consent form). The
applicant signed the consent form before the screening process started. Applicants of 11
years of age and above received a standard postero-anterior view chest radiograph. All
visa applicants with radiological findings classified in group four “major findings
sometimes seen in active tuberculosis” were required to undergo sputum testing for
tuberculosis (Table 5). Individuals with chest radiographs classified as group three
“minor findings occasionally associated with tuberculosis infection” were not
mandatorily required to undergo sputum testing, but the panel physician responsible for
the migrant screening (a medical doctor in charge of screening at an IOM clinic) was
requested to consider sputum testing on a case-by-case basis. A radiologist and the
panel physician both interpreted chest radiographs. Applicants unwilling or unable to
undergo radiographic screening were required to provide three consecutive daily
sputum specimens that were tested in a designated laboratory for smear and culture.
Table 5. Recording of radiographic findings
Minor Findings
1.1 Single fibrous streak/band/scar
1.2 Bony islets
2.1 Pleural capping with a smooth inferior border (<1cm thick at all points)
2.2 Unilateral or bilateral costophrenic angle blunting (below the horizontal)
2.3 Calcified nodule(s) in the hilum / mediastinum with no pulmonary granulomas
Minor findings occasionally associated with tuberculosis infection
3.1 Solitary Granuloma (< 1 cm and of any lobe) with an unremarkable hilum
3.2 Solitary Granuloma (< 1 cm and of any lobe) with calcified / enlarged hilar lymph nodes
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3.3 Single / Multiple calcified pulmonary nodules / micronodules with distinct borders
3.4 Calcified pleural lesions
3.5 Costophrenic Angle blunting (either side above the horizontal)
Major findings sometimes seen in active tuberculosis (or other conditions)
4.0
Notable apical pleural capping (rough or ragged inferior border and/or ≥ 1cm thick at 
any point)
4.1 Apical fibronodular / fibrocalcific lesions or apical microcalcifications
4.2
Multiple / single pulmonary nodules / micronodules (noncalcified or poorly defined) 4.3
Isolated hilar or mediastinal mass/lymphadenopathy (non-calcified)
4.4 Single / multiple pulmonary nodules / masses ≥ 1 cm. 
4.5 Non-calcified pleural fibrosis and / or effusion.
4.6 Interstitial fibrosis/ parenchymal lung disease/ acute pulmonary disease
4.7 Any cavitating lesion OR “fluffy” or “Soft” lesions felt likely to represent active TB
3.3.3 Laboratory testing
Laboratory examination for M.tuberculosis consisted of the provision of at least three
sputum specimens, taken on 3 separate occasions, not less than 24 hours apart and
ideally in the early morning. All specimens underwent microscopy for acid-fast bacilli
(AFB) by an auramine stain (or, if necessary, by Ziehl-Neelsen stain). At the start of the
pilot programme, culture testing was not universally available at all IOM screening
clinics. Where culture testing was available, this was undertaken as a culture on liquid
or solid media for mycobacteria and confirmation of the Mycobacterium species at least
to the M.tuberculosis complex level. Specimens were cultured for a minimum of six
weeks in liquid media and eight weeks in solid media, unless a positive result was
obtained earlier than this. If there was no growth after these time periods, specimens
were reported as negative. Where available, positive M.tuberculosis cultures underwent
drug susceptibility testing (DST) in a designated laboratory in accordance with World
Health Organisation guidelines.(108)
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3.3.4 Outcomes of pre-entry screening
The panel physician could issue applicants with a clearance certificate if they had a
chest radiograph classified as free of any radiological changes, or findings in groups one
or two. In addition to chest radiographs and sputum testing results, physicians were able
to use their clinical judgment in the evaluation of an applicant, and if active pulmonary
tuberculosis was suspected then they were able to refuse to issue a medical clearance
certificate. Panel physicians were under no obligation to treat applicants diagnosed with
tuberculosis, but were required to provide clear and unambiguous advice about the need
to seek treatment immediately and provide a treatment referral letter.
Applicants diagnosed with active tuberculosis were able to restart the screening process
having successfully completed a full course of approved treatment, but not within six
months of the original examination. A written treatment summary from the treatment
provider was required at the time of repeat screening. At rescreening, panel physicians
were required to compare the chest radiograph taken at the time of the original
application with an updated image. Where the panel physician was satisfied that the
applicant no longer had active tuberculosis, a medical clearance certificate could be
issued.
3.3.5 Primary outcome
The primary outcome for this study was the prevalence of bacteriologically confirmed
tuberculosis (culture testing on liquid or solid media, or microscopy for acid fast
bacilli). Cases of bacteriologically confirmed tuberculosis in this study were specified
according to the WHO revised definition as: “one from whom a biological specimen is
positive by smear microscopy, culture or WHO-approved rapid diagnostics (such as
Xpert MTB/RIF)”.(109) No WHO-approved rapid diagnostics were used in this study.
3.3.6 Secondary outcomes
1. Prevalence of tuberculosis
a. Confirmed by culture testing on liquid or solid media.
b. Confirmed by microscopy for acid fast bacilli.
c. Confirmed by culture testing on liquid or solid media and resistant to one
or more anti-tuberculosis drugs.
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2. Prevalence of clinically confirmed tuberculosis.
The WHO definition for a case of clinically diagnosed tuberculosis implies that the
diagnosing clinician or other medical practitioner intends to give the patient a full
course of treatment. As panel physicians were not obliged to treat cases diagnosed as
part of the screening process, the definition of a clinical case for this study was adapted
from the WHO guidelines, and defined as: “A clinically diagnosed case is one that does
not fulfil the criteria for bacteriological confirmation but has been diagnosed with active
tuberculosis by a clinician or other medical practitioner who has decided to give, or
refer the patient for a full course of tuberculosis treatment.” The change to the WHO
definition used in this chapter is highlighted in bold and includes cases diagnosed on the
basis of chest radiograph abnormalities or suggestive histology and extra pulmonary
cases without laboratory confirmation. Clinically diagnosed cases subsequently found to
be bacteriologically positive (before or after starting treatment) were reclassified as
bacteriologically confirmed.(109)
3.3.7 Data sources
The analysis presented in this chapter used data collected by IOM as part of the
screening process, including demographic and clinical data for all individuals screened.
At the start of the pilot study, data were collected by IOM clinics on Microsoft excel
spreadsheets and sent on a monthly basis to the IOM epidemiology unit in Manila,
Philippines. From July 2008, an internet based system called “Global Software” was
rolled out by IOM to replace the previous use of spreadsheets for the collection of data
on migrants (see Table 4 for roll out dates of Global Software at each IOM clinic).
Global Software was a single database with a web interface and integrated all
requirements of the UK technical screening instructions. Global Software included an
automated facility to detect individuals attending multiple sites for screening, and
therefore minimised duplicate entries for individuals. Global Software also contained
digital image capture for personal identification purposes and digital chest radiographic
imaging using Picture Archiving and Communications System (PACS) technology. The
IOM epidemiology unit in Manila checked and reconciled data (from Global Software
or excel sheets) on a monthly basis to ensure they were consistent and that outcomes of
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screening were fully completed. Data were cleaned by the IOM epidemiology unit in
coordination with clinics to ensure that records included all laboratory results on
individuals screened and that any duplicate entries resulting from administrative error
were removed or consolidated into one record. Monthly reports containing aggregate
numbers on the screening process from all 15 clinics were sent to UKBA and Public
Health England’s tuberculosis screening surveillance unit. The dataset used in this
analysis contained a variable to indicate which individuals were screened at clinics
where culture testing was being performed.
3.3.8 Sample size
Before access to the IOM dataset was granted, it was estimated that the database would
contain records on 350,000 migrants. Confidence intervals for the prevalence of
bacteriologically confirmed tuberculosis were estimated for a country with a prevalence
of 100 per 100,000 population, and for three different scenarios based on the number of
migrants screened: 1000, 10,000 and 50,000. It was assumed that the prevalence in
migrants was representative of the general population. Under these assumptions, a
prevalence of 100 per 100,000 population would be estimated with the following 95%
CIs:
x 3 to 556 if 1,000 individuals were screened
x 48 to 184 if 10,000 individuals were screened
x 74 to 132 if 50,000 individuals were screened
3.3.9 Duplicates
It was possible for individuals screened pre-entry to have multiple entries in the IOM
database for several reasons, including: 1) clearance certificates once issued only last
for six months, and if a UK visa application was not processed during this time period,
the applicant was required to undergo repeat screening with a duplicate record being
created; 2) administrative errors leading to two records being created for one individual
during the same screening application. This scenario was more likely to occur prior to
the roll out of the Global Software which automatically checked for these errors; 3)
migrants undergoing a clearance screen after an initial positive screen for tuberculosis.
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Duplicates were therefore analysed on the basis of whether they occurred less than 12
months apart or not. A period of 12 months was chosen a-priori as this was long enough
to capture individuals found to have tuberculosis on their first screen, who were then
undergoing repeat screening for visa clearance, but not too long a time period such that
tuberculosis exposure and risk factors may have changed significantly for a majority of
individuals. On the basis of these considerations, rules used to determine whether
duplicate entries for an individual should be included in the cohort analysis are provided
in Table 6.
Table 6. Rules for dealing with duplicate screens.










Positive Less than or equal to 12 months apart:
1st screen - Include
2nd screen - Exclude
Greater than 12 months apart:
Include all duplicates
Include all
Negative Less than or equal to 12 months apart:
1st screen - Include
2nd screen - Exclude
Greater than 12 months apart:
Include all duplicates
Include all
For duplicates occurring less than 12 months apart where the first screen was positive,
the second screen has been undertaken for clearance purposes. This second screen is
therefore treated as a continuation of the initial screening process taken for the purposes
of clearance and was excluded as it is not a newly prevalent case, the primary outcome
for this analysis. All duplicates occurring greater than 12 months apart were included as
this is sufficient time for the exposure to tuberculosis in an individual to have changed.
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3.3.10 Exclusion criteria
During the start of the pilot phase, not all sites conducted culture testing for
M.tuberculosis. To ensure comparability of estimates for the primary and secondary
outcomes across countries and locations, this analysis was restricted to sites were
culture and smear testing was performed on all sputum samples collected. This analysis
would also be the most useful for informing current screening policy due to the fact that
is now a requirement that sites conducting pre-entry screening perform culture testing
forM.tuberculosis on all sputum samples.
3.3.11 Statistical analysis
Poisson regression (suitable for modelling rare event data) was used to estimate crude
prevalence for the primary and secondary outcomes and was calculated per 100,000
population screened. Adjusted estimates for primary and secondary outcomes in the
population screened were then calculated using the results of multivariable Poisson
regression that included terms for age and sex and using the Margins command in Stata.
Adjusted estimates for each country were compared to WHO estimates of prevalence
for tuberculosis in 2010.(110) To account for duplicate screens included in this analysis,
all crude and adjusted estimates accounted for clustering by individual. A multivariable
logistic regression model was created to identify risk factors for the primary outcome.
Final results were presented as odds ratios, 95% confidence intervals with p-values.
Stata v.13 (Statacorp LP, College Station, TX, USA) was used for all statistical
analyses.
To compare the results with the published literature, the meta-analyses presented in
chapter two (prevalence of all cases, and prevalence of culture confirmed cases) were
updated using the crude estimates from this analysis. Countries with less than 1,000
migrants screened were excluded from the updated meta-analysis of culture confirmed
cases stratified by country of origin due to small numbers of cases detected.
3.3.12 Sensitivity analysis
The main analysis presented in this study included only migrants screened at sites where
culture testing was performed on sputum samples. To examine the impact of the
introduction of this sputum testing on the rates of bacteriologically confirmed cases of
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tuberculosis, a sensitivity analysis was conducted that included all migrants screened
pre-entry by IOM, regardless of whether they were seen at sites undertaking culture
testing or not.
3.3.13 Ethics approval
Ethical approval was received for this analysis from UCL research ethics committee
(3294/002; See Appendix 4 for copy of approval letter). The work was conducted with
Public Health England which has Health Research Authority approval to hold and
analyse national surveillance data for public health purposes under Section 251 of the
NHS Act 2006.
3.4 Results
Between 1st October 2005 and 31st December 2013 a total of 692,362 visa applications
were screened for tuberculosis (Figure 12). A total of 106 duplicate screens were
excluded, all less than 12 months apart, one with a positive first and second screen, and
105 with a positive first screen and negative second screen. After excluding duplicates
screens, and applicants screened at sites not performing culture testing on sputum, there
were a total of 476,455 screening records included in this analysis. A total of 470,223
chest radiographs were performed and 21,772 sputum samples were collected. Chest
radiographs were not carried out on 3,911 children and 2,319 pregnant women.
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Figure 12. Results of the screening process between 17th October 2005 and 31st December
2013 in countries with IOM screening.
*No abnormality, or abnormality in classified in groups 1, 2, 3 and not requiring
sputum testing as determined by the panel physician
The majority of individuals screened were aged between 16 and 44 (444,579; 93.3%)
and male (309,062, 64.9%; Table 7). More migrants were screened in 2009 than any
other year (116,899; 24.5%) and the country conducting the most screening was
Pakistan (243,243; 51.1%), which accounted for just over half of all migrants screened.
The majority of those screened were students (281,703; 59.1%). A total of 1,239 (0.3%)
individuals being screened reported close contact with a case of tuberculosis. There
were no missing data on any of the variables included in the final dataset.
After excluding duplicate records, 439 cases of bacteriologically confirmed tuberculosis
were diagnosed providing a crude prevalence of 92 per 100,000 population screened
(95%CIs: 84, 101). Crude prevalence of smear positive tuberculosis (55 per 100,000;
95%CIs: 49, 62) was lower than culture confirmed tuberculosis (83 per 100,000;
95%CIs: 75, 92). The crude prevalence of clinically diagnosed cases (3 per 100,000;
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95%CIs: 2, 4) and overall prevalence of culture confirmed samples with resistance to
one or more tuberculosis drugs was 3 per 100,000 (95%CIs: 2, 5).
The crude prevalence of bacteriologically confirmed tuberculosis was highest in those
with a history of contact with an infectious case of tuberculosis (1,372 per 100,000;
95%CIs: 855, 2,201) and those over the age of 65 (329 per 100,000; 95%CIs: 172, 631),
but due to the low number of cases in both of these categories, estimates had wide
confidence intervals. Women had higher crude prevalence of bacteriologically
confirmed tuberculosis (116 per 100,000; 95%CIs: 101, 134) than men (79 per 100,000;
95%CIs: 70, 90).
Migrants applying under the visa category of Settlement and Dependents had the
highest crude prevalence of bacteriologically confirmed tuberculosis (108 per 100,000;
95%CIs: 93, 125). Crude prevalence of bacteriologically confirmed tuberculosis did not
increase with WHO prevalence in country of origin, and was highest in migrants from
countries with an estimated WHO prevalence of between 150 and 349 per 100,000
population (225 per 100,000; 95%CIs: 192, 264).
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Table 7. Baseline characteristics of applicants screened for tuberculosis and










All 476455 (100%) 92 (84, 101) 83 (75, 92) 55 (49, 62)
Age group
0-15 18729 (3.9%) 37 (18, 78) 37 (18, 78) 11 (3, 43)
16-44 444579 (93.3%) 92 (83, 101) 83 (75, 92) 53 (47, 60)
45-64 10413 (2.2%) 134 (80, 227) 115 (65, 203) 163 (102, 262)
>65 2734 (0.6%) 329 (172, 631) 293 (147, 584) 256 (122, 536)
Sex
Female 167393 (35.1%) 116 (101, 134) 108 (93, 125) 83 (70, 98)
Male 309062 (64.9%) 79 (70, 90) 70 (61, 80) 40 (33, 47)
Family contact with infectious case of TB
No 475216 (99.7%) 89 (81, 98) 80 (72, 88) 53 (47, 60)
Yes 1239 (0.3%) 1372 (855, 2201) 1211 (732, 2003) 726 (379, 1393)
Visa Type
Student 281703 (59.1%) 85 (75, 96) 76 (66, 86) 52 (44, 61)
Settlement and
Dependent 160436 (33.7%) 108 (93, 125) 99 (85, 116) 60 (49, 73)
Work 14748 (3.1%) 88 (51, 152) 68 (36, 126) 102 (61, 169)
Working Holiday
Maker 7380 (1.6%) 0 (0, 0) 81 (37, 181) 14 (2, 96)
Family Reunion 3389 (0.7%) 59 (15, 236) 59 (15, 236) 0 (0, 0)
Other 8799 (1.9%) 68 (31, 152) 57 (24, 136) 45 (17, 121)
CXR
No abnormality 449401 (94.3%) - - -
TB suspected 19654 (4.1%) 2234 (2036, 2450) 2010 (1822, 2216) 1308 (1158, 1476)
Abnormality not
TB 7400 (1.6%) - - -
WHO prevalence of TB in country of
migration
40-149 18910 (4.0%) 32 (14, 71) 11 (3, 42) 26 (11, 64)
150-349 67574 (14.2%) 225 (192, 264) 223 (190, 263) 200 (169, 236)
350+ 389971 (81.9%) 72 (64, 81) 62 (55, 70) 31 (26, 37)
Year of examination
2007 5489 (1.2%) 146 (73, 291) 128 (61, 267) 109 (49, 243)
2008 34343 (7.2%) 166 (128, 215) 154 (118, 202) 122 (90, 165)
2009 116899 (24.5%) 87 (72, 106) 71 (57, 88) 67 (53, 83)
2010 109356 (23.0%) 68 (54, 85) 56 (43, 72) 47 (35, 61)
2011 97455 (20.5%) 87 (71, 108) 82 (66, 102) 33 (23, 46)
2012 62338 (13.1%) 106 (83, 135) 103 (80, 131) 59 (43, 82)




Burkina Faso 73 (0.0%) - - -
Bangladesh 143154 (30.1%) 85 (71, 101) 77 (64, 93) 39 (30, 51)
Cambodia 621 (0.1%) 161 (23, 1144) 161 (23, 1144) -
Cote D'Ivoire 1026 (0.2%) - - -
Eritrea 152 (0.0%) 658 (92, 4684) - 658 (92, 4684)
Ghana 18649 (3.9%) 32 (14, 72) 11 (3, 43) 27 (11, 64)
Kenya 12867 (2.7%) 101 (59, 174) 101 (59, 174) 39 (16, 93)
Laos 193 (0.0%) - - -
Niger 36 (0.0%) - - -
Pakistan 243243 (51.1%) 63 (54, 74) 52 (44, 62) 26 (20, 33)
Sudan 4025 (0.8%) 25 (4, 176) 25 (4, 176) -
Somalia 2760 (0.6%) 181 (76, 435) 145 (54, 386) 109 (35, 337)
Togo 188 (0%) - - -
Tanzania 4166 (0.9%) 120 (50, 288) 120 (50, 288) 24 (3, 170)
Thailand 45302 (9.5%) 291 (245, 346) 291 (245, 346) 283 (238, 336)
The crude prevalence of bacteriologically confirmed tuberculosis varied greatly
between countries with the highest rates found in Eritrea (658 per 100,000; 95%CIs: 92,
4,684) and Thailand (291 per 100,000; 95%CIs: 245, 346; Figure 13). Adjusting for
age and sex had a minimal impact on the estimates. Adjusted prevalence was highest in
Eritrea at 556 per 100,000 individuals (95%CIs: 0, 1,659), but less than five cases were
detected and therefore the confidence intervals were large for this estimate (Figure 14).
Pakistan had the highest number of bacteriologically confirmed cases (156) and an
adjusted prevalence of 63 per 100,000 individuals screened (95%CIs: 53, 73). Eritrea
and Tanzania had age and sex adjusted estimates for bacteriologically confirmed
tuberculosis that were consistent with WHO estimates of prevalence due to overlapping
95% confidence intervals with the 2010 country estimate. Thailand had an age and sex
adjusted prevalence of bacteriologically confirmed tuberculosis detected at pre-entry
screening greater than WHO prevalence country estimates in 2010. All other country
estimates were lower than WHO prevalence country estimates in 2010.
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Figure 13. Crude prevalence of bacteriological and culture confirmed TB diagnosed at
pre-entry screening compared to 2010 WHO country prevalence estimates.
Note: Error bars on bacteriological and culture confirmed tuberculosis
estimates are 95%confidence intervals. Error bars on WHO 2010
prevalence country estimates are highest and lowest prevalence estimate for
each country between 2007 and 2013. Confidence intervals limited to a
maximum of 1,000 per 100,000 population.
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Figure 14. Age and Sex adjusted prevalence of bacteriological and culture confirmed TB
diagnosed at pre-entry screening compared to 2010 WHO country prevalence
estimates.
Note: Error bars on bacteriological and culture confirmed tuberculosis
estimates are 95%confidence intervals. Error bars on WHO 2010
prevalence country estimates are highest and lowest prevalence estimate for
each country between 2007 and 2013. Confidence intervals limited to a
maximum of 1,000 per 100,000 population.
In order to examine the results of this study in the context of previously published data
on pre-entry screening, the meta-analyses presented in chapter two was updated. The
primary outcome of crude prevalence of bacteriologically confirmed cases across all
countries was used in this updated meta-analysis (92 per 100,000 population screened;
95% CIs 84, 101). This crude estimate was found to be the second lowest of all
published studies (Figure 15) and overlapped with the estimate from one other
study.(90)
The meta-analysis of culture confirmed cases by country of origin was also updated,
including all countries where more than 1,000 migrants had been screened (Figure 16).
Compared to the meta-analysis in chapter two, the level of heterogeneity increased
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when including estimates from this study, with prevalence of culture positive cases no
longer increasing with prevalence of tuberculosis in the country of origin. The summary
estimate of culture confirmed cases was highest in countries with a WHO estimate of
prevalence of tuberculosis between 150-249 per 100,000 population (192 per 100,000
individuals screened; 95%CIs 170, 216). With the exception of Bangladesh and
Pakistan, 95% confidence intervals for the estimates of culture confirmed disease
overlapped with published estimates within each stratified subgroup.
To determine the risk factors for bacteriologically confirmed tuberculosis in migrants at
the time of pre-entry screening, a multivariable logistic regression was conducted
(Table 8). After adjusting for age, sex and clustering by individual, there was strong
evidence that having contact with a case of tuberculosis (OR 11.6; 95%CIs: 7.0, 19.3; p-
value <0.001) was associated with an increased risk of bacteriologically confirmed
tuberculosis at pre-entry screening. Migrants screened in countries with a WHO
prevalence of 40-149 per 100,000 population were at reduced risk of bacteriologically
confirmed tuberculosis at pre-entry screening (OR 0.1; 95%CIs 0.1, 0.3; p-value
<0.001), as were those from countries with a prevalence greater than 350 (OR 0.3;
95%CIs 0.3, 0.4; p-value <0.001) compared to migrants from countries with a
prevalence of 150-349 after adjusting for age and sex. Migrants on a settlement and
dependant visa also had a higher risk after adjusting for age and sex (OR 1.3; 95%CIs
1.0, 1.6; p-value 0.02).
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Figure 15. Forrest plot of pre-entry screening programme prevalence for principal outcome of active tuberculosis cases found by each study
(case definition varies between studies, sorted by year of publication).
72
Figure 16. Forrest plot of pre-entry screening programme prevalence of culture positive cases of tuberculosis, stratified by WHO prevalence
of tuberculosis in country of origin (sorted by prevalence in country of origin).
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Table 8. Multivariable analysis examining risk factors for bacteriologically confirmed
tuberculosis




0-15 0.4 (0.2, 0.9) 0.3 (0.2, 0.7) 0.01
16-44 1.0 1.0
45-64 1.5 (0.9, 2.5) 1.2 (0.7, 2.0) 0.56
>65 3.6 (1.9, 6.9) 3.2 (1.6, 6.3) <0.001
Sex
Female 1.0 1.0
Male 0.7 (0.6, 0.8) 1.0 (0.8, 1.3) 0.73
Contact with case TB
No 1.0 1.0




dependents 1.3 (1.0, 1.5) 1.3 (1.0, 1.6) 0.02
Work 1 (0.6, 1.8) 0.9 (0.5, 1.6) 0.73
Working holiday
maker 1 (0.4, 2.2) 1.2 (0.5, 2.8) 0.63
Family reunion 0.7 (0.2, 2.8) 0.4 (0.1, 1.7) 0.21
Other 0.8 (0.4, 1.8) 0.9 (0.4, 2.1) 0.84
WHO category
40-149 0.1 (0.1, 0.3) 0.1 (0.1, 0.3) <0.001
150-349 1.0 1.0
350+ 0.3 (0.3, 0.4) 0.3 (0.3, 0.4) <0.001
A sensitivity analysis was conducted to examine the prevalence rates of the primary and
secondary outcomes when including all migrants screened pre-entry, not just those seen
at clinics where culture and smear testing was performed on all sputum samples
collected (See Appendix 5 for all results). A total of 692,232 migrants were screened
under this protocol and the overall rate of bacteriologically confirmed tuberculosis was
lower at 75 (95%CIs: 69, 82; Table 31). In a multivariable analysis adjusted for age and
sex, being screened at a site where sputum culture testing was performed on all samples
was associated with increased odds of being bacteriologically confirmed as a case of
tuberculosis (OR 2.4; 95%CIs: 1.9, 3.0; p-value <0.001; Table 32). Eritrea still had the
highest crude rate of bacteriologically confirmed tuberculosis (Figure 54), and after
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adjusting for age and sex, only Thailand had bacteriologically confirmed tuberculosis
rates higher than WHO country prevalence estimates in 2010, Eretria had results that
were consistent with WHO levels, and all other countries had rates lower than WHO
estimates (Figure 55).
3.5 Discussion
Between 1st October 2005 and 31st December 2013 nearly seven hundred thousand pre-
entry screening episodes for tuberculosis were conducted. Almost five hundred
thousand of these migrants were screened at locations using culture testing of sputum
samples. The overall crude prevalence of bacteriologically confirmed tuberculosis was
92 per 100,000 population screened and migrants over the age of 65, those who had
been in contact with an infectious case of tuberculosis, and those with a chest
radiograph classified as suspected tuberculosis had the highest crude prevalence of
bacteriologically confirmed tuberculosis. After adjusting for age and sex, all countries
except Thailand had a prevalence of tuberculosis detected at pre-entry screening that
was consistent with or lower than WHO population estimates in 2010. After adjusting
for age and sex, migrants that had a history of a close contact with a case of tuberculosis
and applicants screened in countries with a WHO prevalence of between 151-349 per
100,000 population, and those on settlement and dependant visas were all associated
with an increased risk of being detected with bacteriologically confirmed tuberculosis at
pre-entry screening. In a sensitivity analysis that included all migrants screened pre-
entry, those individuals screened at a clinics where culture and smear testing was
performed on all sputum samples collected were associated with an increased risk of
being detected with bacteriologically confirmed tuberculosis.
3.5.1 Strengths and weaknesses of the study
There were several strengths to this study including the large sample size and the fact
that the data were highly representative of long-term migrants from the 15 countries
taking part in the pre-entry screening pilot, as a result of the compulsory nature of the
process for all migrants applying to stay for six months or more. The use of WHO
definitions for primary and secondary outcomes means that data were internationally
comparable. After excluding those sites were culture testing was not routinely being
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performed, screening across different sites should be consistent as a result of the quality
assured UK technical instructions that all clinics must conform to.(7) These guidelines
specify in detail how screening should be undertaken and include standardised reporting
guidelines for chest radiographs based on the Canadian immigration system for the
classification of tuberculosis.(8) The technical instructions should therefore reduce
measurement error and misclassification bias for exposures and outcomes, including in
the interpretation and reading of chest radiographs due to the established classification
system used. Prevalence estimates included only the first screen for individuals with
duplicate screens (less than 12 months apart) that were repeatedly positive as these were
not newly prevalent cases. These records represent migrants with tuberculosis detected
at the initial screen who were undergoing repeat screening but found still to have
tuberculosis. Country estimates for the prevalence of bacteriological and culture
confirmed tuberculosis in migrants were adjusted by age and sex, and therefore
comparable across countries in this study for these two confounding factors.
A major limitation of this study is that whilst it is highly representative of migrants
staying for longer than six months in the UK, it does not include data on undocumented
migrants, refugees and those on short visas. Undocumented migrants and refugees in
particular will be at a higher risk of tuberculosis compared to the individuals included in
this dataset for complex reasons including malnutrition, history of living in
overcrowded situations such as refugee camps, higher rates of HIV, and a disruption in
access to health services.(111–116) A large proportion of migrants to the UK on visas
greater than 6 months were also likely to come from higher socio-economic groups in
their country of origin. These biases (compared to a representative country random
sample) were likely to account for some of differences between prevalence estimates in
this analysis and WHO country prevalence estimates.
An alternative explanation for the difference between WHO prevalence estimates and
country prevalence estimates in this study is the potential for misclassification bias in
the WHO country data. WHO estimates were modelled using a beta distribution from
country level case notification data (where available), prevalence surveys, expert
opinion, and UNAIDS estimates of HIV. Recent papers have examined in detail why
WHO estimates were different to those estimated by the Global Burden of Disease
study, which in general found lower estimates of incidence and prevalence, and some of
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these issues about parameterisation and modelling strategies are proposed as potential
explanations.(32,110,117) In particular, the country level case notification data used by
WHO is extremely variable, and this may explain why prevalence did not increase with
WHO prevalence and why those from countries with prevalence between 151-349 per
100,000 population had the highest risk of being detected as a bacteriologically
confirmed case at pre-entry screening.
The number of variables included in the risk factor analysis was limited as the data used
was primarily collected for operational and not epidemiological purposes. Information
on risk factors for tuberculosis, including potentially important exposures such as social
deprivation, HIV, immunosuppressive drugs and social risk factors such as history of
drug use or imprisonment were not available to include in these analyses.(118–124)
Unmeasured confounding may therefore also explain discrepancies in the rates of
tuberculosis found by the pre-entry screening process and WHO estimates of disease.
Drug sensitivity testing on culture positive samples was recorded in very few cases, and
there were a low number of clinically confirmed cases, limiting the conclusions that can
be drawn on the basis of these data. Over half of the migrants in this analysis came from
Pakistan, and as a result the risk factor analysis will be influenced highly by factors
found to be important in this population, but not measured in this study such as
overcrowding, poverty, and language spoken.(125–127) No data were available on the
site of diagnosed disease, and therefore it was not possible to provide prevalence
estimates for pulmonary or extra-pulmonary disease.
3.5.2 Strengths and weaknesses in relation to other studies
The updated meta-analyses comparing overall cases of active tuberculosis identified by
this pre-entry programme demonstrates that compared to 10 other published studies, the
estimates of prevalence of screening (detected by any method) presented here were
lower than all other studies except one.(102) There are several potential explanations for
this finding including the fact that descriptions of how cases were identified and
classified as having tuberculosis in these other published studies was not always clear,
therefore limiting the ability to make strong comparisons.(128) An updated meta-
analysis including only culture confirmed cases of tuberculosis found that there was
only evidence that two countries (Bangladesh and Pakistan) had a lower prevalence of
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culture confirmed tuberculosis in migrants screened pre-entry when compared to other
published studies that had presented data that allowed stratification into subgroups by
WHO population prevalence estimates of tuberculosis. As Bangladesh and Pakistan
accounted jointly for over 80% of all migrants in the study, it is therefore also not
surprising that the combined rate across all countries was highly influenced by these
two countries when combined in this simplistic manner.
Results from this study may differ to previous literature on pre-entry screening for
several additional reasons other than those discussed above. Firstly, the data presented
are for migrants intending to stay in the UK for a minimum of six months, either as a
student, to work, or as a family reunion. An extremely large proportion of migrants
screened were students or young working age adults. No data were available from the
other published studies that would allow adjusted estimates to be compared to take of
differences such as age and socio-economic status. If greater proportion of older
migrants were included in these previously published studies then it is not surprising
that they found a higher prevalence of tuberculosis detected at pre-entry screening
compared to the large number of students in this analysis, who will be younger,
healthier, from a higher socio-economic status (by virtue of the fact they can afford to
study in the UK), all of which reduce their risk of tuberculosis. Secondly, not all other
studies provided exact details of how culture confirmation was performed, and one large
study highlighted the fact that this may not have been uniform across screening
sites.(91) Due to the UK technical instructions, such variability should not be an issue
as once culture testing was introduced it would have been carried out consistently and
continuously by screening centres, and subject to quality assurance inspections by
Public Health England. Finally, the rules used to exclude duplicates in this analysis
were also likely to vary compared to those in other studies. It was not clear from these
other published studies whether repeat screens in an individual were excluded or not
and therefore differences in the way these duplicate screens were handled could also
have accounted for some of the differences found.
3.6 Conclusion
The results of this study provide a comprehensive analysis of the historical data from a
pilot pre-entry screening programme that has been running since 2005. Restricting the
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data to sites where culture testing was routinely performed provides the strongest basis
for which to make recommendations for the improvement of pre-entry screening, as it is
comparable to current processes in the UK technical instructions. There was a great deal
of variation in the prevalence of bacteriologically confirmed tuberculosis by country,
with crude prevalence highest in Cambodia, Eritrea, Somalia and Thailand. Except for
Thailand, prevalence estimates in migrants were lower than WHO country prevalence
estimates, which is likely explained by the fact that migrants to the UK represent a
higher socio-economic group compared to the whole population in the country of origin.
The high number of students is likely to have had a significant influence on the results
presented, as this group had the second lowest of bacteriologically confirmed
tuberculosis. A lack of socio-economic and clinical risk factors within this dataset
limited the ability to explore this issue further. The implications for tuberculosis control,




Accuracy of probabilistic linkage using the Enhanced
Matching System for public health and epidemiological
studies.
4.1 Abstract
Background: The Enhanced Matching System (EMS) is a probabilistic record linkage
program developed by the tuberculosis section at Public Health England to match data
for individuals across datasets. This chapter outlines how EMS works and investigates
its accuracy for linkage across public health datasets.
Methods: To examine the accuracy of EMS, two public health databases were matched
exactly using NHS number as a gold standard unique identifier. Probabilistic linkage
was then performed on the same two datasets without inclusion of NHS number.
Results: Exact matching using NHS number between two datasets (containing 5931 and
1759 records) identified 1071 record pairs. EMS probabilistic linkage identified 1068
record pairs. The sensitivity of probabilistic linkage was calculated as 99.5% (95%CI:
98.9, 99.8), specificity 100.0% (95%CI: 99.9, 100.0), positive predictive value 99.8%
(95%CI: 99.3, 100.0), and negative predictive value 99.9% (95%CI: 99.8, 100.0).
Probabilistic matching was most accurate when including address variables with manual
review, but performed well without manual review, without address information and in
a dataset only containing non-UK born individuals.
Conclusion: The Enhanced Matching System examined in this chapter has been found
to have high accuracy for the linkage of public health datasets that do not contain a
unique identifying variable and in non-UK born individuals.
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4.2 Introduction
The routine collection of electronic health records provides unique opportunities to
investigate important research questions in an efficient and powerful way by linking
individuals across datasets collected by different organisations. Record linkage has been
performed for a number of years in various epidemiological study designs including
case control, cohort studies, capture recapture studies and economic evaluations.(129–
132)
In a majority of studies, three methods have been used to match records between
datasets: Exact matching, deterministic matching, and probabilistic linkage. Exact
matching requires records within the two data sets to contain a universally available and
unique identifying variable. Many databases across health and social care do not contain
such a unique and universally available variable, or accurate and fully available
personal identifiable information, limiting the ability to perform exact matching.
Deterministic matching is defined as: “Record linkage of two (or more) files based on
exact agreement of matching variables”(133) and has many variants, but typically
contains a series of rules to identify record pairs using combinations of personal
identifiers such as first name, surname, date of birth and sex. Probabilistic linkage is
defined as: “Record linkage of two (or more) files that utilizes the probabilities of
agreement and disagreement between a range of matching variables”.(133)
The Enhanced Matching System (EMS) is a probabilistic record linkage program
developed to combine data for individuals across datasets or within a single dataset for
the purposes of de-duplication. EMS was developed over several years and can be
configured with ease for different matching projects.
EMS was designed and developed by the tuberculosis section at Public Health England
and builds upon the classic methods described by Newcombe.(134,135) EMS is used
operationally by the tuberculosis section in Public Health England for many types of
analysis including measuring the levels of drug resistance in tuberculosis cases notified
in the UK, and establishing the amount transmission among these cases.(136)
Historically, probabilistic linkage has been necessary for this work due to the low
recording rates of a unique identifier between the two datasets (Case notifications of
tuberculosis to Public Health England and culture positive isolates from tuberculosis
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reference laboratories across UK) used to establish these estimates. These datasets are
probabilistically linked and de-duplicated to form the Enhanced Tuberculosis
Surveillance (ETS) database.
A potential new application of EMS is to use it for linking data on individuals entering
the UK that have been screened by the pre-entry tuberculosis screening programme. At
present the pre-entry screening database does not contain a unique identifying variable
such as NHS number, and therefore any linkage must be performed using variables such
as first name, surname, date of birth and sex. The accuracy of EMS linkage has not been
previously investigated. This chapter outlines the main features of EMS and presents an
analysis that examines its accuracy at matching two public health tuberculosis datasets.
4.3 Methods
4.3.1 Enhanced Matching System
EMS is a configurable Microsoft SQL Server database program, currently implemented
on Windows 7 and SQL Management studio 2012 and written using the Transact-SQL
programming language. The first step in using EMS is data mediation, whereby
variables are converted into a pre-specified EMS table structure. To increase the
accuracy of the matching, data are then standardised by splitting and parsing of
forenames, postcodes, date of birth and addresses, cleaning of country and hospital
names when available (for example, through the removal of erroneous spaces at the
beginning or end of these country or hospital names), and generating Soundex codes (an
algorithm generated index based on the way a name sounds(137)) for name variables.
Address information, where available, is split into house or flat number, street name,
town or city, postcode and country. EMS is capable of undertaking de-duplication, but
this is not discussed in this chapter.
Pairing and blocking is used by EMS to improve the efficiency of the matching process
by reducing the number of comparisons required. Depending on available fields within
the databases to be matched, blocking involves EMS breaking the records into smaller
blocks in three ways: records having the same surname soundex, year of birth, or
postcode area. Data are then grouped (or blocked) and links within these groups are
examined. Blocks are combined at the end of the linkage using the SQL command
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‘UNION’ that removes any duplicate pairs and merges data into a final single output
table. Blocking reduces the number of record comparisons between two datasets. Three
way blocking is used because, for example, if year of birth is missing for one record
pair, this record pair will still be linked in one of the other two blocks (surname soundex
or postcode district) as long as data are also not missing on these variables in both
datasets.
Probabilistic linkage relies on the generation of weights to identify agreements and
disagreements between the identifying set of fields in two datasets.(138) EMS generates
a weight for matching fields based on the m probability (the probability that the
matching variable agrees given that the comparison pair being examined is a
match(133)) and the u probability (the probability that a matching variable agrees given
that the comparison pair being examined is a non-match(133)). For example, the
probability of random agreement for month of birth in two records that are not a true
match is approximately 0.08 (or 1/12), which corresponds to the u probability. The m
probability depends mainly on the data quality for a matching field. A typical m
probability, for an outcome of agreement, is around 0.9 indicating that 90% of matches
(for two records are in fact a true match) will have the same value for this matching
field. The m probabilities at the start of a matching project are estimates, and several
matching runs can be performed within EMS in order to refine values.
Weights are then calculated for each matching field in a pair of records, depending on
whether they agree or disagree (Equation 1). The weight for each possible matching pair
field is the logarithm to the base 2 (log2) of the likelihood ratio. Logarithms to the base
2 are used in probabilistic linkage as per information theory convention.(139)
ܹ = logଶ ൬݉݌ݎ݋ܾܾ݈ܽ݅݅ݐݕݑ݌ݎ݋ܾܾ݈ܽ݅݅ݐݕ൰
Equation 1. Formula for calculating individual weights for agreed matches. The m
probability and u probability are replaced by (1 – m probability) and (1- u
probability) for disagreement matches.
A weight of zero is used when one or both of the fields have missing or unknown
values. Where the m probability is greater than the u probability, the weight is positive,
and where the 1 – m probability is less than the 1 – u probability then the weight is
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negative. Therefore agreements are generally positive and disagreements generally
negative. EMS carries out matching across multiple fields under the assumption that
they are independent. A total weight is obtained for all matching fields in each record
pair, as per Equation 2. The logs for individual weights are summed, a process
equivalent to multiplying the likelihood ratios.
ܹ = ෍ ௜ܹ
Equation 2. Formula for calculating total weight for a record pair
The prior probability of a random pair matching is then calculated (Equation 3(134))
and a threshold is calculated (Equation 4 adapted from the work by Newcombe(134)),
above which a record pair is considered matched, using a pre-specified positive
predictive value. This threshold is calculated independently of the blocking and is
therefore based on all possible pairs, and not the actual number of pairs compared
during the matching process.
ܲ(ܯ) = ݉݊
where:
m = estimated number of matches
n = possible matching pairs = (n1 ∙ n2) / z
n1 and n2 = dataset sizes (obtained directly from the data)
y = number of years
z = correction factor for restrictions on matching, and where z =1 – ݈݈ܽ݉ܽݐܿℎ݁ݏ݈݈ܽ݋ݓ݁݀(݅. ݁.݊݋݂݂݁݁ܿݐ);
or
ݕଶ(2ݕ − 1) ≈ ݕ2 – ݉ܽݐܿℎ݁ݏݎ݁ݏݐݎ݅ܿݐ݁݀ݐ݋ݓ݅ݐℎ݅݊1ݕ݁ܽݎ;
or
ݕ– ݉ܽݐܿℎ݁ݏ݂ݑݎݐℎ݁ݎݎ݁ݏݐݎ݅ܿݐ݁݀ݐ݋ݏ݈݅݊݃݁ܿ݋ݎ݁ݕ݁ܽݎ.
Equation 3. The prior probability of a random pair matching
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ܶℎݎ݁ݏℎ݋݈݀ = logଶ ൬ܲ(ܷ)ܲ(ܯ)൰+ logଶ ൬ ݌݌ݒ1 − ݌݌ݒ൰
ܲ(ܷ) = ݌ݎ݅݋ݎ݌ݎ݋ܾܾ݈ܽ݅݅ݐݕ݋݂݊݋ݐ݉ܽݐܿℎ݅݊݃ = 1 – ܲ(ܯ)
ppv = positive predictive value, the probability that record pairs with a
total weight above the threshold are truly matches and is specified by the
user performing the matching.
Equation 4. Threshold formula
Records below the threshold are considered unmatched and human (manual) review can
then be carried out to examine matches close to this threshold (above and below) in
order to identify false positives and false negative.
4.3.2 Accuracy of EMS
Two datasets were used to examine the accuracy of EMS: case notifications of
tuberculosis to Public Health England and a laboratory database of all bacteriologically
confirmed isolates from tuberculosis reference laboratories from England, Wales and
Northern Ireland. Case notifications are made to Public Health England by healthcare
workers looking after patients with tuberculosis and include demographic and clinical
details of cases. The laboratory database contains basic demographic, address
information as well as mycobacterial species and drug susceptibility testing results for
positive tuberculosis specimens. It should be noted that the case notifications dataset
referred to in this chapter is not the same as what is referred to as ETS throughout the
rest of the thesis. Instead, the linkage between the two datasets described in this chapter
(case notifications and laboratory data) is part of what ultimately contributes to forming
ETS. Therefore the case notifications data is not referred to as ETS throughout this
chapter.
All case notifications with a NHS number for the calendar year 2012 were used for this
analysis, along with all laboratory database records with an NHS number for the period
1st October 2011 – 31st March 2013. Laboratory database records for the three months
before and after the calendar year of 2012 were included as tuberculosis cases may be
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notified before or after the microbiological result. This strategy therefore aims to
increase the number of possible matches across the two datasets. The laboratory
database was de-duplicated (by linking to itself using EMS) before it was linked to the
case notifications database.
4.3.3 Gold standard comparator
Exact matching using NHS number was used as a gold standard to identify linked
records. NHS number is a ten digit unique identifier for a patient and is used throughout
the health service. It is often formatted 3-4-4, with separating space or hyphen (e.g. 123-
4567-8901). NHS numbers included in the final analysis as the gold standard were
checked for validity. Simple descriptive analysis was performed to examine differences
between tuberculosis notification and laboratory isolate records with and without NHS
numbers.
4.3.4 Probabilistic matching
After exact matching, case notifications and the laboratory database were
probabilistically linked by EMS using first name, surname, date of birth, sex, address
details (including postcode) data, first name soundex and surname soundex. NHS
number was not included as a matching variable in the probabilistic linkage in order that
the matching was independent of this gold standard identifier. Blocking was performed
on surname, year of birth and postcode. A descriptive analysis stratified by NHS
number availability and validity was performed to examine missing data on variables
used for the linkage from the laboratory and case notifications datasets. All records
except for those with a missing or invalid NHS number were included in the accuracy
analysis.
The matching threshold was calculated using a value of y=1 and ppv =0.99. A decision
was taken a-priori to manually review records with a matching score of 10 above and
below the matching threshold. As probabilistic linkage was performed without
including NHS number as matching variable, manual review included all records
regardless of whether or not they were exact matched by NHS number. Manual review
was also performed without data on NHS number for each record pair.
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4.3.5 Primary outcomes and statistical analysis
Outcomes used to assess accuracy of the matching process were sensitivity, specificity,
positive and negative predictive values. A full description of how these were calculated
is provided in Table 33 in Appendix 6. Exact confidence intervals (to the 95% level)
were calculated in Stata version 13 using a binomial distribution.
4.3.6 Sensitivity analyses
Four sensitivity analyses were carried out. Firstly, probabilistic linkage was performed
using first name, surname, date of birth, sex, address details (including postcode), first
name soundex, and surname soundex but without manual review. Secondly,
probabilistic linkage was performed without address variables and without manual
review. Thirdly, to examine the effect that a larger proportion of non-English names
would have on the accuracy, matching was performed without address variables and
manual review, but in a case notifications dataset that only included non-UK born
individuals. This analysis most closely replicates the linkage that would be performed
between ETS and IOM pre-entry screening data. Fourthly, a sensitivity analysis was
carried out to determine the impact of varying the automatically calculated weight
threshold on outcome measures without manual review, but including all matching
variables except NHS number.
4.3.7 Ethics approval
Ethical approval was not required for this accuracy analysis, as Public Health England
has Health Research Authority approval to hold and analyse national surveillance data
for public health purposes under Section 251 of the NHS Act 2006.
4.4 Results
A total of 8,751 records were extracted from the case notifications dataset and 7,538
unique records from the laboratory database. 67.8% of case notifications and 23.3% of
the laboratory database records contained valid NHS numbers. Comparing the
characteristics of records with and without valid NHS number in the laboratory dataset
showed differences in age and higher rates of Isoniazid resistance in those records
without an NHS number (Table 9). No other differences were found.
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A greater number of differences were seen between those records with and without a
valid NHS number in the case notifications dataset. All variables apart from those for
drug sensitivity testing and site of tuberculosis disease showed a difference between
those with and without an NHS number (Table 10). These data show that women, ethnic
minority groups, individuals not born in the UK, and individuals with at least one social
risk factor for tuberculosis (including drug use, homelessness, alcohol misuse/ abuse,
prison) were more likely not to have an NHS number.
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Table 9. Descriptive analysis of laboratory dataset for records with and without an
NHS number.
NHS Number
Available and valid Not available or invalid
All N % N % p-value*
All 7538 1759 23.3 5779 76.7
Age group in years
0 to 14 122 40 32.8 82 67.2
15 to 44 4724 990 21.0 3734 79.0
45 to 64 1576 409 26.0 1167 74.0
65 and over 1061 320 30.2 741 69.8 <0.001
Missing** 55 0 0 55 100.0
Sex of case
Female 2941 726 24.7 2215 75.3
Male 4355 1012 23.2 3343 76.8
Missing 242 21 8.7 221 91.3 0.15
Isoniazid sensitivity result
Resistant 508 95 18.7 413 81.3
Sensitive 6801 1629 24.0 5172 76.0
Missing 229 35 15.3 194 84.7 0.007
Ethambutol sensitivity result
Resistant 84 19 22.6 65 77.4
Sensitive 7217 1699 23.5 5518 76.5
Missing 237 41 17.3 196 82.7 0.84
Rifampicin sensitivity result
Resistant 142 29 20.4 113 79.6
Sensitive 7181 1697 23.6 5484 76.4
Missing 215 33 15.3 182 84.7 0.37
Pyrazinamide sensitivity result
Resistant 108 26 24.1 82 75.9
Sensitive 7161 1690 23.6 5471 76.4
Missing 269 43 16.0 226 84.0 0.91
*Chi squared test, not including missing data for each variable other than NHS number
**It was not possible to calculate the exact age for these records as the date of their laboratory result was
not recorded, but date of birth was available for all records.
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Table 10. Descriptive analysis of case notifications dataset for records with and without
an NHS number.
NHS Number
Available and valid Not available or invalid
All N % N %
p-
value*
Total 8751 5931 67.8 2820 32.2
Age
<14 414 277 66.9 137 33.1
15-44 5291 3495 66.1 1796 33.9
45-64 1830 1273 69.6 557 30.4
65+ 1216 886 72.9 330 27.1 <0.001
Sex
Female 3706 2619 70.7 1087 29.3
Male 5045 3312 65.6 1733 34.4 <0.001
Ethnic group
White 1814 1316 72.5 498 27.5
Black-Caribbean 175 121 69.1 54 30.9
Black-African 1358 859 63.3 499 36.7
Black-other 71 41 57.7 30 42.3
Indian 2295 1471 64.1 824 35.9
Pakistani 1418 1098 77.4 320 22.6
Bangladeshi 320 194 60.6 126 39.4
Chinese 95 67 70.5 28 29.5
Mixed/other 979 625 63.8 354 36.2
Missing 226 139 61.5 87 38.5 <0.001
UK Born
No 6125 4049 66.1 2076 33.9
Yes 2256 1652 73.2 604 26.8
Missing 370 230 62.2 140 37.8 <0.001
Site of disease
Extra-pulmonary
disease only 4095 2754 67.3 1341 32.7
Pulmonary, with or
without extra-
pulmonary disease 4563 3128 68.6 1435 31.4
Missing 93 49 52.7 44 47.3 0.20
Social risk factor **
No 7683 5210 67.8 2473 32.2
Yes 637 390 61.2 247 38.8




Sensitive 4801 3206 66.8 1595 33.2
Resistant 351 235 67.0 116 33.0
Missing 3599 2490 69.2 1109 30.8 0.95
Ethambutol sensitivity
result
Sensitive 5087 3396 66.8 1691 33.2
Resistant 51 35 68.6 16 31.4
Missing 3613 2500 69.2 1113 30.8 0.78
Rifampicin sensitivity
result
Sensitive 5060 3377 66.7 1683 33.3
Resistant 91 63 69.2 28 30.8
Missing 3600 2491 69.2 1109 30.8 0.62
Pyrazinamide sensitivity
result
Sensitive 5043 3364 66.7 1679 33.3
Resistant 45 33 73.3 12 26.7
Missing 3663 2534 69.2 1129 30.8 0.35
*Chi squared test, not including missing data for each variable other than NHS number
**At least one social risk factor including drug use, homelessness, alcohol misuse/ abuse, prison
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Table 11. Description of missing data on variables used for the linkage from the
laboratory, case notifications and an example pre-entry screening dataset, by
NHS number availability and validity.
Missing data for linkage variables
NHS number available and
valid
NHS number not available or
invalid
N % N %
Laboratory dataset
All 1759 100% 5779 100%
First name 1 0% 13 0%
Surname 1 0% 0 0%
Date of birth 0 0% 0 0%
Sex 21 1% 173 3%
Address line 1* 232 13% 4513 78%
Address line 2** 1023 58% 5387 93%
Postcode 126 7% 3939 68%
Case notifications dataset
All 5931 100% 2820 100%
First name 0 0% 0 0%
Surname 1 0% 0 0%
Date of birth 1 0% 1 0%
Sex 0 0% 0 0%
Address line 1* 13 0% 8 0%
Address line 2** 2918 49% 1302 46%
Postcode 6 0% 9 0%
*E.g. house number and street name
**E.g. city.
For assessment of accuracy, only records with an available and valid NHS number were
included in the probabilistic linkage. The final probabilistic linkage dataset therefore
consisted of 5,931 records from the case notifications database and 1,759 records from
the laboratory database (Figure 17). In this final dataset used for the assessment of
accuracy there was one record in the case notification dataset missing surname and date
of birth, but not first name (Table 11). One record in the laboratory dataset was missing
first name and surname information, and no records were missing date of birth. 13
(0.2%) records were missing the first line of their address in the case notifications
database and 232 (15.1%) in the laboratory database. 6 (0.1%) records were missing
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postcode information in the case notifications database, and 126 (7.2%) were missing in
the laboratory dataset. 21 (1.1%) records were missing information on sex in the
laboratory database, and none in the case notifications. With the exception of the
address line 2 (typically city, town, or local area) in the case notifications dataset,
records with a missing or invalid NHS number had slightly higher levels of missing data
than those with a valid and available NHS number.
Figure 17. Flow chart of datasets used for study.
Exact matching between the two datasets using NHS number identified 1,071 matched
pairs. In the case notifications database 4,860 (81.9%) records had no matching pair in
the laboratory database, and 688 (39.1%) records from the laboratory database had no
matching pair in the case notifications database.
Probabilistic linkage of the case notifications database to the laboratory database
identified 1088 linked pairs using the EMS generated threshold of 19.98. Manual
review of 67 pairs with a weight between 10 and 30 resulted in two below the threshold
being changed to matches, and three results above the threshold being marked as not
matching. A total of 19 records that represented multiple matches were removed
(without manual review) – the pair with the highest weight was chosen as the final
match to include in the analysis. A total of 1068 matches were therefore identified by
the EMS process after manual review and de-duplication.
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4.4.1 Accuracy of probabilistic linkage
Using the threshold of 19.98, and after manual review of records above and below the
threshold and de-duplication of matches, 1,066 records were identified as true positives
and 5,546 as true negatives (Table 12). At the threshold of 19.98, and with manual
review, there were 2 false positives and 5 false negatives. The false negatives all had the
same date of birth, several had first names and surnames that were switched, sex was
unknown for one case, and all had different addresses. Both false positives had the same
first name, surname, date of birth, sex and address, but different NHS numbers
suggesting an error in the recording of NHS number. The sensitivity of the probabilistic
linkage was 99.5% (95%CI: 98.9, 99.8) and specificity 100.0% (95%CI: 99.9, 100.0).
The corresponding positive predictive value was 99.8% (95%CI: 99.3, 100.0) and
negative predictive value 99.9% (95%CI: 99.8, 100.0).
Table 12. Comparison of matches identified by exact linkage using NHS number, and
the probabilistic linkage process (without NHS number) and with de-
duplication and manual review.
Probabilistic (EMS)
Exact matching (NHS Number)
+ve -ve Total
+ve 1066 2 1068
-ve 5 5546 5551
Total 1071 5548 6619
Note: the total denominator is calculated using the number of exactly linked pairs (1071), plus the 4,860
records in the case notifications database had no matching pair in the laboratory database, and 688
records from the laboratory database had no matching pair in the case notifications database (i.e. 1071 +
4860 + 688 = 6619).
A series of sensitivity analyses were carried out to examine the performance of the
linkage compared to a gold standard using different assumptions (Table 13). Without
manual review, but using all linkage variables except NHS number, sensitivity was
99.3% (95%CI: 98.7, 99.7) and specificity 99.9% (95%CI: 99.8, 100.0). Matching
without NHS number, address variables and manual review resulted in a sensitivity of
97.1% (95%CI: 95.9, 98.0) and specificity 100.0% (95%CI: 99.9, 100.0). To examine
the effect of having a larger proportion of non-English names has on accuracy,
matching was performed without address variables and manual review in a case
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notifications dataset with only non-UK born individuals and found a sensitivity of
96.5% (95%CI: 94.9, 97.8) and specificity 100.0% (95%CI: 99.8, 100.0).
Varying the threshold between a credible range of 10 and 50 resulted in sensitivity
changing from 86.1% (95%CI: 83.9, 88.1) to 99.6% (95%CI: 99.0, 99.9) and specificity
ranging from 99.5% (95%CI: 99.3, 99.7) to 100.0% (95%CI: 99.8, 100.0; Table 14).
The distribution of the weights for the matching process is shown in figure 18, which
presents pairs with a total weight score greater than zero and therefore excludes the very
large number of non-matches. The number of matches increased rapidly after a weight
of around 50 and decreasing rapidly after the mode of 77.
Table 13. Calculation of sensitivity and specificity for probabilistic matching, without
manual review, not including address variables and using a case notification
dataset that only including non-UK born individuals.
Variables used for matching Sensitivity Specificity
All with manual review 99.5% (95%CI: 98.9, 99.8) 100.0% (95%CI: 99.9, 100.0)
All without manual review 99.3% (95%CI: 98.7, 99.7) 99.9% (95%CI: 99.8, 100.0)
No address variables (without
manual review) 97.1% (95%CI: 95.9, 98.0) 100.0% (95%CI: 99.9, 100.0)
No address variables, only
individuals born outside UK
(without manual review) 96.5% (95%CI: 94.9, 97.8) 100.0% (95%CI: 99.8, 100.0)
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Table 14. Sensitivity, specificity, positive predictive value and negative predictive value

















10 1067 1094 5521 99.6% 99.5% 97.5% 99.9%
15 1065 1086 5527 99.4% 99.6% 98.1% 99.9%
20 1064 1069 5543 99.3% 99.9% 99.5% 99.9%
25 1060 1062 5546 99.0% 100.0% 99.8% 99.8%
30 1047 1049 5546 97.8% 100.0% 99.8% 99.6%
35 1022 1024 5546 95.4% 100.0% 99.8% 99.1%
40 987 989 5546 92.2% 100.0% 99.8% 98.5%
45 946 948 5546 88.3% 100.0% 99.8% 97.8%
50 922 924 5546 86.1% 100.0% 99.8% 97.4%
Figure 18. Number of pairs by total weight score, without manual review or de-
duplication and not including NHS number. Only pairs with a total weight
score greater than zero are presented.
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4.5 Discussion
The Enhanced Matching System uses probabilistic linkage that was found to have high
accuracy compared to gold standard exact matching based upon NHS number.
Probabilistic linkage was most accurate when including address variables and using the
automatically generated threshold for determining matches with manual review.
Accuracy remained relatively high even after exclusion of address information from the
linkage process, in linkage without manual review, and in a case notifications dataset
that only included non-UK born individuals. Varying the weight threshold within a
plausible range had minimal impact on the sensitivity and specificity of probabilistic
linkage.
4.5.1 Strengths and weaknesses of this analysis
The characteristics of records in the case notification and laboratory datasets with
missing or invalid NHS numbers were examined. As a result of the lack of demographic
data in the laboratory database, the only differences found were for age and isoniazid
resistance, which has been associated with an outbreak of tuberculosis in homeless,
prison, certain ethnic groups and drug using populations in London.(140) In the case
notifications database there were more differences for records with and without NHS
numbers. NHS numbers were missing for more records in those aged between 15 and
44, males, ethnic minorities, non-UK born and individuals with social risk factors. It is
not surprising that there were greater levels of missing NHS numbers for those with
social risk factors, as these individuals tend to have poorer access and usage of NHS
services.(141)
The dataset used for main analysis, which only included records with a valid NHS
number, comprised of low levels of missing data on linkage variables and is therefore
likely to represent the higher end of accuracy achievable by EMS. The datasets used in
this study contained a high proportion of individuals not born in the UK, and ethnic
minority groups making this analysis relevant to these populations. The sensitivity
analysis examining probabilistic linkage in a case notifications dataset that only
contained UK born individuals without address information found that the accuracy of
EMS remained high. This provides reassurance that a linkage between the IOM pre-
entry screening dataset and ETS would have a high level of accuracy.
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NHS number is a unique identifying variable that is verifiable and reliable, making it an
ideal gold standard comparator. However, it is not always available in public health
datasets, demonstrated by the fact that it was available and valid for only 23.3% of
laboratory database records, and 67.8% of case notification records. The high level of
missing or invalid NHS numbers highlights a strength of probabilistic linkage over
exact matching, in addition to the fact that it is able to account for errors and omissions
of other data on linkage variables. However, the accuracy of probabilistic matching is
still dependent on what identifying variables are available, and the quality of data
contained within these variables. The amount of missing data on linkage variables (e.g.
first name, surname, date of birth, sex and address) for those records with or without a
valid NHS number was similar in the case notifications dataset, but the laboratory
dataset had more missing data in those records without an NHS number. This may mean
that linkage performs less well on such records, but this issue is complicated by the fact
that the laboratory dataset may contain records that should not have an NHS number or
address information (e.g. those isolated from animals). It is therefore difficult to
generalise with certainty, whether linkage to the laboratory records without a valid NHS
number will be lower than those with a valid NHS number.
Not all tuberculosis cases are microbiologically confirmed, and it is therefore not
unexpected that the case notification dataset included more individuals than the
laboratory database. Despite this, it is still possible that some patients recorded in the
laboratory database were not notified as a case of tuberculosis and are therefore not
included in the case notifications dataset. There are many reasons for laboratory records
not to be found in the case notification dataset including those isolated from animals,
cases reported to the case notification surveillance system in subsequent years after
laboratory confirmation, cases of non-tuberculosis mycobacterium, samples positive
due to laboratory contamination, and samples originating from the Channel Islands
which are not notified to the surveillance system.
The accuracy of matching was assessed using a relatively small dataset. Repeating the
analysis on a larger dataset may have some effect on the measures of accuracy found in
this analysis, depending on the frequency of matches between the datasets. For this
analysis, matching was performed between two data sets of the same disease, using
several matching variables including names, date of birth and address data that had low
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levels of missing data, and therefore a high degree of matching is to be expected. In
scenarios where a small sample is being matched into a very large database (such as
national records of hospital attendance) then the positive predictive value or sensitivity
will drop according to the prevalence of the sample within the larger database. This may
lead to overestimation of the frequency of occurrence of the sample within the larger
database. If this linked dataset was used to calculate incidence or prevalence of an
outcome, such a bias within the linked dataset would result in estimates were higher
than the true values.(133)
Manual review of matches introduces subjectivity into the matching process and this
may have implications for repeatability of this part of the linkage. Additionally, as the
treating tuberculosis clinician does not perform the manual review (as is usually the
case), those performing manual review were quite removed from the clinical situation
and this may bias results. Such human error is likely to be differentially (and not
randomly) biased. Further work should be carried out to assess the impact of the
subjectivity of the manual review process, and examine the applicability of developing
rules to provide consistent and potentially unbiased results.
4.5.2 Strengths and weaknesses in relation to other studies
When used for epidemiological studies, errors in probabilistic linkage have the potential
to impact on findings and conclusions drawn. Linkage is typically used for the
generation of outcome data in cohort studies, for example, to determine the vital status
for individual participants by matching data into death registries. Assuming there is
non-differential misclassification bias of exposure variables, false positive links will
bias risk ratios and risk differences towards the null.(133,142,143) Risk ratios will be
unaffected by false negative results (assuming there is non-differential misclassification
bias); however, risk differences in cohort studies will be biased towards the null. False
positive and negative probabilistic links in public health surveillance or outbreak studies
will also result in under or over estimation of the number of cases. We are not aware of
studies that have analysed this directly, but capture recapture studies attempt to examine
this issue and in the UK have demonstrated the utility of the probabilistic linkage for
improving data quality and case ascertainment levels.(144)
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For this study, there were insufficient numbers of false positive and false negative
results to enable examination of the issue of misclassification bias further, however, the
fact that there was very high sensitivity and specificity means misclassification should
introduce minimal bias. Further research is needed to understand the implications of
these misclassification biases, particularly when such analyses are being conducted to
estimate disease incidence or prevalence.
Probabilistic linkage has been widely adopted in research and service public health
analyses. Several studies have previously examined the accuracy of probabilistic
linkage using datasets ranging in size from 250 to 3,131,176 records. (145) Findings in
these studies are consistent with the results presented in this analysis, with sensitivities
ranging from 86% (database sizes: 250 records with N of second dataset not published
(146)) to 99.2% (database sizes: 6,000 records in both(147)), and specificity ranging
from 99.4% (database sizes: 6,000 records in both(147)) to 100% (database sizes: 822
and 450(148)). Variation in these results may be due to algorithms used for probabilistic
linkage, as well as characteristics of the datasets such as the rates of missing data, errors
and omissions which impact on the results.
4.6 Conclusion
EMS was demonstrated to have high accuracy for the linkage of public health datasets.
With the establishment of national electronic datasets across health and social care, the
accuracy of this software enables previously unanswerable research questions to be
tackled.(149–151) Probabilistic linkage has great potential to be used where exact or
deterministic linkage isn’t possible, including in low-income settings, and for
vulnerable populations, where the absence of unique identifiers has historically hindered
the ability to identify individuals across separate datasets in order to establish outcomes
or exposures as required by many types of epidemiological study design. This analysis
provides reassurance that the Enhanced Matching System can be appropriately used to
link a dataset of pre-entry screened migrants to the UK national tuberculosis
surveillance system using first name, surname, date of birth, nationality and sex as
matching variables.
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Incidence of tuberculosis in migrants screened pre-entry after
arrival in England, Wales and Northern Ireland: a
retrospective cohort study.
5.1 Abstract
Background: UK tuberculosis surveillance data in their current configuration allow only
a period prevalence of tuberculosis to be calculated in individuals not born in the UK.
Probabilistic matching can be used to identify incident cases of disease and missed
prevalent cases, among individuals screened by the pre-entry programme.
Methods: A database of migrants screened pre-entry between 1st January 2006 and 31st
December 2012 was probabilistically linked to ETS notifications during the period 1st
January 2006 and 31st December 2013. A cohort study was performed, incidence rates
were estimated and a multivariable risk factor analysis conducted.
Results: 519,955 migrants entered the cohort. There were 622 cases of bacteriologically
confirmed pulmonary tuberculosis with an estimated incidence rate of 65 cases per
100,000 person years at risk (95%CIs: 60, 70). After adjusting for age and sex, there
was strong evidence that a history of contact with a case of tuberculosis before
migration (IRR 4.9; 95%CIs: 2.5, 9.4; p-value <0.001) and a chest radiograph classified
as consistent with tuberculosis at migration (IRR 4.4; 95%Cis: 3.5, 5.5; <0.001) were
associated with an increased risk of bacteriologically confirmed pulmonary tuberculosis
in the UK.
Conclusion: Several novel findings are presented, including the first time direct
estimates of the incidence of tuberculosis in a high-risk population that has been
screened for active pulmonary disease prior to arrival.
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5.2 Introduction
The UK pre-entry screening of migrants aims to detect prevalent cases of active
tuberculosis at the time of migration.(7) Individuals moving to the UK from countries
with a prevalence of tuberculosis greater than 40 per 100,000 are likely to remain at
higher risk of developing active disease after migrating through reactivation of infection
acquired abroad. Migrants are also likely to be at higher risk of acquiring tuberculosis
and developing active disease in the UK due to other risk factors that are common in
new entrants including poor housing, behavioural and lifestyle factors or
immunosuppression due to HIV.(74–76)
UK surveillance data in their current configuration allow only a period prevalence of
tuberculosis to be calculated in individuals not born in the UK.(136) Self-reported data
on country of birth was known in 97% (7,632/7,892) of tuberculosis cases notified in
2013, and 72% (5,529/7,632) of these individuals were born outside the UK. The
notification rate of tuberculosis in migrants was 18 times higher than the rate in the UK
born, at 70 per 100,000. Time since entry into the country was known for 91% of cases
among individuals not born in the UK, and 44% of cases were diagnosed within five
years of entering the country. Data were only available on country of birth for non-UK
born migrants, and not the country of migration, which, depending on migration
patterns may have an important impact on the subsequent risk of developing active
tuberculosis.
Follow-up of migrants for epidemiological and public health purposes after entering the
UK has not previously been possible as no dataset existed to facilitate this process.
Therefore, it has not been possible until now to calculate the incidence of active
tuberculosis post-migration or the risk factors associated with these incident cases. Such
data would be helpful for several reasons. Firstly, removing prevalent cases from
estimates of incidence after arrival in the UK enables more accurate estimates to be
made as well as the ability to explore risk factors for newly developed cases. Secondly,
it would enable more accurate estimates of the burden of disease within migrant
populations. Instead of reporting data by country of birth, it is possible to estimate rates
by country of migration, which more accurately reflects the risk of disease particularly
if, for example, an individual was born in a low incidence country, but migrated to the
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UK from a high incidence country (or vice versa). Thirdly, incidence data has the
potential to improve the pre-entry screening programme, by identifying groups that may
be an appropriate target for latent tuberculosis screening. Finally, a linked dataset that
enables follow up of pre-entry screened migrants in the UK also has a role in quality
assurance by identifying potential “missed prevalent” cases at pre-entry screening that
were notified very shortly after migration. Probabilistic matching, as described and
validated in the previous chapter, can be used to identify incident cases of disease (and
missed prevalent cases) notified in the UK among individuals screened by the pre-entry
programme. Linking these two datasets would enable the estimation of incidence of
tuberculosis among migrants as well as the risk factors associated with these cases.
5.2.1 Research questions:
The analysis presented in this chapter aims to answer the following research questions:
1. What is the incidence of tuberculosis in migrants screened pre-entry?
2. What are the risk factors for incident cases of tuberculosis notified in migrants
screened pre-entry?
5.3 Methods
5.3.1 Study design and setting
This study was a retrospective cohort in migrants to the UK. Between 2005 and April
2013 the International Organisation of Migration (IOM) conducted a pilot pre-entry
screening programme in 15 countries with a tuberculosis prevalence of greater than 40
per 100,000 population. Individuals from these 15 countries were screened for active
tuberculosis according to the UK technical instructions described in Chapter 3.(152)
Individuals undergoing pre-entry screening consented to their data being shared with the
UK government agencies including UK immigration authorities, the UK Department of
Health, Public Health England and the UK National Health Service.
5.3.2 Outcomes
The primary outcomes for this study were:
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1. Incidence of all cases of tuberculosis notified to the Enhanced Tuberculosis
Surveillance system.
2. Incidence of bacteriologically confirmed pulmonary tuberculosis.
3. Incidence of bacteriologically confirmed extra-pulmonary tuberculosis.
The secondary outcomes for the study were:
1. Incidence of pulmonary tuberculosis
a. Confirmed by culture testing on liquid or solid media
b. Confirmed by microscopy for acid fast bacilli (AFB)
c. Resistant to at least one first-line drug (isoniazid, rifampicin,
pyrazinamide & ethambutol)
2. Incidence of extra-pulmonary tuberculosis
a. Confirmed by culture testing on liquid or solid media
b. Resistant to at least one first-line drug (isoniazid, rifampicin,
pyrazinamide & ethambutol)
WHO reporting definitions are used to define bacteriologically, pulmonary and extra-
pulmonary cases.(109) A bacteriologically confirmed case is one “from whom a
biological specimen is positive by smear microscopy, culture or WHO-approved rapid
diagnostics (such as Xpert MTB/RIF)”. Pulmonary tuberculosis (PTB) is: “any
bacteriologically confirmed or clinically diagnosed case of tuberculosis involving the
lung parenchyma or the tracheobronchial tree. Miliary tuberculosis is classified as PTB
because there are lesions in the lungs. Tuberculosis intra-thoracic lymphadenopathy
(mediastinal and/or hilar) or tuberculosis pleural effusion, without radiographic
abnormalities in the lungs, constitutes a case of extra-pulmonary tuberculosis. A patient
with both pulmonary and extra-pulmonary tuberculosis should be classified as a case of
PTB”. Finally, extra-pulmonary tuberculosis refers to: “any bacteriologically confirmed
or clinically diagnosed case of tuberculosis involving organs other than the lungs, e.g.
pleura, lymph nodes, abdomen, genitourinary tract, skin, joints and bones, meninges”.
The Enhanced Tuberculosis Surveillance system contains data on all cases notified in
Cases in England, Wales and Northern Ireland. All ETS notified cases of tuberculosis
meet the following criteria, as defined by Public Health England: “All new tuberculosis
cases that meet one of the two following case definitions Culture confirmed case due to
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M. tuberculosis complex (including M. tuberculosis, M.bovis, M. africanum or
M.microti). In the absence of culture confirmation, a case that meets the following
criteria: a clinician’s judgement that the patient’s clinical and/or radiological signs
and/or symptoms are compatible with tuberculosis, AND a clinician’s decision to treat
the patient with a full course of anti- tuberculosis therapy. The requirement to notify
applies if there is reasonable ground for suspecting that a patient has died with, but not
necessarily from, active tuberculosis (including post mortem diagnoses). Notification
requirement applies also to UK residents who are diagnosed abroad but continue with
their anti-tuberculosis therapy in the UK and to non-UK residents diagnosed in the UK,
even if anti-tuberculosis therapy is not initiated in the UK.”(153)
5.3.3 Data sources and linkage
Two data sources were used for this analysis: 1) The IOM database of migrants
screened pre-entry between 1st January 2006 and 31st December 2012; and 2) ETS
notified cases between 1st January 2006 and 31st December 2013. These two datasets
were probabilistically linked using the enhanced matching system described in chapter 4
using first name, surname, date of birth, nationality and sex as matching variables.
Cleaning and consistency checking of the final dataset was undertaken by examining
the distribution of variables, the range of individual variables, and missing data.
5.3.4 Censoring
Migrants entered the cohort upon receiving a certificate of medical clearance after pre-
entry screening at IOM clinics. Individuals were followed up until the first of
tuberculosis, death, or emigration. Primary and secondary outcomes were identified
through probabilistic linkage of the cohort of migrants screened by IOM to ETS.(136)
5.3.5 Exclusions
Any primary and secondary outcomes occurring within 90 days of the issue of a
medical certificate of clearance were assumed to be prevalent cases that were missed by
pre-entry screening. These cases were therefore excluded for all primary or secondary
outcomes. This assumption was examined further in a sensitivity analysis.
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5.3.6 Duplicates
Individuals screened pre-entry may have multiple records on the IOM screening
database. Duplicate records were analysed on the basis of whether they occurred within
12 months of each other or not. 12 months was chosen to distinguish duplicates on the
basis that this period of time was long enough to capture individuals who were found to
have tuberculosis on their first screen, and were undergoing repeat screening for visa
clearance, but not too long a time period such that tuberculosis risk factors (as described
in the previous section) would have changed significantly between screens.
Duplicates within 12 months:
Rules used to determine whether duplicate records within 12 months were included in
the cohort or not are provided in Table 15. Individuals with a positive first and second
screen would not have received a medical certificate of clearance, and therefore will
never have been able to enter the UK and are excluded from this analysis. Migrants with
a positive first screen and negative second screen are likely to have undergone
treatment, been rescreened and found to be clear and will then have been able to enter
UK. Therefore the first screen is excluded, but the second included in the cohort.
Migrants with a negative first screen and positive second are unlikely to have entered
the UK due to short time period involved. These records are likely to represent
individuals who weren’t able to get their visa processed within six months of the initial
clearance and on repeat screening were found to be positive. They are therefore all
excluded. Records negative on both screens are likely to be individuals who weren’t
able to get their visa processed within six months of the initial clearance and therefore
the first is excluded, but the second is included.
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Table 15. Rules for dealing with duplicate screens less than 12 months apart.




+ve Exclude all Exclude all





Duplicates greater than 12 months apart:
Rules used to determine whether duplicate records occurring more than 12 months apart
were included in the cohort analysis are provided in Table 16. Individuals with a
positive first and second screen will not have been given a medical certificate of
clearance, and therefore will never have been able to enter the UK. All these records are
therefore excluded. Records with a positive first screen, but negative second screen are
likely to represent migrants reapplying after treatment because their initial screen was
positive. Therefore the first screen is excluded but the second included. Migrants with
the negative first screen, but positive second screen are allowed to enter the cohort after
the first screen but are censored one month prior to the second screen, and the second
screen is excluded. Records with negative first and second screen could represent a
variety of different scenarios, including: 1) individuals that have visited the UK and are
reapplying for a new visa having returned to their country of origin after their initial
visa ran out; and 2) individuals reapplying because their medical clearance ran out in
the time they were able to get their visa application processed (clearance certificates are
only valid for 6 months). These individuals are therefore allowed to enter the cohort
after each screen, but are censored one month prior to the next screen to allow for return
to the country of origin.
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Table 16. Rules for dealing with duplicate screens greater than 12 months apart.




+ve Exclude all 1st: Include and censor at 1 month






1st: include and censor at 1 month
prior to 2nd screen
2nd: Include
5.3.7 Sample size
Before access to the IOM database was granted, it was assumed there would be 350,000
individuals eligible for this study with an estimated length of follow up 1,040,000
person years. It was estimated that incidence rates in individuals from high, medium and
low risk countries (defined as 300, 150 and 40 cases per 100K person years
respectively) would be calculated with the following confidence intervals: 300: 95% CIs
294-306; 150: 95% CIs 142-158; and 40: 95% CIs 32-48.
5.3.8 Confounding variables and risk factors
Age and sex were considered a-priori as confounding variables. Risk factor variables
from the IOM dataset included: visa category, contact with a case of tuberculosis, CXR
classification at pre-entry screening, whether a migrant was screened at a clinic where
culture testing of sputum samples was performed, and WHO prevalence estimates of
tuberculosis in the country of origin. WHO prevalence was used to stratify countries
estimates, rather than incidence estimates, for consistency with Chapters 2 and 4 of this
thesis.
5.3.9 Statistical analysis
Baseline descriptive statistics of the cohort were provided using simple counts and
proportions. To account for the uncertainty of death, migration to Scotland and
emigration, multiple imputation was performed. External data were used to inform the
imputation models as described in the following two sections. Ten imputed datasets
were created. Individual imputed datasets were analysed using Poisson regression, a
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suitable method for modelling rare event data, and estimates of crude and adjusted
incidence rates for the primary and secondary outcomes were calculated. A
multivariable Poisson regression model was used to identify risk factors for the primary
outcomes. All results were adjusted for clustering by individual, to take account of
repeated entries by migrants into the cohort. The results of the analyses from individual
imputed datasets were then combined using Rubin’s rules; these appropriately account
for uncertainty in the imputed information. Final results were presented as incidence
rate per 100,000 person years at risk, incidence rate ratios, 95% confidence intervals
and p-values. Stata v.13 (Statacorp LP, College Station, TX, USA) was used for all
statistical analyses.
5.3.10 Migration out of the country
No data were available to be able to determine how long each individual migrant
screened pre-entry was able to stay in England, Wales and Northern Ireland. It was
therefore necessary to impute data on length of stay, and hence time at risk of being
notified as a case of tuberculosis was based on visa category that was collected at the
time of pre-entry screening. Lengths of stay were imputed using data on UK entry
clearance visas, which details length of stay by type of visa and year of issue.(154)
These data have high coverage for all visas issued outside the UK to non-EEA nationals
who are subject to immigration control and require a visa to enter the UK. These data
includes the number of visas issued, by year and by duration of stay (0-3mths, 3-6mths,
6mths-1yr, 1-2yrs, 2-3yrs, 3-4yrs, 4+yr). For the purposes of imputation, visas were
grouped into four categories: total; work; study; or student visitor (which relates to
individuals attending short courses for a period of less than one year). The “total”
category excluded visitor and transit visas, but included all other categories including
work, both types of study, family reunion, dependant’s joining or accompanying
individuals already in the UK, and other rarer visa types. The proportion of study and
student visas that were issued for short courses is detailed in Table 17.
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IOM pre-entry screening data had the following visa type categories: family reunion,
settlement, work, working holiday, students and other. Table 18 shows how IOM visa
categories were matched to visa duration data. Imputation assumed that migrants
remained in England, Wales and Northern Ireland for the duration of the visa issued.
Table 18. Rules for imputing visa duration
IOM visa category Visa duration data
category
Imputation rule
Family reunion Included in “total” Assume these stay for the duration of the
cohort analysis.
Settlement Included in “total” Assume these stay for the duration of the
cohort analysis.
Students Study and short study (i) Select long/short course according to
probabilities in Table 17.
(ii) Then impute from either the study or
short-course study distribution.
Work Work Impute from work distribution.
Working holiday Work Impute from work distribution, restricting
to categories < 2yrs (working holidays are
maximum 2yrs)
Other Included in “total” Impute from overall distribution
The distributions of visa duration over time provide data for the imputation of length of
stay. Figures 19-22 show the distribution of the duration of visas issued over time by
visa category, from 2005 to 2012. Overall (Figure 19), fewer long-term (4+yrs) visas
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were issued from 2009, with a corresponding increase short-term (3mths-1yr) and mid-
long-term visas (3-4yrs). For work visas, fewer long-term visas (4+yrs) have been
issued since 2009. The duration of study visas has stayed broadly similar over time,
whereas the short course study visas for 0-3mths were not issued in recent years.
Figure 19. Changes in the distribution of all visa durations over time.
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Figure 21. Changes in distribution of study visa duration over time
Figure 22. Changes in distribution of short study visa duration over time
The distributions in the visa issue data provide an imputed visa category for length of
stay e.g. 1-2 yrs. To impute the exact duration of stay, a time for each migrant within a
visa category was chosen by linear interpolation. For example, if a random uniform
variable used for this imputation lands 25% of the way between the cumulative
probabilities of categories 1-2yrs, the duration that lies 25% of the way between 2yrs
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To estimate survivor functions, Kaplan-Meier product-limit survival probabilities were
calculated using the survival rates from 2009 data for England and Wales (Figure 23).
These data were created by the Cancer Research UK Cancer Survival Group at
LSHTM, and is based upon mortality data provided by ONS.(155)
Figure 23. Survival probabilities calculated from England and Wales 2009 data, with
fitted line
To model these survival probabilities, the logit transformation of the survival
probability was created, and then modelled using linear regression as a cubic function of
exponentiated age. The logit transformation provides a fit to the observed data with a
smoother and more stable gradient. The exponential transformation of age enables a
better fit for older ages, which is where the survival changes rapidly, and is therefore
important to represent accurately. The fitted model is given in Equations 5 and 6.ln ൬ ݌1 − ݌൰ = 9.231431 − 5.106226 × eୟ୥ୣ + 2.250698 × (eୟ୥ୣ)ଶ − 0.7572033× (eୟ୥ୣ)ଷ
Equation 5. For men
ln ൬ ݌1 − ݌൰ = 11.45322 − 8.980079 × eୟ୥ୣ + 4.07654 × (eୟ୥ୣ)ଶ − 1.049887× (eୟ୥ୣ)ଷ




















As illustrated in Figure 24, this function provides a good fit to the observed data. In
order to draw from this distribution it was necessary to be able to calculate the age
corresponding to a particular fitted value of the survival probability. This was done by
solving the cubic equation created by entering a specific value for p in the two equations
above. Figure 25 shows the ages calculated from survival probabilities across the
interval 0-1, with the fitted survival probabilities generated from the model above
overlaid.
Figure 24. Ages calculated from survival probabilities, with fitted line from
Age at of death for someone entering the cohort at age 0 was imputed by:
(i) Drawing a random value from the standard uniform distribution, U~[0,1].
(ii) Setting the predicted age of death to be the age that corresponds to the survival
probability U.
Age at death for someone who is already aged x years, death was imputed by:
(i) Drawing a random value from the standard uniform distribution, U~[0,1].
(ii) Calculated the survival probability for age x, Sx
(iii) Set the predicted age at death to be the age that corresponds to the survival
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5.3.12 Migrants to Scotland:
Personal identifiable information was not available for tuberculosis notifications in
Scotland. Therefore migrants to Scotland could not be identified as incident cases for
any of the primary or secondary outcomes. It was therefore necessary to specify that a
proportion of migrants given a medical certificate of clearance would not enter the
cohort. Using data on long-term international migration produced by ONS, it was
estimated that 7.3% of migrants entering the UK between 2006 and 2012 would be
resident in Scotland.(156) Therefore, for each imputation, 92.7% of migrants issued
with a medical certificate of clearance were randomly selected (from a uniform
distribution) to enter the cohort. This issue is examined further in a sensitivity analysis.
5.3.13 Sensitivity analyses:
The assumptions made in this analysis were examined by several sensitivity analyses.
The rules used to de-duplicate the cohort were examined in order to assess changes in
the primary outcomes. In a sensitivity analysis, all individuals apart from those with a
positive screen were allowed to enter the cohort, but censored one month prior to any
re-screening. This analysis will provide a more conservative estimate for person time at
risk, and therefore reduce the incidence rates to a lower estimate.
Migration out of England, Wales and Northern Ireland was examined. In the first
analysis, all migrants were assumed to stay for one and a half years, providing a lower
estimate of person time at risk. In a second sensitivity analysis, all migrants were
assumed to stay until the end of the study period of 31st December 2013. This is the
more conservative assumption, and whilst it unrealistically inflates the denominator, it
provides a lower bound for the estimates of incidence.
Death was examined by assuming there were no deaths in the cohort. This is the most
conservative assumption and unrealistically inflates the denominator, but also provides
a lower bound for the estimates of incidence.
Varying the definition of how incident and prevalent cases were distinguished (i.e. the
90 day cut off between pre-entry screening and notification) was examined. For the
main analysis, it was assumed that cases notified within 90 days of pre-entry screening
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were ‘missed’ prevalent and not incident cases. The impact of varying this definition
(up to 180 days) on the outcomes was assessed.
5.3.14 Ethics approval
Ethical approval was received for this analysis from UCL research ethics committee
(3294/002; See Appendix 4 for copy of approval letter). The work was conducted with
Public Health England which has Health Research Authority approval to hold and
analyse national surveillance data for public health purposes under Section 251 of the
NHS Act 2006.
5.4 Results
Between 2006 and 2012 there were 640,808 visa applicants screened for tuberculosis
pre-entry by the IOM programme (Figure 25). Records from these migrants were
probabilistically matched to the UK Enhanced Tuberculosis Surveillance dataset for the
years 2006 to 2013, which contained 83,781 records. Missing data on linkage variables
was low and less than 2% for all variables used in both the IOM and ETS dataset (Table
19). After excluding duplicates, individuals migrating to Scotland, and missed prevalent
cases, 519,955 visa applicants entered the cohort between 2006-2012, representing
514,968 individual migrants.
A majority of migrants were aged between 16 and 44 (490,806; 94.4%) and were male
(346,839; 66.7%; Table 20). Self-report of contact with a case of tuberculosis at pre-
entry screening was rare (1,220; 0.2%) and this was the only variable within the dataset
with missing data on 2,025 records (0.4%). Student visas were the most common visa
type among the migrants in this cohort (307,127; 59.1%) and most applicants had no
abnormality on their chest radiograph at the time of pre-entry screening (489,733;
94.2%), with tuberculosis suspected in 21,862 individuals (4.2%). Just under two thirds
of migrants were screened at sites where sputa were smear and culture tested for
tuberculosis (340,020; 65.4%).
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Figure 25. Study participant flow diagram
*Numbers assumed to migrate to Scotland varied by imputation, and sum of those
excluded does not equal difference between total visa applicants and the number of
migrants included in final cohort, as groups are not mutually exclusive.
Table 19. Description of missing data for linkage variables in ETS and IOM pre-entry
screening dataset
ETS Missing data IOM Missing data
Variable N % N %
All 83781 100% 640808 100%
First name 0 0% 13078 2%
Surname 0 0% 4824 1%
Date of Birth 32 0% 910 0%
Sex 186 0% 786 0%
Nationality 1823 2% 796 0%
The total length of follow up for the cohort was 1,038,000 person years at risk with a
mean follow up of 2.0 years per person. Considering all cases of tuberculosis notified to
ETS, there were 1,863 cases identified in pre-entry screened migrants, with a crude
notified incidence rate of 194 per 100,000 person years at risk (95%CIs: 186, 203;
Table 20). The crude rates were highest in those with a self-reported history of contact
with a case of tuberculosis (662; 95%CIs: 399, 1098) and those with a chest radiograph
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classified as consistent with tuberculosis at pre-entry screening (599; 95%CIs: 528,
680). A multivariable risk factor analysis was performed to examine the evidence for
risk factors associated with all notified case of tuberculosis, with results presented as
incidence rate ratios (IRR). There was strong evidence that contact with a case of
tuberculosis (2.9; 95%CIs: 1.8, 4.9; p-value <0.001), chest radiographs classified as
suspected tuberculosis (3.4; 95%CIs: 2.9, 3.9; p-value <0.001), settlement and
dependant (1.6; 95%CIs: 1.5, 1.8; p-value <0.001) and family reunion (5.3; 95%CIs:
4.0, 7.1; p-value <0.001) visa categories were at increased risk of being notified as a
case of tuberculosis in the UK after adjusting for age and sex. There was also strong
evidence that migrants from countries with a WHO prevalence of 40-149 (0.2; 95%CIs:
0.2, 0.3; p-value <0.001), and those from countries with a prevalence between 150-349
(0.6; 95%CIs: 0.5, 0.7; p-value <0.001), migrants screened at sites where culture testing
was routinely performed (0.6; 95%CIs: 0.5, 0.6; p-value <0.001), and working holiday
visa holders (0.4; 95%CIs: 0.3, 0.7; p-value <0.001) were at lower risk after adjusting
for age and sex.
There were 622 cases of bacteriologically confirmed pulmonary tuberculosis with an
estimated incidence rate of 65 cases per 100,000 person years at risk (95%CIs: 60, 70;
Table 21). The incidence of bacteriologically confirmed pulmonary tuberculosis was
highest in those reporting a history of contact with a case of tuberculosis (398; 95%CIs:
207, 766) and lowest in those on a working holiday visa (6; 95%CIs: 2, 25). Incidence
was also high in those with a chest radiograph classified as suspected tuberculosis at
pre-entry screening, but not found to have tuberculosis at the time (249; 95%CIs: 205,
303).
After adjusting for age and sex in a multivariable analysis, there was strong evidence
that several risk factors were associated with being detected as a case of
bacteriologically confirmed pulmonary tuberculosis, including a history of contact with
a case of tuberculosis before migration (IRR 4.9; 95%CI: 2.5, 9.4; p-value <0.001) and
those with a chest radiograph classified as consistent with tuberculosis disease (IRR 4.4;
95%CI 3.5, 5.5; p-value <0.001). There was strong evidence that individuals screened
pre-entry at clinics where culture testing was performed had a lower incidence of
bacteriologically confirmed pulmonary tuberculosis post entry than those screened at
sites where this was not conducted (IRR 0.6; 95%CI 0.5, 0.7; p-value <0.001). Migrants
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on settlement and dependent, and family reunion visas had increased incidence of
bacteriologically confirmed pulmonary tuberculosis (IRR 1.4; 95%CI 1.2, 1.7; and 3.0;
95%CI 1.6, 5.3 respectively). Compared to migrants from countries with a WHO
prevalence of greater than 350 per 100,000, bacteriologically confirmed pulmonary
tuberculosis post migration was lower in those from countries with an incidence of 150-
349 (IRR 0.7; 95%CIs: 0.6, 0.9; p-value 0.01) and 40-149 (IRR 0.4; 95%CIs: 0.2, 0.7;
p-value <0.001).
There were 674 incident cases of bacteriologically confirmed extra-pulmonary
tuberculosis in migrants screened pre-entry, with an incidence rate of 70 per 100,000
person years at risk (95%CIs: 65, 76; Table 22). The rate of bacteriologically confirmed
extra-pulmonary tuberculosis was highest in migrants on a family reunion visa (201 per
100,000 person years at risk; 95%CIs: 123, 328). After adjusting for age and sex, there
was no evidence that being in contact with a case of tuberculosis pre-entry increased the
incidence of bacteriologically confirmed extra-pulmonary tuberculosis (IRR 1.9;
95%CIs: 0.6, 5.9; p-value 0.28). Migrants had a lower incidence of bacteriologically
confirmed extra-pulmonary disease if they were from countries with a WHO prevalence
of tuberculosis between 40-149 per 100,000 population (IRR 0.1; 95%CIs: 0.1, 0.3; p-
value <0.001) and 150-349 (IRR 0.6; 95%CIs 0.5, 0.8; p-value <0.001) compared to
those from a prevalence of greater than 350 per 100,000 population.
There were 619 cases of culture confirmed pulmonary tuberculosis in the cohort, with
an incidence rate of 64 per 100,000 person years at risk (95%CIs: 59, 70; Table 23), and
therefore the majority of bacteriologically confirmed cases were also culture confirmed
(619/627; 99%). As a result the multivariable analysis was also very similar to that for
bacteriologically confirmed cases (Table 21).
There were fewer cases of smear positive pulmonary tuberculosis with 228 in total. The
estimated incidence of 24 per 100,000 person years at risk (95%CIs: 21, 27; Table 24).
Higher rates were seen in those with a reported history of contact with a case of
tuberculosis at pre-entry screening (160 per 100,000 person years at risk; 95%CIs: 60,
427). After adjusting for age and sex there was strong evidence that self-reported
history of contact with a case of tuberculosis at pre-entry screening was associated with
an increased incidence of AFB positive pulmonary tuberculosis (IRR 5.7; 95%CIs 2.2,
15.3; p-value <0.001). There was also strong evidence that individuals screened pre-
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entry at clinics where culture testing had a lower incidence of AFB positive pulmonary
tuberculosis than those screened at sites where this was not conducted (IRR 0.6; 95%CI
0.4, 0.7; p-value <0.001).
There were 41 cases of pulmonary tuberculosis with resistance to at least one first-line
drug (isoniazid, rifampicin, pyrazinamide or ethambutol). There were no cases of extra-
pulmonary tuberculosis with resistance to at least one first-line drug. As a result of these
low numbers no univariable or multivariable risk factor analysis was undertaken for
these estimates.
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Table 20. Baseline characteristics, univariate and multivariate analysis of incidence rates for all ETS notified cases of tuberculosis in
migrants screened pre-entry (2006-2012) and notified in ETS (2006-2013)











All 519955 (100.0%) 1863 1038 194 (186, 203) - - -
Age
0-15 15468 (3%) 54 31 188 (144, 245) 1 (0.7, 1.3) 0.7 (0.5, 1.0) 0.02
16-44 490806 (94.4%) 1743 979 193 (184, 202) 1.0 1.0
45-64 11243 (2.2%) 50 23 238 (180, 314) 1.2 (1.0, 1.6) 1 (0.7, 1.3) 0.89
65+ 2438 (0.5%) 16 5 354 (217, 577) 2 (1.2, 3.3) 1 (0.6, 1.6) 0.92
Sex
Female 173116 (33.3%) 713 347 223 (207, 240) 1.0
Male 346839 (66.7%) 1150 691 180 (170, 191) 0.8 (0.7, 0.9) 1 (0.9, 1.1) 0.81
Contact with case TB
No 516710 (99.4%) 1841 1030 193 (184, 202) 1.0
Yes 1220 (0.2%) 15 3 662 (399, 1098) 3.4 (2.0, 5.6) 2.9 (1.8, 4.9) <0.001
Missing 2025 (0.4%) 7 5
Visa
Students 307127 (59.1%) 904 609 160 (150, 171) 1.0
Settlement and Dependents 159986 (30.8%) 790 320 267 (249, 287) 1.7 (1.5, 1.9) 1.6 (1.5, 1.8) <0.001
Work 21140 (4.1%) 75 45 183 (146, 229) 1.1 (0.9, 1.5) 1 (0.8, 1.3) 0.99
Working Holiday Maker 17526 (3.4%) 20 35 63 (40, 97) 0.4 (0.2, 0.6) 0.4 (0.3, 0.7) <0.001
Family Reunion 3989 (0.8%) 53 8 720 (550, 943) 4.5 (3.4, 5.9) 5.3 (4.0, 7.1) <0.001
Other 10187 (2.0%) 21 21 107 (69, 163) 0.7 (0.4, 1.0) 1 (0.6, 1.5) 0.88
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CXR
No abnormality 489733 (94.2%) 1605 977 178 (169, 187) 1.0
TB suspected 21862 (4.2%) 240 45 599 (528, 680) 3.4 (2.9, 3.9) 3.4 (2.9, 3.9) <0.001
Abnormality not TB 8360 (1.6%) 18 17 116 (73, 184) 0.6 (0.4, 1.0) 0.8 (0.5, 1.4) 0.48
WHO category
40-149 29143 (5.6%) 24 59 44 (30, 66) 0.2 (0.2, 0.3) 0.2 (0.2, 0.3) <0.001
150-349 75294 (14.5%) 231 151 166 (146, 189) 0.9 (0.8, 1.0) 0.6 (0.5, 0.7) <0.001
350+ 415518 (79.9%) 1608 828 210 (200, 220) 1.0 1.0
Sputum culture testing
No 179935 (34.6%) 867 353 268 (251, 286) 1.0
Yes 340020 (65.4%) 996 685 157 (147, 167) 0.6 (0.5, 0.6) 0.6 (0.5, 0.6) <0.001
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Table 21. Baseline characteristics, univariate and multivariate analysis of incidence rates for bacteriological confirmed pulmonary
tuberculosis in migrants screened pre-entry (2006-2012) and notified in ETS (2006-2013)











All 519955 (100%) 622 1038 65 (60, 70) - - -
Age
0-15 15468 (3%) 20 31 70 (45, 108) 1.1 (0.7, 1.7) 0.9 (0.5, 1.4) 0.51
16-44 490806 (94.4%) 583 979 64 (59, 70) 1.0 1.0
45-64 11243 (2.2%) 12 23 57 (32, 101) 0.9 (0.5, 1.6) 0.7 (0.4, 1.2) 0.23
65+ 2438 (0.5%) 7 5 155 (74, 325) 2.7 (1.3, 5.9) 1.4 (0.6, 3.1) 0.42
Sex
Female 173116 (33.3%) 240 347 75 (66, 85) 1.0
Male 346839 (66.7%) 382 691 60 (54, 66) 0.8 (0.7, 0.9) 0.9 (0.8, 1.1) 0.49
Contact with case TB
No 516710 (99.4%) 610 1030 64 (59, 69) 1.0
Yes 1220 (0.2%) 9 3 398 (207, 766) 6.2 (3.2, 11.9) 4.9 (2.5, 9.4) <0.001
Missing 2025 (0.4%) 3 5 60 (54, 66)
Visa
Students 307127 (59.1%) 323 609 57 (51, 64) 1.0
Settlement and Dependents 159986 (30.8%) 255 320 86 (76, 98) 1.5 (1.3, 1.8) 1.4 (1.2, 1.7) <0.001
Work 21140 (4.1%) 23 45 56 (37, 84) 1 (0.6, 1.5) 0.9 (0.6, 1.3) 0.48
Working Holiday Maker 17526 (3.4%) 2 35 6 (2, 25) 0.1 (0, 0.4) 0.1 (0, 0.5) <0.001
Family Reunion 3989 (0.8%) 12 8 163 (93, 288) 2.8 (1.6, 5.1) 3.0 (1.6, 5.3) <0.001
Other 10187 (2%) 7 21 35 (17, 74) 0.6 (0.3, 1.3) 0.8 (0.4, 1.7) 0.61
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CXR
No abnormality 489733 (94.2%) 516 977 57 (52, 62) 1.0
TB suspected 21862 (4.2%) 100 45 249 (205, 303) 4.4 (3.6, 5.5) 4.4 (3.5, 5.5) <0.001
Abnormality not TB 8360 (1.6%) 6 17 39 (17, 86) 0.7 (0.3, 1.5) 0.8 (0.4, 1.9) 0.64
WHO category
40-149 29143 (5.6%) 10 59 18 (10, 34) 0.3 (0.1, 0.5) 0.4 (0.2, 0.7) <0.001
150-349 75294 (14.5%) 86 151 62 (50, 76) 0.9 (0.7, 1.2) 0.7 (0.6, 0.9) 0.01
350+ 415518 (79.9%) 526 828 69 (63, 75) 1.0 1.0
Sputum culture testing
No 179935 (34.6%) 282 353 87 (77, 98) 1.0
Yes 340020 (65.4%) 340 685 54 (48, 60) 0.6 (0.5, 0.7) 0.6 (0.5, 0.7) <0.001
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Table 22. Baseline characteristics, univariate and multivariate analysis of incidence rates for bacteriological confirmed extra-pulmonary
tuberculosis in migrants screened pre-entry (2006-2012) and notified in ETS (2006-2013)











All 519955 (100.0%) 674 1038 70 (65, 76) - - -
Age
0-15 15468 (3.0%) 11 31 35 (19, 63) 0.5 (0.3, 1.0) 0.4 (0.2, 0.7) 0.003
16-44 490806 (94.4%) 639 979 66 (61, 71) 1.0 1.0
45-64 11243 (2.2%) 21 23 97 (64, 147) 1.4 (0.9, 2.2) 1.3 (0.8, 2.0) 0.26
65+ 2438 (0.5%) 3 5 61 (20, 190) 0.9 (0.3, 2.9) 0.6 (0.2, 1.8) 0.35
Sex
Female 173116 (33.3%) 244 347 71 (63, 81) 1.0
Male 346839 (66.7%) 430 691 63 (57, 69) 0.9 (0.8, 1.0) 1.1 (0.9, 1.3) 0.58
Contact with case TB
No 516710 (99.4%) 668 1030 65 (61, 70) 1.0
Yes 1220 (0.2%) 3 3 120 (39, 372) 1.9 (0.6, 5.9) 1.9 (0.6, 5.9) 0.28
Missing 2025 (0.4%) 3 5 60 (54, 66)
Visa
Students 307127 (59.1%) 343 609 57 (51, 63) 1.0
Settlement and Dependents 159986 (30.8%) 271 320 85 (76, 96) 1.5 (1.3, 1.8) 1.6 (1.3, 1.9) <0.001
Work 21140 (4.1%) 27 45 63 (43, 91) 1.1 (0.7, 1.6) 1 (0.6, 1.4) 0.81
Working Holiday Maker 17526 (3.4%) 11 35 32 (18, 57) 0.6 (0.3, 1.0) 0.7 (0.4, 1.3) 0.27
Family Reunion 3989 (0.8%) 16 8 201 (123, 328) 3.6 (2.2, 5.9) 4.9 (2.9, 8.3) <0.001
Other 10187 (2.0%) 6 21 33 (16, 69) 0.5 (0.2, 1.1) 0.8 (0.4, 1.8) 0.6
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CXR
No abnormality 489733 (94.2%) 615 977 63 (59, 69) 1.0
TB suspected 21862 (4.2%) 51 45 118 (90, 155) 1.9 (1.4, 2.5) 1.9 (1.4, 2.5) <0.001
Abnormality not TB 8360 (1.6%) 8 17 48 (24, 96) 0.8 (0.4, 1.5) 1.1 (0.5, 2.1) 0.86
WHO category
40-149 29143 (5.6%) 6 59 12 (6, 25) 0.1 (0.1, 0.3) 0.1 (0.1, 0.3) <0.001
150-349 75294 (14.5%) 75 151 50 (40, 62) 0.7 (0.6, 0.9) 0.6 (0.5, 0.8) <0.001
350+ 415518 (79.9%) 593 828 72 (66, 78) 1.0 1.0
Sputum culture testing
No 179935 (34.6%) 303 353 86 (77, 96) 1.0
Yes 340020 (65.4%) 371 685 55 (50, 61) 0.6 (0.5, 0.7) 0.6 (0.5, 0.7) <0.001
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Table 23. Baseline characteristics, univariate and multivariate analysis of incidence rates for culture confirmed pulmonary tuberculosis in
migrants screened pre-entry (2006-2012) and notified in ETS (2006-2013)











All 519955 (100.0%) 619 1038 64 (59, 70) - - -
Age
0-15 15468 (3.0%) 20 31 64 (41, 99) 1.0 (0.7, 1.6) 0.9 (0.5, 1.4) 0.53
16-44 490806 (94.4%) 582 979 60 (56, 66) 1.0 1.0
45-64 11243 (2.2%) 11 23 48 (27, 88) 0.8 (0.4, 1.4) 0.6 (0.4, 1.2) 0.16
65+ 2438 (0.5%) 6 5 122 (55, 272) 1.9 (0.9, 4.2) 1.1 (0.5, 2.4) 0.88
Sex
Female 173116 (33.3%) 240 347 71 (62, 80) 1.0
Male 346839 (66.7%) 379 691 56 (50, 61) 0.8 (0.7, 0.9) 0.9 (0.8, 1.1) 0.5
Contact with case TB
No 516710 (99.4%) 607 1030 60 (55, 65) 1.0
Yes 1220 (0.2%) 9 3 400 (215, 744) 6.2 (3.2, 12) 5 (2.6, 9.6) <0.001
Missing 2025 (0.4%) 3 5 60 (54, 66)
Visa
Students 307127 (59.1%) 322 609 54 (48, 60) 1.0
Settlement and Dependents 159986 (30.8%) 253 320 81 (71, 91) 1.5 (1.3, 1.8) 1.4 (1.2, 1.7) 0.001
Work 21140 (4.1%) 23 45 52 (34, 78) 1.0 (0.6, 1.5) 0.9 (0.6, 1.3) 0.52
Working Holiday Maker 17526 (3.4%) 2 35 6 (1, 23) 0.1 (0, 0.4) 0.1 (0.0, 0.5) 0.003
Family Reunion 3989 (0.8%) 12 8 151 (86, 265) 2.9 (1.6, 5.1) 3 (1.7, 5.4) <0.001
Other 10187 (2.0%) 7 21 33 (16, 69) 0.6 (0.3, 1.3) 0.8 (0.4, 1.8) 0.65
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CXR
No abnormality 489733 (94.2%) 516 977 53 (49, 58) 1.0
TB suspected 21862 (4.2%) 97 45 237 (196, 287) 4.2 (3.4, 5.3) 4.2 (3.4, 5.3) <0.001
Abnormality not TB 8360 (1.6%) 6 17 36 (16, 80) 0.7 (0.3, 1.5) 0.8 (0.4, 1.9) 0.69
WHO category
40-149 29143 (5.6%) 10 59 19 (10, 34) 0.3 (0.2, 0.6) 0.4 (0.2, 0.7) 0.001
150-349 75294 (14.5%) 88 151 60 (49, 73) 1 (0.8, 1.3) 0.7 (0.6, 0.9) 0.02
350+ 415518 (79.9%) 521 828 64 (58, 69) 1.0 1.0
Sputum culture testing
No 179935 (34.6%) 279 353 81 (72, 91) 1.0
Yes 340020 (65.4%) 340 685 50 (45, 56) 0.6 (0.5, 0.7) 0.6 (0.5, 0.7) <0.001
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Table 24. Baseline characteristics, univariate and multivariate analysis of incidence rates for smear positive pulmonary tuberculosis disease
in migrants screened pre-entry (2006-2012) and notified in ETS (2006-2013)











All 519955 (100.0%) 228 1038 24 (21, 27) - - -
Age
0-15 15468 (3.0%) 7 31 22 (11, 47) 1 (0.5, 2.2) 0.9 (0.4, 1.8) 0.72
16-44 490806 (94.4%) 215 979 22 (19, 25) 1.0 1.0
45-64 11243 (2.2%) 3 23 13 (4, 41) 0.6 (0.2, 1.9) 0.5 (0.2, 1.5) 0.21
65+ 2438 (0.5%) 3 5 41 (10, 163) 2.8 (0.6, 12.1) 1.4 (0.3, 6.5) 0.65
Sex
Female 173116 (33.3%) 94 347 27 (22, 33) 1.0
Male 346839 (66.7%) 134 691 19 (16, 23) 0.7 (0.5, 0.9) 0.8 (0.6, 1.1) 0.24
Contact with case TB
No 516710 (99.4%) 224 1030 22 (19, 25) 1.0
Yes 1220 (0.2%) 4 3 160 (60, 427) 7.5 (2.8, 20.1) 5.7 (2.2, 15.3) <0.001
Missing 2025 (0.4%) 0 5
Visa
Students 307127 (59.1%) 117 609 21 (17, 25) 1.0
Settlement and Dependents 159986 (30.8%) 97 320 32 (26, 39) 1.6 (1.2, 2.1) 1.4 (1, 1.9) 0.03
Work 21140 (4.1%) 9 45 22 (11, 42) 1.1 (0.5, 2.1) 0.9 (0.5, 1.8) 0.84
Working Holiday Maker 17526 (3.4%) 1 35 3 (0, 22) 0.2 (0.0, 1.1) 0.2 (0, 1.2) 0.07
Family Reunion 3989 (0.8%) 4 8 54 (20, 145) 2.6 (1.0, 7.1) 2.5 (0.9, 7) 0.07
Other 10187 (2.0%) 0 21 - - - <0.001
130
CXR
No abnormality 489733 (94.2%) 187 977 21 (18, 24) 1.0
TB suspected 21862 (4.2%) 39 45 95 (69, 130) 4.7 (3.3, 6.7) 4.6 (3.2, 6.6) <0.001
Abnormality not TB 8360 (1.6%) 2 17 13 (3, 52) 0.6 (0.2, 2.5) 0.8 (0.2, 3.1) 0.69
WHO category
40-149 29143 (5.6%) 3 59 6 (2, 17) 0.2 (0.1, 0.7) 0.3 (0.1, 1.1) 0.07
150-349 75294 (14.5%) 34 151 24 (17, 34) 1 (0.7, 1.4) 0.8 (0.5, 1.1) 0.17
350+ 415518 (79.9%) 191 828 25 (21, 28) 1.0 1.0
Sputum culture testing
No 179935 (34.6%) 104 353 32 (26, 38) 1.0
Yes 340020 (65.4%) 124 685 20 (16, 23) 0.6 (0.5, 0.8) 0.6 (0.4, 0.7) <0.001
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The peak in bacteriologically confirmed pulmonary and non-pulmonary tuberculosis
cases notified in ETS occurred one year after migration (Figure 26). There is a gradual
decline in cases up to the maximum of 7 years after pre-entry screening. Adding in the
prevalent cases detected by pre-entry screening (439 as described in Chapter 3) and
post-entry prevalent cases (42 cases notified within 90 days of pre-entry screening)
there is a clear decline in the number of cases notified post-migration.
Figure 27 illustrates the contribution of all ETS notified incident cases screened pre-
entry (1863) in the context of all UK born and non-UK born tuberculosis cases in the
UK. This figure demonstrates that an increasing number of migrants screened pre-entry
are notified in the more recent years, but these remain a small proportion of all cases
(578/7892; 7.3%), and of those not born in the UK (578/5529; 10.4%) in 2013.
Figure 26. Pre-entry prevalent, post-entry prevalent (cases notified 90 days post
migration) and incident bacteriologically confirmed (pulmonary and non-
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Figure 27. Tuberculosis case reports by place of birth and whether screened pre-entry or
not (all ETS notified cases of tuberculosis in migrants screened pre-entry),
2004-2013, UK.
Several assumptions were made in estimating the incidence rates presented in this
analysis. In order to examine the influence of these assumptions on the estimates and
risk factors for bacteriologically confirmed pulmonary tuberculosis, several sensitivity
analyses were carried out. Varying the assumption of prevalent cases up to 180 days
(from 90 days) post migration made very little difference to crude incidence rates and
the multivariable analyses (Figures 28 & 29). Several assumptions on when to censor
migrants in the cohort were also tested. Assuming no deaths, no migrants leaving
England, Wales and Northern Ireland until the end of study follow up (31st December
2013) and reducing the length of stay to a mean of 1.5 years for all visa categories, had
minimal effect on incidence rates of bacteriologically confirmed pulmonary tuberculosis
and the results of multivariable analyses. Increasing the number of migrants assumed to
be living in Scotland increased the incidence rates slightly, but had no discernible effect
on the multivariable analysis. Including all duplicates except those with a positive
screen pre-entry had minimal effect on the incidence estimates, but did change the
magnitude of some of the multivariable associations. Unlike the baseline analysis, when
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including these duplicates there was evidence that those under the age of 15 were at
lower risk of bacteriologically confirmed pulmonary tuberculosis (IRR 0.4; 95%CIs:
0.2, 0.7) and there was no longer evidence that those on working holiday makers were
at lower risk of bacteriologically confirmed pulmonary tuberculosis (IRR 0.7; 95%CIs:
0.4, 1.3).
Figure 28. Sensitivity analysis of estimates bacteriologically confirmed cases of
pulmonary tuberculosis incidence rates by age and sex under different model
assumptions.
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Figure 29. Sensitivity analysis of multivariable risk factor analysis for bacteriologically




The analysis presents data on 640,808 visa applications, representing 514,968 migrants
from 15 high incidence countries between 2006 and 2012 and over a million person
years of follow up. The overall incidence of all notified cases was 194 per 100,000
person years at risk. The incidence of bacteriologically confirmed pulmonary
tuberculosis was 65 per 100,000 person years at risk, which was slightly lower than the
incidence of extra-pulmonary tuberculosis at 70 per 100,000 person years. Migrants
with the highest crude incidence of bacteriologically confirmed pulmonary tuberculosis
were those with a history of contact with a case of tuberculosis prior to migration, and
those with a chest radiograph suggestive of active pulmonary disease at pre-entry
screening. These two factors not only had the highest crude incidence rates of
bacteriologically confirmed pulmonary tuberculosis, but they were also associated with
the highest incidence rate ratio in a multivariable risk factor analysis adjusting for age
and sex. Migrants screened at locations where sputum samples underwent culture
testing had a lower incidence rate ratio for bacteriologically confirmed pulmonary and
extra-pulmonary tuberculosis after migration in a multivariable risk factor analysis.
Self-reported history of contact with a case of tuberculosis was associated with an
increased risk of bacteriological confirmed tuberculosis after arrival, and therefore this
may be a useful group to target health improvement interventions at. The fact that there
was no corresponding increased risk for extra-pulmonary disease is potentially
explained by the small number of cases, but could also represent the longer time period
between exposure and disease outcome, and the potential for a recall bias in the extra-
pulmonary disease group.(157,158) Unlike the analysis in chapter 3, this study found an
increasing risk of incident tuberculosis with migration from higher prevalence countries.
This finding not only provides some additional evidence that the results of the analysis
are robust, but also suggests that risk after migration is, to some extent, determined by
historical exposures prior to migration, although it raises questions about why migrants
from these countries when screened at pre-entry do not have the highest prevalence of
active disease. This finding will be explored further in the next chapter by examining
the incidence of tuberculosis reactivation and transmission in migrants in England,
Wales and Northern Ireland, using additional strain typing data available in ETS.
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5.5.1 Strengths and weaknesses of the study
All visa applicants from 15 countries taking part in the UK pre-entry screening
programme between 2006-2012 were included in this analysis which as a result is
highly representative of migrants from these locations applying to stay for 6 months or
longer. Levels of missing data were low on matching variables and therefore
probabilistic linkage accuracy should be high and consistent with findings presented in
chapter 4. Migrants entering the cohort had between one and seven years of follow up,
with a mean of two years. The large sample size and follow up time minimize statistical
chance as an alternative explanation for the majority of findings. The primary outcomes
were based upon WHO case definitions for bacteriologically proven pulmonary and
extra-pulmonary tuberculosis, enabling international comparisons. The analysis
presented in chapter 4 of the thesis established the ability of probabilistic matching
algorithms to be used to determine outcomes in such a cohort with a high level of
accuracy. Chapter 4 also highlighted the possibility that linkages performed between
large datasets with a low match rate between them could lead to overestimates in
incidence rates when the combined dataset was used for such purposes. This was
therefore a possibility with this analysis, however, the estimate of incidence rates for all
ETS cases was 194 per 100,000 person years at risk (95%CIs: 186, 203), which is lower
that the incidence rate in non-UK born cases of Pakistani ethnicity in ETS which was
286 per 100,000 population in 2014. Whilst this does not definitely rule out the
possibility of over estimation due to a linkage bias, it provides some reassurance that the
estimates are within an appropriate range.
Whilst there was a high level of certainty that migrants receiving a visa for entry into
the UK do migrate, there is less certainty about when and whether these same
individuals leave after their visa expires. The statistical approach taken in this analysis
attempts to account for the unknown duration of stay and death rates through the use of
imputation that was based on historical visa length data and national death rates. Several
sensitivity analyses were undertaken to examine the reliability of these assumptions.
To provide conservative estimates of incidence rates, by using a maximum potential
person time at risk for the cohort, one sensitivity analysis assumed that all migrants
stayed until the end of the cohort (31st December 2013). This assumption had little
effect on both the crude incidence rates, and the risk factor analysis. Assuming no
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deaths in the cohort, again to provide a more conservative person time at compared to
the baseline imputation, and had minimal impact on crude incidence rates and the
results of a multivariable analysis. Mortality rates in migrants may be higher than
general population from which these estimates were derived, but given the fact that the
population included in this analysis was young, with the majority of individuals within
the 16-44 age range, it is unlikely to lead to a substantial bias and it is also not
surprising that assuming no deaths had little effect on the results.
The IOM pre-entry screening database was linked to ETS, which contains personal
identifiable information for all cases in England, Ireland and Wales, but not for
Scotland. It was therefore necessary to account for the fact that the probabilistic
matching would not identify tuberculosis cases in Scotland, and to reduce the
denominator used in estimating incidence rates to account for this issue. This
assumption was examined by increasing the number of migrants in the cohort assumed
to reside in Scotland. This sensitivity analysis resulted in an increase in the incidence
rates for bacteriologically confirmed pulmonary tuberculosis, but had minimal effect on
the multivariable risk factor analysis.
The baseline analysis assumed that cases of tuberculosis notified within 90 days of a
medical clearance certificate were missed prevalent cases and therefore should therefore
be excluded from the estimates of incidence. Increasing this time period to 180 days had
very little difference to incidence rates and the results of the multivariable analyses.
The assumptions used to exclude duplicates from the analysis were also examined. In
the baseline analysis, individuals were excluded according to the rules described in
Tables 15 & 16. A sensitivity analysis, which included all duplicates except for those
classified as active tuberculosis had little impact on the incidence rates, but did
influence the multivariable analysis. Under this new assumption, migrants under the age
of 15 were found to have evidence for being at lower risk of bacteriologically confirmed
pulmonary tuberculosis (there was no evidence in the base case analysis) and migrants
on working holiday visas were no longer at lower risk. These two groups were both
small categories within the analysis, and although the number of duplicates for these
two groups was similar to others (13.5% for 0-15 year olds and 9.8% for working
holiday visas) the absolute number of individuals within the analysis was smaller. The
changes with regards to de-duplication could therefore be explained by several factors
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including chance (due to the small numbers), confounding by age and sex, or bias by
created by inappropriately including the duplicates in this new analysis. Overall the
sensitivity analyses provide reassurance that the main results of this analysis were
reliable despite changes in some of the underlying assumptions.
Whilst this analysis has several strengths, some important limitations should be
considered when interpreting these results. These data are highly representative of
migrants to the UK who are intending to stay for month than six months, but they do not
cover undocumented migrants, asylum seekers or those intending to stay in the UK for
less than 6 months.(79) Asylum seekers and undocumented migrants are likely to have
the highest risk tuberculosis, particularly when compared with visa applicants in this
analysis who will be of a higher socio-economic status.(111–116,159–161) These two
groups are therefore likely to have a higher risk of tuberculosis than migrants included
in this study, but due to the small numbers, will account for a smaller proportion of the
total cases in ETS.
It has not been possible to account for visits back to the country of origin, where the risk
of being exposed to a case of tuberculosis will be increased compared with those in the
UK.(76) However, whilst these trips will increase the likelihood of exposure to a case of
infectious tuberculosis, the decrease in case numbers over time since migration (Figure
26) suggests that the impact of return visits is likely to account for only a small
proportion of all cases notified in migrants screened pre-entry.
The use of probabilistic linkage to determine outcomes in migrants screened pre-entry
introduces several potential biases in the study, including false positive and false
negative matches. False positive links will bias incidence rate ratios towards the null,
and false negatives will have no impact on incidence rate ratios, assuming there is non-
differential misclassification bias of risk factor variables.(133,142,143) Chapter 4
provides some reassurance that the number of false positive and false negative results
will be negligible, however, it is hard to provide a more robust estimate of the likely
impact of these issues using the current dataset which lacks the ability to confirm with
certainty whether matches are true or not.
Several important risk factors for tuberculosis were included within this analysis, but
there were no data on socio-economic status, clinical conditions associated with an
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increased risk of tuberculosis (such as HIV) or lifestyle and behavioural risk factors
such as smoking, problem drug and alcohol use, and a history of imprisonment, all of
which have been shown to be associated with an increased risk of tuberculosis in the
UK.(35,74,75,162–165) The limited duration of follow up prevents looking at incidence
after first few years of migration.
5.5.2 Strengths and weaknesses in relation to other studies
Several previous studies have examined the incidence of tuberculosis in migrant
populations screened pre-entry after arrival in a host country.(166–169) None of these
studies included all migrants from pre-entry screening programmes, and included only
migrants to certain geographical locations in the destination country. One study used
probabilistic matching to identify migrants in a national case notification database.(166)
Consistent with the data presented here, two studies found a reduction in incidence of
tuberculosis post-arrival in those migrants screened using a protocol that included
culture testing of sputum samples, compared to one that only used smear
testing.(166,168) One of these studies was not able to link records between the pre-entry
screening programme and notification data post arrival, and therefore the analysis was
based on a description of incidence rates in non-US born migrants in the periods before
and after the introduction of culture testing within the pre-entry screening protocol. A
second study also presented data on a small high-risk population (Hmong refugees
screened at a camp in Thailand) which will be at much higher risk of tuberculosis than
the population in this cohort analysis.(168) Therefore the results presented in this
analysis provide stronger evidence of the ability of the culture testing to reduce the
incidence of tuberculosis after migration from a large representative sample of longer-
term migrants compared to the existing literature.
One US study used probabilistic matching to identify tuberculosis cases in California-
bound Filipino migrants, and found that those migrants with an abnormal chest
radiograph when screened pre-entry had a higher incidence of tuberculosis post-
arrival.(170) This study also found that the incidence of tuberculosis decreased with
time since follow up, both results are therefore consistent with the findings presented in
this chapter. This US study had additional risk factor data on migrants, including self-
reported data on current or historical smoking and clinical risk factors such as diabetes
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and malignancy, but unfortunately did not include these within a risk factor analysis to
examine which were associated with an increased risk of tuberculosis.
5.6 Conclusion
This is the first comprehensive study to examine the incidence of tuberculosis in
migrants from high to low incidence countries, after they have been screened for active
tuberculosis as part of a visa application system. The large sample size, mix of countries
involved, and representativeness of the study for migrants intending to stay for longer
than six months mean that the study is appropriately powered and representative.
Several novel findings are presented, including for the first time true estimates of the
incidence of tuberculosis in a high-risk population that have been screened for active
pulmonary disease prior to arrival. The risk factors identified can be used to improve
existing health programmes and policy in this area. The public health implications of
this analysis, recommendations, and directions of future research are discussed in the
final chapter of the thesis.
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CHAPTER 6
Molecular epidemiology of tuberculosis cases detected in
England, Wales and Northern Ireland in migrants screened
pre-entry: A cross-sectional and cohort study.
6.1 Abstract
Background: A better understanding of the amount of tuberculosis in migrants screened
pre-entry that leads to transmission in the UK, and the burden that is due to reactivation
from infection acquired abroad, would guide screening policy and the development of
health improvement interventions in this high-risk group.
Methods: Strain typing data from ETS notifications were linked to pre-entry data. First
cases in a cluster and cases of reactivation were examined in a cross-sectional study
comparing migrants screened pre-entry with non-UK born individuals. A cohort study
was also performed in pre-entry screened migrants. Incidence rates were estimated and
a multivariable risk factor analysis conducted.
Results: In the cross-sectional analysis, after adjusting for age and sex, there was strong
evidence that having been screened pre-entry was associated with a lower odds of being
the first case in a cluster (OR 0.6; 95%CIs: 0.5, 0.8; p-value <0.001). In the cohort
analysis, there were 35 migrants who were the first case of tuberculosis in a cluster with
an estimated crude incidence rate of 6 per 100,000 person years at risk (95%CIs 4, 8).
There were 301 cases of reactivation with a crude incidence rate estimated at 38 per
100,000 person years at risk (95%CIs: 33, 43).
Conclusion: These results will inform the effective strategies to improve the health of
migrants and can be used to parameterise health economic models examining the most
cost effective strategies to reduce burden of disease in this population.
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6.2 Introduction
As chapter 3 demonstrated, pre-entry screening for tuberculosis in migrants detects
cases of active disease prior to entering the UK with a prevalence of culture confirmed
cases consistent with other published international studies. Prevalent cases detected at
pre-entry screening undergo treatment and re-screening before they are given medical
clearance for entry. Removing these prevalent cases of tuberculosis in migrants prior to
entering the UK may mean they are less likely to result in clusters of transmission than
migrants who have not been screened. Chapter 5 provides evidence that after arrival in
the UK, the incidence rate of tuberculosis among migrants screened pre-entry from high
burden countries remains higher than UK born population in England, Wales and
Northern Ireland. This higher incidence post migration compared to the UK born
population is likely to be due to several reasons, including an increased risk of latent
tuberculosis reactivation (from exposure to cases of tuberculosis before migration), or
through contact with active tuberculosis cases after arrival.
Molecular epidemiology data can be used to understand whether migrants screened pre-
entry are at lower risk of reactivation and less likely than non-UK born individuals to
transmit tuberculosis (using the proxy marker of being the first case in a cluster of
tuberculosis cases). Clustered cases indicate transmission, and first in cluster cases arise
when transmission occurs from a reactivation case followed by progression to disease in
secondary cases. Therefore, the occurrence of first in cluster cases indicates
opportunities to improve tuberculosis control, such as promoting early diagnosis
through awareness raising activities and through the provision of better access to
healthcare, reducing time at risk for exposing other individuals. Estimating the
incidence of reactivation cases is important as these cases are potentially preventable
through screening and treatment for latent infection, but currently there is poor
information on risk of progression in new migrants.
The molecular epidemiology data required for these analyses are available from the UK
tuberculosis strain typing service that was set up to reduce misdiagnoses and
transmission by improving detection of active and latent cases through improved
targeting of outbreak investigations.(171) Several molecular epidemiological techniques
have been developed in order to help better understand the transmission of tuberculosis,
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several of which are summarized in image 2, including: IS6110-RFLP (Image 2: 1);
IS6110-Based polymerase chain reaction (PCR) Fingerprinting (Image 2: 5, 6 & 7);
Spoligotyping (Image 2: 2) and Mycobacterial Interspersed Repetitive Units (MIRU)
strain typing (Image 2: 3). MIRU based on 24 loci has been used by the UK
tuberculosis strain typing service on all culture confirmed cases since 2010 (45). MIRU
strain typing is based on a PCR technique that targets specific regions on the
M.tuberculosis chromosome that contain repeated sequences of DNA. The technique
uses primers (“a strand of short nucleic acid sequences that serves as a starting point for
DNA synthesis”(3)) that are specific to regions on either side of these repeated
sequences, which are then amplified using PCR. The size of the products resulting from
this PCR amplification (yellow horizontal lines in image 2) are estimated to deduce the
number of repeats in each individual locus, which provides the basis for classifying the
strain type using this technique.(172)
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Image 2. Schematic representation of the chromosome of a hypothetical M.tuberculosis
complex isolate with marked repetitive elements as targets for different typing
methods.
Source: Jagielski T et al. Current Methods in the Molecular Typing of Mycobacterium
tuberculosis and Other Mycobacteria. BioMed Res Int. 2014 Jan 5;2014:e645802.
Reproduced with permission under creative commons.(172)
Several studies have examined the extent of tuberculosis transmission in migrants from
high incidence countries to a host population. Using data from 1995-2006, a study in the
Netherlands estimated that 38% of tuberculosis cases were a result of infection acquired
abroad, and 36% resulted from recent transmission in the Netherlands, 18% resulting
from longer term infection in the Netherlands, and 9% undetermined.(173) A study in
Barcelona using restriction fragment length polymorphism (RFLP)-IS6110 and
MIRU12 as a secondary typing method, concluded that there was evidence of
transmission occurring between Spanish-born and migrant populations (in both
directions), but that over half of the cases in migrants occurred within two years of







examined lineage-specific trends and found that phylo-geographic strain type lineage
was highly conserved in migrants up to five years after migration, indicating either
reactivation of strains acquired in the country of origin, or transmission between people
originating from the same geographical area post migration.(175) A study of molecular
epidemiology data from cases of tuberculosis reported in San Francisco between 1
January 1991 and 31 December 2003 found that the rate of clustering decreased during
this time period from 11.4 to 3.1 cases per 100,000 population.(176)
This chapter will create a dataset that links pre-entry screening data to strain typing data
in the UK case notification system to enable the investigation of whether a pre-entry
screened population is less likely to be the first case in a transmission cluster, compared
to migrants not screened, as well as the ability to examine whether they are at a lower
risk of tuberculosis reactivation as a result of screening. The chapter also estimates the
incidence of first in cluster cases of tuberculosis and the incidence of reactivation in
pre-entry screened migrants. Evidence that migrants screened pre-entry for active
tuberculosis were at lower risk of being the first case in a cluster, would support the
effectiveness of pre-entry screening. Additionally, a better understanding of the
incidence of first in cluster cases and reactivation, and the risk factors associated with
each of these outcomes, is of public health importance as it could be used to guide
screening policy and the development of health improvement interventions in this high
risk group.
6.2.1 Research questions:
The analysis presented in this chapter aims to answer the following research questions:
1. Are migrants screened pre-entry at a lower risk of being the first case in a cluster
of transmission compared to non-UK born individuals not screened pre-entry?
2. Are migrants screened pre-entry at a lower risk of reactivation of tuberculosis
compared to non-UK born individuals not screened pre-entry?
3. What is the incidence of first cases in a cluster of transmission and reactivation
tuberculosis in migrants screened pre-entry to England, Wales and Northern
Ireland?
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4. What are the risk factors for being the first case in a cluster of transmission, and
of reactivation notified in in migrants screened pre-entry to England, Wales and
Northern Ireland?
6.3 Methods
6.3.1 Study design, participants and settings
Cross-sectional study
Two different study designs were used in this analysis. The first was a classical analysis
of risk factors for clustering, which could be described as a cross-sectional analysis, and
included all Enhanced Tuberculosis Surveillance system cases notified between 1st
January 2010 and 31st December 2013. Migrants screened pre-entry between 1st January
2009 and 31st December 2012 were included in this analysis and identified through
probabilistic linkage. In this cross-sectional study, those migrants screened pre-entry
were compared to other non-UK born individuals notified in the same time period, who
were able to arrive at the UK at any time point. It should be noted that for the rest of this
chapter the comparator population of individuals not screened pre-entry will be called
non-UK born as per convention in ETS, from where they have been identified. This
population is not called migrants as they will include refugees and asylum seekers and
no details are available from where they migrated to the UK - instead data are available
as to which country they were born in. This study will be referred to as the cross-
sectional study for the remainder of this chapter.
Cohort study
The second study was a retrospective cohort of migrants screened pre-entry by IOM.
Migrants included in this cohort were screened pre-entry between 1st January 2009 and
31st December 2012. Tuberculosis outcomes were identified in the ETS between 1st
January 2010 and 31st December 2013 using the probabilistic linkage methods described
in chapter 4. This second part of the study will be referred to as the cohort analysis for
the remainder of the chapter.
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6.3.2 Strain typing
Prospective strain typing on culture confirmed cases of tuberculosis diagnosed in the
UK was undertaken from January 2010 until 31st December 2013 using 24 loci
MIRU.(177) Strain typing was carried at regional centres for Mycobacteriology with the
aim of typing over 95% of all initial M.tuberculosis isolates as part of the routine
service.(178)
6.3.3 Outcomes
For the cross-sectional study the primary outcomes were:
1. The first case of tuberculosis in a cluster.
2. Reactivation cases of tuberculosis.
Two primary outcomes were considered for the cohort study:
1. Incidence of first in cluster cases of tuberculosis.
2. Incidence of reactivation tuberculosis cases.
6.3.4 Definitions of a cluster, first case of tuberculosis in a cluster, and
reactivation
Cases of tuberculosis classified as first case of tuberculosis in a cluster or reactivation
must have been culture confirmed and have MIRU profiles with at least 22 complete
loci notified in ETS between 1st January 2010 and 31st December 2013.(179) As per the
definition used by Public Health England, a cluster was defined as: “two or more cases
with indistinguishable 24 MIRU strain types with at least one case with a complete 24
loci profile”.(136,179,180) Patients were clustered irrespective of geographical area of
residence in England, Wales and Northern Ireland. This first case in a cluster was
identified by recorded date of notification, and used the primary outcome for the cross-
sectional and cohort study.
Reactivation cases were all cases with a unique 24 MIRU strain type between 1st
January 2010 and 31st December 2013, and the first reported case in a cluster with an
indistinguishable MIRU strain type to others as this first case in a cluster was assumed




Age and sex were considered a-priori as confounding variables. Risk factor analysis for
incident disease included the following variables from ETS: BCG vaccination status; at
least one social risk factor (drug use, homelessness, alcohol misuse/ abuse, prison); time
since entry in the UK; whether a case had been screened pre-entry (identified through
probabilistic linkage as described in next section); and WHO prevalence estimates of
tuberculosis in the country of origin at the time of migration. WHO prevalence, rather
than incidence data was used to stratify countries estimates in order to remain consistent
with results presented in Chapters 2, 4 and 5.
Cohort study
Age and sex were considered a-priori as confounding variables. Risk factor analysis for
incident disease included the following variables from the IOM dataset: visa category,
contact with a case of tuberculosis, chest radiograph classification at pre-entry
screening, whether a migrant was screened at a centre with culture testing of sputum
samples, and WHO prevalence estimates of tuberculosis in the country of origin.
6.3.6 Statistical methods
Cross-sectional study
Baseline descriptive statistics were provided using simple counts and proportions. A
multivariable logistic regression model was used to identify risk factors for primary
outcomes. Final results were presented as odds ratios, 95% confidence intervals and p-
values. Missing data were examined with a descriptive analysis, and variables with
missing data levels greater than 1% were included as a separate “missing” category in
the final multivariable regression analysis.
Cohort study
Baseline descriptive statistics of the cohort were provided using simple counts and
proportions. To account for the uncertainty of death, migration to Scotland and
emigration, multiple imputation was performed. External data were used to inform the
imputation models. Ten imputed datasets were created. Individual imputed datasets
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were analysed using Poisson regression, a suitable method for modelling rare event
data, and estimates of crude and adjusted incidence rates for the primary and secondary
outcomes were calculated. A multivariable Poisson regression model was used to
identify risk factors for the primary outcomes. All results were adjusted for clustering
by individual, to take account of repeated entries by migrants into the cohort. The
results of the analyses from individual imputed datasets were then combined using
Rubin’s rules; these appropriately account for uncertainty in the imputed information.
Final results were presented as incidence rate per 100,000 person years at risk,
incidence rate ratios, 95% confidence intervals and p-values. Stata v.13 (Statacorp LP,
College Station, TX, USA) was used for all statistical analyses.
6.3.7 Data sources
The datasets for both analyses were created using two sources: 1) The IOM database of
migrants screened in their country of origin between 1st January 2009 and 31st
December 2012; and 2) Enhanced Tuberculosis Surveillance system for cases notified
between 1st January 2010 and 31st December 2013. These two datasets were
probabilistically linked using the enhanced matching system described in chapter 4
using first name, surname, date of birth, nationality and sex as identifying variables.
Cleaning and consistency checking of the final dataset was undertaken by looking at the
distribution of variables, the range of individual variables, and missing data.
6.3.8 Exclusions:
Cross-sectional study
The dataset for the cross-sectional study excluded migrants screened pre-entry that were
not notified as a case of tuberculosis, and included all other ETS cases notified during
1st January 2010 and 31st December 2013 for baseline descriptions of the data. The
analysis to determine risk factors for first in cluster cases and reactivation excluded UK
born individuals.
Cohort study
The dataset for the cohort study excluded all ETS cases that had not been screened pre-
entry. Any primary outcomes occurring within 90 days of issue of a medical certificate
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of clearance by IOM were assumed to be prevalent cases that were missed by pre-entry
screening and were not included as a primary outcome. This assumption was examined
further in a sensitivity analysis.
6.3.9 Sensitivity analyses
The assumptions made in these analyses were examined in several sensitivity analyses.
Cross-sectional study
In the primary analysis all cases in non-UK born migrants notified during 1st January
2010 and 31st December 2013 were included. Many of these individuals will have
migrated to the UK before 2005 when the first pre-entry case would have arrived. The
primary analysis included a variable for time since arrival in the analysis to control for
this issue. However, as time since infection is important factor that distinguishes
infection versus reactivation, a multivariable analysis to determine risk factors for the
primary outcomes was performed on a dataset restricted to non-UK born cases that
arrived after 2005 to make this population more comparable (in terms of time since
entry to the UK) with the pre-entry screened migrants.
Cohort study
Varying the definition of how incident and prevalent cases were distinguished (i.e. a 90
day cut off between pre-entry screening and notification) was examined. For the main
analysis, it was assumed that cases notified within 90 days of pre-entry screening were
‘missed’ prevalent and not incident cases. The impact of varying this definition to
include all ‘missed’ prevalent cases, and increasing it up to 180 days was assessed. A
sensitivity analysis was conducted to include only migrants screened under the routine
pre-entry culture testing protocol as this is likely provide a better indication of those
who were genuinely disease free at time of entry due to its increased sensitivity.
6.3.10 Cohort study specific methods:
Censoring
Migrants entered the cohort upon receiving a certificate of medical clearance for
tuberculosis after screening pre-entry by IOM. Individuals were followed up until the
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first of tuberculosis, death, or emigration. Death and migration out of the country
were imputed as described in the baseline scenario for Chapter 5.
Duplicates and migrants to Scotland
Duplicates were removed from the analysis according to the rules described in Tables
15 & 16 in chapter 5. It was also assumed that 92.7% of migrants issued with a medical
certificate would reside in Scotland, and therefore would not have primary outcomes
identified as part of the probabilistic matching process. Therefore for each imputation
92.7% of the total population screened were randomly selected not enter the cohort.
Estimating rates in the non-UK born population
Estimates of the first in cluster cases of tuberculosis and reactivation from this study
were compared to rates found in all non-UK born cases not screened pre-entry. To
undertake this analysis, estimates of population denominator for non-UK born
individuals entering the UK between 1st January 2009 and 31st December 2013 were
required. The denominator population was estimated using data on long-term migrants
(staying more than 12 months) and short term migrants (staying longer than 3
months).(181,182) The number of migrants screened pre-entry was removed from this
denominator estimate. For long-term migrants, person time at risk was assumed to be
the same as the mean estimated through imputation for migrants included in the cohort
analysis. Short-term migrants (who stay less than 12 months) were assumed to stay for
nine months.
Numerator cases for first in cluster cases of tuberculosis and reactivation were identified
from the ETS dataset, using the definitions for the primary outcomes as described
above, but excluding migrants screened pre-entry with these outcomes. Year of
migration was not known for 10.9% (2,606/23,911) of non-UK born cases in ETS. For
migrants with year of migration known, 30% migrated after 1st January 2009. It was
assumed that there were no biases in missing data for year since migration, and




Ethical approval was received for this analysis from UCL research ethics committee
(3294/002; See Appendix 4 for copy of approval letter). The work was conducted with
Public Health England which has Health Research Authority approval to hold and
analyse national surveillance data for public health purposes under Section 251 of the
NHS Act 2006.
6.4 Results
Between 1st January 2009 and 31st December 2012 there were 402,053 visa applicants
screened for tuberculosis pre-entry by the IOM programme (Figure 30). Records from
these applications were probabilistically matched to ETS for the period 1st January 2010
and 31st December 2013, which contained 33,942 records. Probabilistic linkage
identified 1,590 migrants screened pre-entry who were included in the cross-sectional
study. After excluding duplicates, individuals migrating to Scotland, and missed
prevalent cases, 318,983 visa applicants (315,631 individuals) entered the cohort
analysis.
Figure 30. Study participant flow diagram
*Numbers assumed to migrate to Scotland varied by imputation. Sum of those
excluded does not equal difference between total visa applicants and the number of
migrants included in final cohort, as groups are not mutually exclusive.
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6.4.1 Cross-sectional analysis
For ETS cases notified between 2010 and 2013, 80.7% (16,602/20,560) of all culture
confirmed cases had at least 23 loci strain typing performed, compared with 79.5%
(836/1,051) in migrants screened pre-entry (Table 25). Clustering occurred in 53.5% of
all ETS cases (8,890/16,602), with a total of 1,854 molecular clusters. There were 1,605
clusters including at least one non-UK born individual not screened pre-entry, and 247
involving at least one pre-entry screened case. For all UK notified cases, unique strain
types were found in 46.5% (7,712/16,602), 50.3% (5,575/11,090) for migrants not pre-
entry screened, and 53.8% (450/836) for pre-entry screened migrants, respectively.
Of those cases in clusters, the largest proportion of all UK notified cases were in
clusters that involved more than 10 others of the same strain type (0.20; 3,396/16,602;
Figure 31). The proportion of migrants screened pre-entry that were in clusters
involving more than 10 other individuals was 0.18 (146/836), and it was also 0.18
(1,966/5,575) for migrants not screened pre-entry. The 95% confidence intervals for
estimates of unique cases in migrants screened pre-entry, compared to non-UK born
migrants overlap, providing no statistical evidence for a difference in these two
populations.
When considering the proportion of all clusters by size, 0.46 (858/1854) of all UK
clusters involved only 2 cases with the same strain type (Figure 32). Clusters involving
two cases with at least one of these being an individual screened pre-entry, accounted
for 0.32 of all clusters (80/247), compared to 0.45 in all ETS clusters (724/1,605) that
involved at least one non-UK born individual not screened pre-entry.
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Figure 31. Proportion of all cases by unique strain or cluster size.
*Clusters with at least one non-UK born, or pre-entry screen person in the cluster
Figure 32. Proportion of clusters by size, 2010-2013.
*Clusters with at least one non-UK born, or pre-entry screen person in the cluster
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Place of birth was missing for 1,354 individuals notified as a case of tuberculosis
between 2010-2013, of which 44.7% (95%CIs: 42.0, 47.4) were culture confirmed cases
with a strain type, compared to 49.9% (95%CIs: 49.2, 50.5) in non-UK born individuals
and 46.9% (95%CIs: 45.9, 48.0) in UK born individuals. There were a total of 11,926
culture confirmed cases with a strain type in individuals not born in the UK between
2010 and 2013 (Table 26). These records were included in the cross-sectional analysis
to identify risk factors for being a case of tuberculosis reactivation in migrants.
The majority of cases were men (59.8%; 7,130/11,926) and 71.7% of cases
(8,547/11,926) were aged between 16-64 (Table 26). Over half of all non-UK born
individuals had been BCG vaccinated (51.6%; 6,156/11,926) and 44.8% (5,346/11,926)
came from countries with a WHO prevalence of greater than 350 per 100,000
population. A total of 836 (7%) of cases were identified as having been screened pre-
entry, with a median time since entry of two years compared to six years for migrants
not screened pre-entry.
There were 1,316 (11.0%) first cases in a cluster in non-UK born individuals. Those
migrating within three to five years had a higher percentage of first cases in a cluster
(11.5%; 238/2,076). Those screened pre-entry were at lowest risk of being the first case
in a cluster at 8.0% (67/836). A multivariable logistic regression was performed to
identify risk factors for being the first case in a cluster. After adjusting for age and sex,
there was strong evidence that having been screened pre-entry was associated with a
lower odds of being the first case in a cluster (OR 0.6; 95%CIs: 0.5, 0.8; p-value
<0.001). There was evidence that compared to individuals from countries with a WHO
prevalence of tuberculosis greater than 350 per 100,000 population, those from
countries with a prevalence between 150 and 349 were at reduced odds (OR 0.8;
95%CIs: 0.7, 1.0; p-value 0.03) after adjusting for age and sex. No other risk factors
were identified.
There were 6,025 (50.5%) cases of reactivation in non-UK born individuals between
2010-2013 (Table 27). The highest percentage of reactivation was found in those
migrants screened pre-entry (53.8%; 450/836) compared to 50.3% (5,575/11,090) in
those not screened. The lowest percentage of reactivation was found in non-UK born
individuals with a social risk factor (drug use, homelessness, alcohol misuse/ abuse,
prison) at 42.1% (334/794).
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A multivariable logistic regression was performed to identify risk factors for being a
case of tuberculosis reactivation in migrants and non-UK born individuals notified
between 2010-2013. After adjusting for age and sex, there was strong evidence that
having a social risk factor was associated with a lower odds of being notified as a case
of reactivation (OR 0.7; 95%CIs: 0.6, 0.9; p-value <0.001). There was no evidence that
being screened pre-entry was associated with lower odds of being a case of reactivation
compared to non-UK born individuals not screened pre-entry (OR 1.1; 95%CIs: 0.9,
1.3; p-value 0.39). Compared to individuals from countries with a WHO prevalence of
tuberculosis greater than 350 per 100,000 population, there was weak evidence that
those from countries with a prevalence between 40 and 149 were at increased odds of
reactivation (OR 1.0; 95%CIs: 1.0, 1.3; p-value 0.08) and that those from a country with
a prevalence of less than 39 were at reduced risk (OR 0.8; 95% CIs: 0.7, 0.9; p-value
0.01) after adjusting for age and sex. Migrants between the aged between 45 and 64 had
an increased risk of reactivation (OR 1.1; 95%CIs: 1.0, 1.3; p-value 0.01), as did those
over the age of 65 (OR 1.4; 95%CIs: 1.2, 1.6; p-value <0.001).
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with a strain type*
Number of cases





N N % N % N % N % N
All UK notified cases 33,942 20,560 60.6% 16,602 80.7% 7,712 46.5% 8,890 53.5% 1,854
Non-UK born not
screened 22,321 13,820 61.9% 11,090 80.2% 5,575 50.3% 5,515 49.7% 1,605
Non-UK born screened* 1,590 1,051 66.1% 836 79.5% 450 53.8% 386 46.2% 247
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Table 26. Baseline characteristics, univariable and multivariable logistic regression to
examine risk factors for first in cluster cases of tuberculosis in non-UK born













All 11926 (100%) 1316 (11.0%)
Age
0-15 125 (1.1%) 24 (19.2%) 1.9 (1.2, 2.9) 1.8 (1.2, 2.9) 0.01
16-44 8547 (71.7%) 959 (11.2%) 1.0 1.0
45-64 2101 (17.6%) 221 (10.5%) 0.9 (0.8, 1.1) 0.9 (0.8, 1.1) 0.40
65+ 1152 (9.7%) 112 (9.7%) 0.9 (0.7, 1.0) 0.9 (0.7, 1.1) 0.22
Missing 1 (0.0%) 0 (0.0%)
Sex
Female 4786 (40.1%) 520 (10.9%) 1.0
Male 7130 (59.8%) 795 (11.2%) 1.0 (0.9, 1.2) 1 (0.9, 1.2) 0.51
Missing 10 (0.1%) 1 (10.0%)
WHO prevalence
0-39 614 (5.2%) 62 (10.1%) 0.9 (0.7, 1.2) 0.8 (0.6, 1.1) 0.17
40-149 771 (6.5%) 87 (11.3%) 1.0 (0.8, 1.3) 0.9 (0.7, 1.2) 0.46
150-349 3713 (31.1%) 402 (10.8%) 1.0 (0.9, 1.1) 0.8 (0.7, 1.0) 0.03
350+ 5346 (44.8%) 590 (11.0%) 1.0 1.0
Not known 1482 (12.4%) 175 (11.8%) 1.1 (0.9, 1.3) 1.0 (0.7, 1.5) 0.93
BCG vaccinated
No 2273 (19.1%) 235 (10.3%) 1.0 1.0
Yes 6156 (51.6%) 696 (11.3%) 1.1 (0.9, 1.3) 1.1 (0.9, 1.3) 0.30
Missing 3497 (29.3%) 385 (11.0%) 1.1 (0.9, 1.3) 1.0 (0.9, 1.2) 0.59
Social risk factor
No 9189 (77.1%) 997 (10.8%) 1.0 1.0
Yes 794 (6.7%) 87 (11.0%) 1.0 (0.8, 1.3) 1.0 (0.8, 1.3) 0.98
Missing 1943 (16.3%) 232 (11.9%) 1.1 (1.0, 1.3) 1.1 (0.9, 1.3) 0.27
Time since entry to UK
0-2 3403 (28.5%) 385 (11.3%) 1.0 1.0
3-5 2076 (17.4%) 238 (11.5%) 1.0 (0.9, 1.2) 1.0 (0.8, 1.2) 0.78
6-10 2148 (18.0%) 235 (10.9%) 1.0 (0.8, 1.1) 0.9 (0.7, 1) 0.13
11+ 2937 (24.6%) 301 (10.2%) 0.9 (0.8, 1.1) 0.8 (0.7, 1) 0.07
Not known 1362 (11.4%) 157 (11.5%) 1.0 (0.8, 1.2) 0.9 (0.6, 1.3) 0.57
Screened pre-entry
No 11090 (9.03%) 1249 (11.3%) 1.0 1.0
Yes 836 (7.0%) 67 (8.0%) 0.7 (0.5, 0.9) 0.6 (0.5, 0.8) <0.001
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Table 27. Baseline characteristics, univariable and multivariable logistic regression to
examine risk factors for being a case of tuberculosis reactivation in














All 11926 (100%) 6025 (50.5%)
Age
0-15 125 (1.1%) 53 (42.4%) 0.7 (0.5, 1.0) 0.7 (0.5, 1.0) 0.08
16-44 8547 (71.7%) 4286 (50.1%) 1.0 1.0
45-64 2101 (17.6%) 1057 (50.3%) 1.0 (0.9, 1.1) 1.1 (1.0, 1.3) 0.01
65+ 1152 (9.7%) 628 (54.5%) 1.2 (1.1, 1.3) 1.4 (1.2, 1.6) <0.001
Missing 1 (0.0%) 1 (100.0%)
Sex
Female 4786 (40.1%) 2468 (51.6%) 1.0
Male 7130 (59.8%) 3550 (49.8%) 0.9 (0.9, 1.0) 0.9 (0.9, 1.0) 0.12
Missing 10 (0.1%) 7 (70.0%)
WHO prevalence
0-39 614 (5.2%) 267 (43.5%) 0.8 (0.6, 0.9) 0.8 (0.7, 0.9) 0.01
40-149 771 (6.5%) 411 (53.3%) 1.1 (1.0, 1.3) 1.1 (1.0, 1.3) 0.08
150-349 3713 (31.1%) 1915 (51.6%) 1.1 (1.0, 1.1) 1.0 (0.9, 1.1) 0.84
350+ 5346 (44.8%) 2685 (50.2%) 1.0 1.0
Not known 1482 (12.4%) 747 (50.4%) 1.0 (0.9, 1.1) 0.9 (0.7, 1.2) 0.51
BCG vaccinated
No 2273 (19.1%) 1140 (50.2%) 1.0 1.0
Yes 6156 (51.6%) 3055 (49.6%) 1.0 (0.9, 1.1) 1.0 (0.9, 1.1) 1.0
Not known 3497 (29.3%) 1830 (52.3%) 1.1 (1.0, 1.2) 1.1 (1.0, 1.2) 0.14
Social risk factor
No 9189 (77.1%) 4670 (50.8%) 1.0 1.0
Yes 794 (6.7%) 334 (42.1%) 0.7 (0.6, 0.8) 0.7 (0.6, 0.9) <0.001
Not known 1943 (16.3%) 1021 (52.5%) 1.1 (1.0, 1.2) 1.1 (1, 1.2) 0.28
Time since entry to UK
0-2 3403 (28.5%) 1803 (53.0%) 1.0 1.0
3-5 2076 (17.4%) 1075 (51.8%) 1.0 (0.9, 1.1) 1 (0.9, 1.1) 0.47
6-10 2148 (18%) 1060 (49.3%) 0.9 (0.8, 1.0) 0.9 (0.8, 1.0) 0.02
11+ 2937 (24.6%) 1391 (47.4%) 0.8 (0.7, 0.9) 0.7 (0.7, 0.8) <0.001
Not known 1362 (11.4%) 696 (51.1%) 0.9 (0.8, 1.1) 0.9 (0.7, 1.2) 0.62
Screened pre-entry
No 11090 (93.0%) 5575 (50.3%) 1.0 1.0
Yes 836 (7.0%) 450 (53.8%) 1.2 (1.0, 1.3) 1.1 (0.9, 1.3) 0.39
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6.4.2 Cohort analysis
A cohort analysis was undertaken to examine the incidence of being the first case of
tuberculosis in a cluster and reactivation of tuberculosis. The majority of migrants in
this cohort analysis were aged between 16 and 44 (301,358; 94.5%) and male (217,268;
68.1%; Table 28). Self-reported contact with a case of tuberculosis at the time of pre-
entry screening was uncommon (857; 0.3%). Most applicants had no abnormality on
their chest radiograph at the time of pre-entry screening (302,364; 94.8%), with 12,304
(3.9%) classified as tuberculosis suspected. The majority of migrants were screened in
countries with a WHO prevalence of greater than 350 per 100,000 population (267,294;
83.8%).
There was a total of 598,000 person years at risk within the cohort and a mean follow
time of 1.87 years per migrant. There were 35 migrants who were the first case of
tuberculosis in a cluster, providing an estimated crude rate of 6 per 100,000 person
years at risk (95%CIs 4, 8). The crude incidence rate for the first case of tuberculosis in
a cluster was highest in those with chest radiographs suggestive of active tuberculosis
(39; 95%CIs: 20, 74). A multivariable Poisson regression analysis was performed to
identify risk factors associated with being the first case of tuberculosis in a cluster, with
results presented as incidence rate ratios (IRR). After adjusting for age and sex, there
was strong evidence that a chest radiograph classified as consistent with tuberculosis
disease (IRR 9.6; 95%CI 4.5, 20.8; <0.001) was associated with being the first case of
tuberculosis in a cluster. No other risk factors were identified.
There were 301 cases of reactivation with a crude incidence rate estimated at 38 per
100,000 person years at risk (95%CIs: 33, 43; Table 29). The highest rate of
reactivation was found in those with a chest radiograph classified as suspected
tuberculosis at pre-entry screening at 168 per 100,000 person years at risk (95%CIs:
123, 230). Rates of reactivation increased with increasing prevalence in the country in
which screening was conducted from 8 per 100,000 person years at risk (95%CIs: 2, 34)
in countries with a prevalence of 40-149 per 100,000 population, to 57 per 100,000
person years at risk (95%CIs: 50, 64) in countries with a prevalence greater than 350
per 100,000 population.
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After adjusting for age and sex, there was evidence that compared with migrants from
countries with prevalence greater than 350 per 100,000 population, those from countries
with a prevalence of 40-149 were at lower risk of reactivation (IRR 0.2; 95%CI 0.1, 0.9;
p-value 0.03) as were those from countries with a prevalence of 150-349 (IRR 0.3;
95%CI 0.2, 0.6; p-value <0.001). There was also strong evidence that migrants with a
chest radiograph classified as suspected tuberculosis at pre-entry screening were at
increased of reactivation (3.9; 95%CI 2.8, 5.5; p-value <0.001) after adjusting for age
and sex.
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Table 28. Baseline characteristics, univariable and multivariate analysis of incidence rates for first in cluster cases of tuberculosis in
migrants screened pre-entry (2009-2012) and notified in ETS (2010-2013)










All 318983 (100%) 35 598 6 (4, 8)
Age
0-15 9542 (3.0%) 1 18 6 (1, 39) 0.9 (0.1, 6.7) 1.2 (0.2, 8.3) 0.86
16-44 301358 (94.5%) 34 565 6 (4, 8) 1.0 1.0
45-64 6466 (2.0%) 0 12 -
65+ 1617 (0.5%) 0 3 -
Sex
Female 101715 (31.9%) 6 192 3 (1, 7) 1.0
Male 217268 (68.1%) 29 406 7 (5, 10) 2.3 (0.9, 5.5) 2 (0.8, 4.7) 0.12
Contact with case TB
No 318126 (99.7%) 35 596 6 (4, 8)
Yes 857 (0.3%) 0 2 -
Visa
Students 206142 (64.6%) 25 385 6 (4, 10) 1.0
Settlement and Dependents 94118 (29.5%) 9 177 5 (3, 10) 0.8 (0.4, 1.7) 1.1 (0.5, 2.6) 0.74
Work 10578 (3.3%) 1 21 5 (1, 35) 0.7 (0.1, 5.5) 0.8 (0.1, 5.3) 0.83
Working Holiday Maker 861 (0.3%) 0 2 -
Family Reunion 2335 (0.7%) 0 4 -
Other 4949 (1.6%) 0 10 -
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CXR
No abnormality 302364 (94.8%) 26 566 5 (3, 7) 1.0
TB suspected 12304 (3.9%) 9 23 39 (20, 74) 8.4 (4.0, 18) 9.6 (4.5, 20.8) <0.001
Abnormality not TB 4315 (1.4%) 0 8 -
WHO category
40-149 12402 (3.9%) 1 24 - 0.6 (0.1, 4.7) 1.2 (0.2, 7.7) 0.88
150-349 39287 (12.3%) 1 75 1 (0, 10) 0.2 (0.0, 1.5) 0.2 (0.0, 1.7) 0.15
350+ 267294 (83.8%) 33 500 7 (5, 9) 1.0 1.0
Sputum culture testing
No 11570 (3.6%) 1 22 5 (1, 33) 1.0 1.0
Yes 307413 (96.4%) 34 576 6 (4, 8) 1.3 (0.2, 9.2) 1.1 (0.2, 7.2) 0.90
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Table 29. Baseline characteristics, univariable and multivariate analysis of incidence rates for reactivation cases of tuberculosis in migrants
screened pre-entry (2009-2012) and notified in ETS (2010-2013)










All 318983 (100%) 301 598 38 (33, 43)
Age
0-15 9542 (3.0%) 3 18 17 (5, 52) 0.3 (0.1, 1.0) 0.4 (0.1, 1.1) 0.07
16-44 301358 (94.5%) 292 565 52 (46, 58) 1.0 1.0
45-64 6466 (2.0%) 5 12 41 (17, 98) 0.8 (0.3, 1.9) 0.9 (0.4, 2.3) 0.89
65+ 1617 (0.5%) 1 3 33 (5, 232) 0.6 (0.1, 4.5) 0.4 (0.1, 3.3) 0.44
Sex
Female 101715 (31.9%) 78 192 41 (33, 51) 1.0 1.0
Male 217268 (68.1%) 223 406 55 (48, 63) 1.3 (1.0, 1.7) 1.2 (0.9, 1.6) 0.35
Contact with case TB
No 318126 (99.7%) 300 596 50 (45, 56) 1.0 1.0
Yes 857 (0.3%) 1 2 63 (9, 446) 1.2 (0.2, 8.8) 1.2 (0.2, 8.9) 0.83
Visa
Students 206142 (64.6%) 209 385 54 (47, 62) 1.0 1.0
Settlement and Dependents 94118 (29.5%) 81 177 46 (37, 57) 0.8 (0.6, 1.1) 1 (0.7, 1.3) 1.0
Work 10578 (3.3%) 6 21 29 (13, 65) 0.5 (0.2, 1.2) 0.5 (0.2, 1.2) 0.12
Working Holiday Maker 861 (0.3%) 0 2 - - - -
Family Reunion 2335 (0.7%) 5 4 114 (48, 275) 2.1 (0.9, 5.1) 4.9 (2.0, 11.9) <0.001
Other 4949 (1.6%) 0 10 - - - -
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CXR
No abnormality 302364 (94.8%) 261 566 46 (41, 52) 1.0 1.0
TB suspected 12304 (3.9%) 39 23 168 (123, 230) 3.7 (2.6, 5.2) 3.9 (2.8, 5.5) <0.001
Abnormality not TB 4315 (1.4%) 1 8 12 (2, 87) 0.3 (0.0, 1.9) 0.5 (0.1, 3.7) 0.52
WHO category
40-149 12402 (3.9%) 2 24 8 (2, 34) 0.2 (0.0, 0.6) 0.2 (0.1, 0.9) 0.03
150-349 39287 (12.3%) 16 75 21 (13, 35) 0.4 (0.2, 0.6) 0.3 (0.2, 0.6) <0.001
350+ 267294 (83.8%) 283 500 57 (50, 64) 1.0 1.0
Sputum culture testing
No 11570 (3.6%) 14 22 65 (38, 109) 1.0 1.0
Yes 307413 (96.4%) 287 576 50 (44, 56) 0.8 (0.4, 1.3) 0.7 (0.4, 1.2) 0.23
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The incidence rates for being the first in a cluster and reactivation were compared
between migrants screened pre-entry during the period 1st January 2009 and 31st
December 2012 and non-UK born individuals not screened, but entering the UK
between 1st January 2009 and 31st December 2013 (Figure 33). The incidence of being
the first case of tuberculosis in a cluster in migrants screened pre-entry was 6 per
100,000 person years at risk (95%CI 4, 8) compared to 6 per 100,000 person years at
risk (95%CI 5, 7) in non-UK born individuals not screened entering the UK during the
same period. The incidence of tuberculosis reactivation in migrants screened pre-entry
was 38 per 100,000 person years at risk (95%CI 33, 43) compared to 33 per 100,000
person years at risk (95%CI 32, 35) in non-UK born individuals not screened. As the
95% confidence intervals overlapped for both of these comparisons there was no
statistical evidence that the incidence rates were different between the two groups.
Figure 33. Rates of reactivation and first in cluster cases of tuberculosis in all notified
cases of tuberculosis in non-UK born individuals not screened and migrants
screened pre-entry, 2010-2013.
A series of sensitivity analyses were carried out to examine the effect varying the
assumptions made in the cohort analyses. Varying the definition of a prevalent case
from zero to 180 days after issuing a medical certificate of clearance (from the baseline
assumption of 90 days) had little impact on the estimates of the incidence of first in
167
cluster or reactivation (Figures 34 & 35). Incidence rates increased slightly when
reducing the prevalent case definition to zero days and when including only cases
screened using the culture confirmation protocol, but reduced when increasing the
prevalent case definition to 180 days. The 95% confidence intervals for the incidence
rates overlapped for each sensitivity analysis, providing no evidence that any of these
estimates were statistically different to the baseline scenario.
Varying these same assumptions in multivariable analyses to look at risk factors for the
primary outcomes also had very little effect on the results. There was strong evidence in
each sensitivity analysis that having a chest radiograph classified as suspected
tuberculosis was associated with an increased risk of being the first case in a cluster
(Figure 36). In the baseline analysis this was the only group associated with an
increased risk, and this remained the case in all scenarios in the sensitivity analysis, but
due to the fact that there were no first cases in a cluster for some subcategories, several
variables had null results in sensitivity analysis (e.g. work and other visa categories, and
WHO prevalence countries between 40 and 149). In the sensitivity analysis for
reactivation as the primary outcome, there remained strong evidence that coming from a
country with WHO prevalence of less than 350 per 100,000 population resulted in a
reduced risk of reactivation (Figure 37). All other results in the sensitivity analysis for
this outcome remained consistent with the baseline assumptions.
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Figure 34. Sensitivity analysis of incidence rates for first in cluster cases by age and sex
under different model assumptions.
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Figure 35. Sensitivity analysis of incidence rates for reactivation by age and sex under
different model assumptions.
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Figure 36. Sensitivity analysis of multivariable risk factor analysis of incidence rates for
first in cluster cases under different model assumptions.
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Figure 37. Sensitivity analysis of multivariable risk factor analysis of incidence rates for
reactivation under different model assumptions.
In the primary analysis all cases in non-UK born migrants notified during 1st January
2010 and 31st December 2013 were included regardless of when they arrived in the UK.
A separate sensitivity analysis of the cross-sectional study was conducted which
included all pre-entry screened cases (from 2005-2012) and non-UK born individuals
for the same time period. The full results are presented in Appendix 7, Tables 34 and
35. The number of pre-entry screened migrants in the study is reduced to 5,998, but
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there remains strong evidence that pre-entry screening is associated with a reduced odds
(0.6; 95%CIs: 0.4, 0.8; p-value <0.001) of being the first case in a cluster. There was no
longer strong evidence that coming from a country with WHO prevalence less than 350
per 100,000 was associated with a lower risk of reactivation, but the direction of effect
remained constant (Table 35).
A final sensitivity analysis was performed to examine the effect of the time window
used to determine whether cases were clustered or not (Figure 38). As the time window
increased from one year of strain typing data (2010) up to four years of strain typing
data (2010-2013) the proportion of cases clustered increased from 48.3% (95%CIs:
46.6, 50.0; 3,494 cases included) to 53.5% (95%CIs: 52.8, 54.3; 16,602 cases included).
There was no evidence that clustering increased when including four years of data
(2010-2013) compared to three years of data (2010-2012) when it was estimated that
53.1% of cases were clustered (95%CIs: 52.3, 54.0; 12,764 cases included).
Figure 38. Proportion of all cases clustered by time window.
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6.5 Discussion
This analysis examines molecular epidemiology data for ETS notified cases of
tuberculosis and found strong evidence that migrants screened pre-entry were less likely
than non-UK born individuals not screened to be the first case in a cluster of
tuberculosis. There was no evidence that migrants screened pre-entry were less likely to
be a reactivation case of tuberculosis. In a multivariable analysis conducted in a cohort
of migrants screened pre-entry, there was evidence that having a chest radiograph
classified as active tuberculosis was associated with increased risk of being both the
first case in a cluster, and for tuberculosis reactivation. Coming from a lower prevalence
country was associated with a lower risk of reactivation, but sputum culture testing was
not associated with either an increased or decreased odds of reactivation.
6.5.1 Strengths and weaknesses of the study
This study provides the first description of strain typing data in migrants that were
screened for active tuberculosis by the UK pre-entry programme. The study includes all
migrants from 15 high incidence countries intending to stay for more than six months,
and is the first time strain typing data has been analysed in migrants whilst accounting
for person time at risk. Unlike existing data on tuberculosis notifications in the UK, this
study was able to identify migrants screened pre-entry, and not just those self-reporting
that they were born outside the UK. The work builds on the previous chapter examining
the incidence of tuberculosis in pre-entry screened migrants by including strain typing
data to investigate how much of the tuberculosis in this population is due to reactivation
of disease acquired in the country of origin and how many cases may lead to chains of
local transmission.
As described in Chapter 4, the probabilistic matching used to identify primary outcomes
has a high level of accuracy, and the outcomes used in the study were clearly defined.
Whilst there is relatively high certainty that those migrants who were issued with a
medical certificate travel to the UK, there is less certainty about when they might
emigrate or die. The analysis presented in this chapter therefore builds upon the
methodology described in chapter 5 to censor migrants within the cohort to account for
duration of stay and death. The assumptions made in estimating person time at risk were
consistent under several sensitivity analyses.
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Limitations with the primary outcomes
The definition of reactivation depends upon several assumptions. Reactivation cases
were identified as those with a unique strain type and the first case in a cluster. There
are several alternative explanations for an individual having a unique strain, other than
this being due to reactivation. Firstly, the unique strain may be involved in a cluster
with another case that has not yet been reported. For example, a case currently classified
as reactivation in the dataset in ETS 2013, may in fact be re-classified as transmission in
ETS 2014 if an associated case were notified. However, the sensitivity analysis
examining the proportion of cases clustered over time in this chapter (Figure 38)
suggests that after four years of data there is a plateau in the number of cases clustered.
Therefore whilst further years of follow up will provide more data for cases clustered
(reducing the number of reactivation cases) it is likely to only have minimal effect.
Secondly, the rate of mutation of the strain types may lead to cases being classified as
reactivation, when transmission had occurred, along with a strain type mutation. Both of
these misclassification biases would therefore lead to an over-estimation in the number
of cases of reactivation.
Cross-sectional study
The study is limited by the fact that strain typing was only performed on UK notified
cases since 2010. These results therefore provide helpful estimates of what happens in
the first four years after migration, but may not be representative of time periods before
or after this. Undocumented migrants, and asylum seekers were not included in the pre-
entry screened dataset and these individuals will be at higher risk of tuberculosis
reactivation compared to those migrating on visas for longer than 6 months who are
included.(166) This selection bias is a potential alternative explanation for the finding
that pre-entry screening reduces the risk of being the first case of transmission, as the
two groups being compared may not have comparable risks.
Cohort analysis
There are several reasons why the incidence rates estimated in the cohort analysis will
differ from the true values. Firstly, the time period for identifying cases of reactivation
was short, and whilst time at risk was included in the denominator, estimates over a
longer time period will change. Secondly, as approximately 60% of cases are culture
confirmed, and only 80% of these are strain typed, numerator data for the in the
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incidence rates will be missing for approximately 50% of all cases. Assuming that cases
without missing data were representative of those not strain typed then the true
estimates would be twice those presented here, i.e. 12 per 100,000 person years at risk
for first in cluster cases of tuberculosis, and 76 per 100,000 person years at risk for
reactivation. Thirdly, due to the limitations of strain typing data (which is based on
MIRU), it is possible that cases will be assigned to a cluster when they should not be.
This could result in cases that truly are reactivation being misclassified in a cluster and
if they are not deemed “first in cluster” then they are assumed not to be reactivation
cases. Finally, the person years at risk used to calculate both incidence rates is an
overestimate of the true value as it includes migrants from 2009, when no outcome data
were available. The decision to include these cases was taken, because as Figure 26 in
chapter 5 shows, the greatest number of cases occurs one year after migration. This
means that someone migrating on 1st January 2009 will contribute 12 months of person
time at risk when it would not be possible to find any associated primary outcomes for
them. However, it does mean that a migrant entering the UK on 1st June 2009 with a
case notification between 1st June 2010 and 31st December 2010 would be found – six
months of which is the time period when the analysis in Chapter 5 shows a large
number of cases do occur. Excluding all cases from 2009 would therefore miss such
cases.
Several important risk factors for first in cluster and reactivation were not included in
the cohort analysis as they are not recorded by IOM, including socio-economic status,
clinical conditions associated with an increased risk of tuberculosis reactivation (such as
HIV and immunosuppression with biological drugs) and lifestyle risk factors such as
smoking. These factors have been shown to be associated with an increased risk of
reactivation of tuberculosis both in the UK and internationally and these unmeasured
risk factors may be stronger risk factors for reactivation than those included in this
analysis.(74,162,183,184)
Comparing incidence estimates for first in cluster and reactivation between those not
born in the UK with those pre-entry screened (both groups migrating between 2009 and
2012), found no evidence that rates of in pre-entry screened migrants are lower than the
rest of the non-UK born cases (Figure 33). These data should be interpreted in the
context of the limitations discussed above for the primary outcomes, but also
considering several limitations for the population denominator estimates used for non-
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UK born individuals. For the national estimates of non-UK born populations it was
assumed that non-UK born individuals stayed in the UK for the same length of as those
screened pre-entry. This may be an over-simplification given the greater range of
countries that non-UK born individuals in the comparison group, and could bias the
estimates of incidence in either direction. The comparison of rates have an additional
limitation as the denominator for the non-UK born population had to include short term
migrants planning to stay less than 6 months as it was not possible to identify and
exclude these in ETS, but the pre-entry screened population did not contain a
comparable group of short term migrants. Given the heterogeneity of short-term visa
applicants it is very difficult to state whether this is under or overestimate the person
time at risk, but it is likely to be somewhat different to that used in this analysis. The
cross-sectional analysis provides some support for the assumptions made, as consistent
with the cohort analysis, it also found no evidence for pre-entry screening on the risk of
reactivation, but nonetheless it seems appropriate to interpret these results with some
caution. For these reasons, it is felt that results from the cross-sectional analysis provide
a stronger basis on which to understand whether migrants screened pre-entry were at a
lower risk of tuberculosis after arrival in the UK.
6.5.2 Strengths and weaknesses in relation to other studies
A key strength of this study, in comparison to the existing analyses of strain typing data
in the UK, is that it attempts to estimate the incidence of the first case of tuberculosis in
a cluster and reactivation, in addition to the proportion of cases clusters in non-UK born
individuals. The proportion of cases clustered does not account for person time at risk
for each population, which may be very different for the UK and non-UK born groups.
Incidence rates also provide measure of disease frequency rather than just a measure of
first case in a cluster and reactivation among all strain typed cases.(136)
Studies conducted in the US have estimated incidence rates of reactivation in migrants
screened pre-entry in 2008 to be 98 per 100,000 person years at risk (95%CIs: 96, 100),
which is higher than the estimated incidence in this study.(169) Direct comparisons
between these studies are difficult for several reasons. Overall in the US, 80.1% of cases
were due to reactivation (including US and non-US born), compared to 46.5% in the
UK, representing a significantly different epidemiological situation in the whole
population. In 2008 just under 80% of US notified cases were culture confirmed, and
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80% of these were strain typed, therefore the coverage of strain typing for all notified
cases was significantly higher than in the UK. The US study may over-estimate the
number of cases of reactivation as it attempts to take account of epidemiological links
between identical strains, and only classifying cases into a cluster if they were resident
within the same local geographical area. This analytical strategy will serve to increase
the number of cases classified as reactivation compared to those presented in this
chapter where geographical location was not included in this analysis. Therefore, unlike
this US study, and others examining reactivation and transmission in migrants, this
study presents data for all cases in England, Wales and Northern Ireland over a four
year period of time.(170,173,185) Conversely, compared to whole genome sequencing,
24 loci MIRU misclassifies cases as clustered due to the lack of resolution, particularly
compared to whole genome sequencing which if it had been used universally, the
number of cases of reactivation may have been higher, and more consistent with US
estimates.(186–189)
6.6 Conclusion
This analysis examines strain typing data for ETS notified cases of tuberculosis in
migrants screened pre-entry, estimating for the first time the incidence of first in cluster
cases and reactivation, and the risk factors associated with these incident cases. It
provides some evidence that pre-entry screening may reduce the chance of being a first
in cluster case of tuberculosis, compared to non-UK born individuals that have not been
screened, suggesting that pre-entry screening may have a role in reducing tuberculosis
transmission in the UK. These results are crucial to be able to inform the most effective
ways of improving the health of this population and can be used with health economic
models to determine cost effective strategies aimed at reducing the burden of disease in
this group through the use of latent tuberculosis screening. The full public health
implications of this analysis, recommendations, and directions of future research are
discussed in the final chapter of the thesis.
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CHAPTER 7
Summary of research and main findings, recommendations
for evidence-based migrant tuberculosis screening, and final
conclusions
7.1 Summary of research and main findings
The global epidemiology of tuberculosis in high-income countries is changing with a
higher proportion of cases occurring in individuals born outside their country of
residence.(32,40) Screening new migrants for tuberculosis has therefore become a high
public health priority, and there has been a renewed interest in the approaches that can
be taken to tackle the burden of disease in this vulnerable group.(55,61,73,77)
Historically the UK used a combination of upon- and post-entry screening of migrants,
but the upon-entry system was not cost-effective.(59) A decision was therefore taken to
discontinue the upon-entry programme and fully roll out a pre-entry screening system to
all countries with a prevalence of tuberculosis greater than 40 per 100,000
population.(59,190) The pre-entry screening programme was operating in 101 countries
as of 31st March 2014.
This PhD aimed to inform the development of evidence-based migrant screening for
tuberculosis by examining the epidemiology of tuberculosis in migrants. Table 30
summarises the findings from chapters 2, 3, 5 and 6 of this thesis in relation to
improving our understanding of the epidemiology of tuberculosis in migrants.
Despite the long history of migrant screening for tuberculosis, pre-entry screening is
comparatively new and also had a relatively weak evidence-base compared to upon- and
post-entry screening of migrants.(55,128) The first part of this thesis set out to
systematically review published literature on this topic and describe the data from the
15 countries taking part in the pilot UK pre-entry screening programme. The systematic
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review presented in chapter 2 identified 15 unique studies with data on nearly 4 million
migrants that had been screened for tuberculosis. Restricting a meta-analysis to include
only studies that used culture confirmation of cases found that the prevalence of
tuberculosis detected by pre-entry screening increased with WHO prevalence of
tuberculosis in the country of origin.
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The systematic review and meta-analysis was the first study to identify and synthesis all
published pre-entry screening data and established the state of the existing literature on
this topic. To reduce bias in the review process, empirically based systematic review
and meta-analysis guidelines were used, and double screening of identified papers was
performed. There was a great deal of variation in the protocols being used to screen
migrants and this was likely to be part of the explanation for the high levels of
heterogeneity found in the prevalence of tuberculosis reported by each screening
programme. A further limitation of the study was the fact that data were not entirely
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representative of global migrant flows and therefore may not be generalizable to all pre-
entry screening programmes, particularly new ones set up for countries without
previously published data.
No data had been previously published using the 15 countries taking part in the pilot
UK pre-entry programme and chapter 3 set out to examine these data. The crude
prevalence of bacteriologically confirmed (culture or smear positive) tuberculosis was
92 per 100,000 population screened. Compared to studies identified by the systematic
review in chapter 2, this prevalence was the second lowest, but this finding is likely to
be explained by differences in the populations screened, the screening protocols used,
and rates of sputum culture testing (rather than smear microscopy) for suspected cases
of tuberculosis. A multivariable regression model was built to determine risk factors for
being identified with bacteriologically confirmed tuberculosis at pre-entry screening.
After adjusting for age and sex, migrants reporting a history of contact with a case of
tuberculosis, and those from higher prevalence countries were at increased risk.
This study was the first comprehensive analysis of UK data on pre-entry screening of
migrants. The results were highly representative of migrants from the 15 countries
included in the pilot programme due to the compulsory nature of the screening process.
Standardised definitions were used for the primary outcomes, and the UK technical
instructions for pre-entry screening were implemented at all sites conducting the
screening, both factors therefore reduce issues of measurement error and
misclassification bias. Despite the study being highly representative of migrants taking
part in the pilot programme, no data were included on refugees or asylum seekers,
which are likely to be at higher risk tuberculosis. The findings are therefore likely to
under estimate prevalence compared to what would be expected in these higher-risk
populations. The data used in the analysis did not include important additional risk
factors for tuberculosis such as HIV status, other medical conditions, and no
information on socio-economic status. These unmeasured confounding factors may
explain some of the differences found between estimates of prevalence across countries.
In 2013 there were 7,892 cases of tuberculosis in the UK and 5,529 of these cases were
in individuals not born in the UK. The existing tuberculosis surveillance system does
not routinely link data from pre-entry screened migrants to notified cases in the UK,
partly because of the lack of a single unique identifying variable between the two
datasets. Chapter 4 therefore set out to examine the accuracy of a probabilistic matching
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algorithm to identify individuals in the two datasets based on demographic variables
such as first name, surname, date of birth and sex, and without the use of a single
unique identifying variable. Compared to the gold standard variable of NHS number,
the Enhanced Matching System was able to identify individuals with a high sensitivity
and specificity. Accuracy remained high in an analysis linking to non-UK born
individuals without manual review and only using first name, surname, date of birth,
nationality and sex as matching variables. The results of this study therefore provided
reassurance that this system can correctly identify individuals across datasets using a
minimal number of identifying variables, and whilst manual review had improved
accuracy further, its effect was minimal. Given the potential to introduce bias through
manual review it may be appropriate to not conduct this step, particularly for large
datasets where those conducting the analysis have little or no knowledge of the
individuals being linked.
This validation analysis of probabilistic matching using the Enhanced Matching System
then formed the basis of the analysis presented in chapters 5 and 6 by linking the pre-
entry screening dataset of migrants screened in 15 countries between 2005 and 2012 to
the UK tuberculosis register. Using this linked dataset, it was possible to undertake a
cohort analysis to examine the incidence of tuberculosis in the UK among migrants
screened pre-entry and identify risk factors for these cases. The overall incidence rate
for all notified cases was 194 per 100,000 person years at risk and 65 per 100,000 for
bacteriologically confirmed pulmonary cases. After adjusting for age and sex,
individuals reporting contact with a case of tuberculosis before migration, those with a
chest radiograph classified as suspected tuberculosis, migrants on settlement and
dependant or family reunion visas, and those from higher prevalence countries were all
at a higher risk of tuberculosis after migration. Those migrants screened under a
protocol that included culture confirmation of sputum samples were at lower risk of
being a case of tuberculosis after arrival in the UK.
This cohort analysis was the first international study to comprehensively link records
from migrants screened pre-entry for tuberculosis to a national tuberculosis disease
register. It provided unique insights into the burden of disease in this group after pre-
entry screening had removed the majority of prevalent cases, and the risk factors for
these incident cases. The analysis contained many assumptions, particularly in relation
to person time at risk used in the survival analysis, but varying these assumptions in a
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series of sensitivity analyses had minimal effect on the estimates of incidence and risk
factors identified in the multivariable analyses. Similar to the analysis of prevalent cases
detected at pre-entry screening, this cohort analysis was not representative of some
higher risk groups such as asylum seekers and refugees. Data were not analysed by
country due to the fact that some countries had a low number of cases, and therefore
whilst the findings are likely to generalizable by WHO prevalence category, there still
may be some issues when comparing individual countries, particularly if the socio-
economic mix of migrants is different, or if there are large difference in unmeasured
variables such as HIV, compared to those included in this analysis.
Since 2010 the UK surveillance system has collected data on the strain type for culture
confirmed cases of tuberculosis. In chapter 6, molecular epidemiology was used to
make inferences about whether tuberculosis cases in migrants arose due to reactivation
of disease acquired abroad (assumed to be likely in cases with unique molecular strain
types and in those who were the first case in a cluster). First cases in a cluster were also
assumed more likely than others to be the originator of a local chain of transmission and
in migrants was used as a proxy for imported disease that subsequently transmitted or
imported infection that reactivated and subsequently transmitted. Chapter 6 included
these additional data into two separate analyses. A cross-sectional analysis was
conducted to examine the evidence for whether migrants screened pre-entry were at
lower risk of being the first case in a cluster of transmission or of being reactivation
case, compared to non-UK born individuals. Compared to non-UK born individuals,
migrants screened pre-entry were less likely to be the first case in a cluster of
tuberculosis. There was also evidence that those who had been in the country for
greater than five years were at lower risk of being the first in a cluster as were those
from lower prevalence countries. The cross-sectional analysis also examined risk factors
for cases of tuberculosis reactivation (i.e. those who might have benefitted from
screening for and treatment of latent infection) and found that those over the age of 45
were at higher risk. Migrants from countries with a prevalence less than 40 per 100,000
population, those with a social risk factor (problem drug or alcohol use, homelessness or
history of imprisonment), and individuals having entered the country more than 5 years
previously were at lower risk.
The final analysis was conducted in a cohort of pre-entry screened migrants alone who
entered the UK after 2009. This study examined the incidence and risk factors for being
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first case in a cluster of tuberculosis and for being a case of reactivation. The incidence
rate for first in cluster cases of tuberculosis was low at 6 per 100,000 person years at
risk, and due to small number of cases the only risk factor identified was having a chest
radiograph at pre-entry screening classified as suspected tuberculosis. The incidence
rate for reactivation cases of tuberculosis was 38 per 100,000 person years at risk.
Migrants from lower prevalence countries were at lower risk of reactivation. There was
no evidence that pre-entry screening for active tuberculosis reduced the incidence of
reactivation after migration to the UK.
This final chapter is the first international study that has comprehensively compared the
outcomes of migrants screened pre-entry to a large population that had not been
screened. The results were consistent with chapter 5 and provide unique insights into
the benefits (or not) of pre-entry screening and form the basis of several policy
recommendations. Similar to the analysis in chapter 5, the assumptions made in the
cohort analysis were largely unaffected by the various sensitivity analyses conducted,
and whilst the duration of strain typing data were limited to four years, an analysis
looking at the likely importance of this suggested that this is likely to have little effect
on the overall conclusions drawn. The incidence estimates provide a lower bound for
the true values due to the fact that only 60% of cases are culture confirmed, and only
80% of these are strain typed. Therefore the true estimates of incidence could be up
double those presented in this chapter. An important limitation with the cross-sectional
analysis is that the pre-entry screening variable may contain a potentially important
bias, as those not screened pre-entry will include refugees and asylum seekers, whereas
those screened pre-entry will not. Finally unmeasured confounding variables such as
HIV and socio-economic status could change some of the results of the risk factor
analysis in both the cross-sectional and the cohort analysis if they were available.
7.2 Recommendations for evidence-based migrant tuberculosis
screening
The findings across the chapters in this thesis can inform evidence-based
recommendations for UK technical instructions for pre-entry screening.(7) This work
has been conducted in close collaboration with the tuberculosis pre-entry screening unit
at Public Health England. These results have, and will continue, to inform their work on
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pre-entry screening and the technical instructions. Evidence-based recommendations
from the chapters in this thesis are outlined in the following sections, along with a set of
research questions that should be answered as a priority.
7.2.1 Recommendations and research questions for active tuberculosis pre-entry
screening
Pre-entry screening programmes may require the migrant to bear the bulk of costs of
testing and treatment, but they still may not be entirely cost-neutral for the receiving
country as a result of the governance and oversight required to appropriately run these
programmes.(59) The systematic review found a paucity of cost-effectiveness data on
these schemes which should be addressed as a priority as there remains uncertainty as to
the value of pre-entry screening compared to other tuberculosis control activities. There
was a great deal of heterogeneity in the results published by different screening
countries which should be investigated further to better understand the strengths and
limitations of the different screening approaches.
x Recommendation: To continue to ensure that countries conducting pre-entry
screening are able to share best practice and further understand the strengths and
limitations of the different approaches to pre-entry screening, epidemiological
data on these screening programmes should continue to be collected and
published internationally.
x Research question:What is the cost-effectiveness of pre-entry screening from a
receiving country, migrant and wider societal perspective?
Culture testing sputum samples in suspected cases of tuberculosis
The findings from this analysis provide strong support for the previous change to UK
technical instructions for the inclusion of culture testing in the screening protocol.
Those screened at sites where culture testing was performed were more likely to be
found as a prevalent case of tuberculosis, but were less likely to be notified as an
incidence case after arrival in the UK. The reduced risk of being an incident case is
likely to be a result of appropriate treatment after detection at pre-entry screening,
particularly for those cases with a low bacillary load in the sputum that would have not
been detected by sputum smear.
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Many of the individuals screened pre-entry are entering the UK to take up places in
higher education or employment as described by the high number of migrants with these
visa categories in these analyses. There is a potential concern that delays introduced by
the requirement for culture testing, which can take a minimum of six weeks in liquid
media and eight weeks in solid media, could mean that students miss the beginning of
the academic year or that employers do not have the skilled migrants they require. New
rapid tests with high sensitivity are available and could potentially reduce these delays,
but these should be tested in the operational setting of pre-entry screening and compared
to traditional culture methods.(65,66)
x Recommendation: UK technical instructions should continue to include culture
testing of sputum.
x Research question:What is the sensitivity of rapid molecular tests compared to
traditional solid culture when used in a pre-entry screening setting, and what is
the cost effectiveness of these tests?
Migrants with chest radiographs classified as suspected tuberculosis
Across all the chapters in the study, those with a positive chest radiograph had the
highest risk of tuberculosis. They were more likely to be an incident case of tuberculosis
after arrival in the UK, as well being at increased risk of being the first case in a cluster.
This important high-risk group, identified by these analyses, provides support for the
current chest radiograph classification system specified in the UK technical instructions.
It may be possible to identify categories of chest radiograph (as defined in Table 5) that
are at particularly high risk, and as these data are available in the pre-entry dataset this
analysis could be relatively easily and quickly undertaken.
x Recommendation: UK technical instructions should continue to use the
classification system for chest radiographs, although this may be improved
further with additional analysis to identify particularly high-risk groups.
x Recommendation:Migrants with suspected tuberculosis on chest radiograph,
but negative sputum smears and cultures should be assessed for latent
tuberculosis infection and offered treatment where appropriate.
x Recommendation: After migration to the UK, those migrants with suspected
tuberculosis on chest radiograph, but negative sputum smears and cultures
should be given additional health improvement advice in order to reduce their
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risk of tuberculosis, such as smoking cessation and appropriate treatment for
medical conditions that increase risk of tuberculosis.
x Recommendation: Migrants with suspected tuberculosis on chest radiograph,
but negative sputum smears and cultures should be targeted with information
that will inform them about how to seek medical help in a timely manner if they
develop tuberculosis systems, including information about how to access the
health service.
x Recommendation: Barriers to accessing health services that may result in a
delay in presentation among migrants should be carefully examined as these
could result in increased risk of transmission in those migrants with tuberculosis.
x Research question: Are any sub-categories of suspected tuberculosis on
radiological classification (as defined in the UK technical instructions)
associated with an increased risk of incident cases of tuberculosis after arrival in
the UK.
Screening in lower WHO prevalence countries
Consistently across all chapters of the thesis, including the systematic review and meta-
analysis of studies from other countries, migrants from low prevalence countries were at
the lowest risk tuberculosis. A total of 1,863 cases of tuberculosis were notified in
migrants screened pre-entry and 1% (24/1,863) of these were migrants from countries
with a prevalence of less than 150 per 100,000 population despite the fact that they
accounted for 6% (29,143/519,955) of all migrants screened. These individuals had an
incidence of tuberculosis of 44 per 100,000 person years at risk compared 210 in those
migrants from countries with a WHO prevalence greater than 350 per 100,000 person
years. The UK government invests a substantial amount of money into the quality
assurance of pre-entry screening, cost-effectiveness analyses should therefore be
undertaken to examine the cost effectiveness of screening countries with a prevalence of
less than 150 per 100,000 population.
x Research question:What is the cost-effectiveness of pre-entry screening in
countries with a prevalence of less than 150 per 100,000 population?
Visa categories and socio-economic factors among migrants
As the largest group of visa applicants, students were used as the baseline comparator in
all of the analyses presented in the thesis. In the prevalence analysis in Chapters 3, 5
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and 6, migrants on a family reunion or settlement and dependant visas were at increased
risk compared to students, and in Chapter 5 working holiday visas were at a lower risk.
Although students were at a lower risk than family reunion or settlement and dependant
visas, they accounted for a large number of the incident cases, and had a reasonably
high incidence of tuberculosis post entry. Therefore it would not seem appropriate to
consider exempting this group from screening, but health improvement interventions
could be targeted efficiently at this group through higher education institutions.
x Research question:What evidence-based interventions could be targeted at
family reunion or settlement and dependant visas and students to ensure they
receive quick and appropriate diagnosis and treatment if they develop
tuberculosis after arrival in the UK?
Enlightened self-interest approach to tuberculosis control
Emerging evidence suggests that domestic returns for investment in tuberculosis control
programmes overseas may make them cost effective, and policy-makers may wish to
consider implementation alongside pre-entry screening programmes.(191,192) Such an
“enlightened self-interest” approach to global tuberculosis control may be not only more
cost effective, but could overcome screening-induced inequalities, so that a greater
number of individuals in need benefit from treatment, not just those in a position to
leave their country of origin. This broader view would enhance global collaboration in
efforts to eliminate tuberculosis.
x Research question:What is the cost-effectiveness of an enlightened self-
interest approach to global tuberculosis control when considering migration
patterns to the UK?
7.3 Recommendations for latent tuberculosis screening and tuberculosis
control in the UK and globally
In January 2015 Public Health England published a collaborative tuberculosis strategy
for England that included ten evidence-based recommendations that are described in
Box 3.(64) Several members of the team who produced this strategy (including
Professor Ibrahim Abubakar, secondary supervisor of this PhD thesis and head of the
tuberculosis at Public Health England, and Dominik Zenner, head of the tuberculosis
screening section) have been directly involved in the analyses presented in this thesis.
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Additionally, the author of this thesis has an honorary appointment with the tuberculosis
section at Public Health England and has had access to many key decision makers for
tuberculosis screening policy. Further work will be undertaken to support or refine
recommendations in the strategy to ensure results from this thesis are translated into
evidence-based public health policy. Several findings from the thesis relate to the ten
priorities in the collaborative tuberculosis strategy for England and are outlined below
under the appropriate heading from the strategy.
Box 3. Recommendations from collaborative tuberculosis strategy for England.(64)
Ten evidence-based recommendations from collaborative tuberculosis strategy for
England:
1. Improve access to services and ensure early diagnosis
2. Provide universal access to high quality diagnostics
3. Improve treatment and care services
4. Ensure comprehensive contact tracing
5. Improve BCG vaccination uptake
6. Reduce drug-resistant TB
7. Tackle TB in under-served populations
8. Systematically implement new entrant latent TB screening
9. Strengthen surveillance and monitoring
10. Ensure an appropriate workforce to deliver TB control
7.3.1 Ensure comprehensive contact tracing
The cohort analysis examining the incidence of first in cluster cases of tuberculosis in
chapter 6 found that children under the age of 16 were at higher risk. Many studies
report that children are less likely to be infectious than adults, possibly as a result of
being less likely to have cavitary lesions, and producing smaller numbers of droplets as
a result of a weaker cough compared to adults.(193–195) It is therefore more likely that
this finding is consistent with misclassification of the first in cluster case, with an adult
family member being the source, but getting notified as a case of tuberculosis later than
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the child. This potential explanation supports a continued focus on household contact
tracing, and particularly rigorous efforts should be made for each paediatric case found.
x Recommendation: Tuberculosis services should continue to ensure robust
contact tracing mechanisms are in place particularly for incidents involving
young children.
7.3.2 Systematically implement new entrant latent tuberculosis screening
The tuberculosis strategy for England recognised that many cases of tuberculosis in
migrants to the UK were a result of reactivation and recommended latent infection
screening for new entrants from high incidence areas. The specific recommendations
relating to the roll out of new entrant latent tuberculosis screening in the strategy are
outlined in Box 4.
Box 4. Collaborative tuberculosis strategy for England – actions relating to
systematic implementation of new entrant latent tuberculosis screening.(64)
Actions in relation to latent tuberculosis screening in new entrants:
• Establish co-ordinated LTBI screening for new entrants from areas of the
world with high incidence living in England and ensure TB control board support to
implement systematic LTBI screening nationally and as a high priority intervention
in high burden areas (areas with an incidence of TB over 20 per 100,000)
• Offer LTBI screening to new entrants who were born or lived in Sub Saharan
Africa or countries with an estimated TB incidence of greater than 150 per 100,000
and who arrived in the UK within the last five years
• Ensure robust policies for LTBI screening for other high risk population
groups, where this is NICE recommended (such as in patients with
immunosuppression)
• Work with local authorities, communities and third sector organisations to
raise awareness and improve health education regarding LTBI screening
• Ensure local LTBI screening is well resourced, co-ordinated and quality
assured and as appropriate embedded in local health check procedures for other
illnesses such as hepatitis or HIV
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Several findings from Chapter 6 could inform additional recommendations for the
targeted roll out of a new systematic new entrant latent tuberculosis screening
programme. Given the evidence that those migrants who had been in the UK for more
than 5 years were at lower risk of reactivation, little or no resource should be put in to
any sort of ‘catch up’ screening programme targeted at this longer term group due to the
unlikely benefit this would have. The cross-sectional analysis in chapter 6 found that
those over the age of 45 remained at higher risk of reactivation. NICE guidelines
currently recommend limiting screening to those under the age of 35, reflecting the
increased risk hepatotoxicity from the drugs given as chemoprophylaxis to those with
latent infection. (196) The findings from this chapter therefore suggest that the risk and
benefit of screening and treatment should be re-examined, and this new information
should be provided to those identified at risk using appropriate decision making tools.
Those with an abnormal chest radiograph at pre-entry screening were at increased risk
of reactivation compared to other migrants, and therefore this group should be a high
priority for the offer of treatment for latent infection. As these individuals were negative
by sputum culture, smear or both, the high likelihood is that the chest radiograph
finding is the result of infection and then reactivation. It may therefore be appropriate to
offer these individuals treatment for infection, with or without the additional offer of a
test for latent infection. In the cohort analysis, migrants from countries with a
prevalence of less than 350 per 100,000 population were at lower risk of reactivation
with an incidence rate of 21 per 100,000 person years at risk compared to those from
countries greater than 350 per 100,000 at 57 per 100,000 person years at risk. Therefore
the cost effectiveness of offering migrants from countries with a prevalence of between
150-349 per 100,000 population should be carefully examined to ensure this is an
appropriate use of time and resource.
x Research question:What are the risks and benefits of providing treatment for
latent infection in migrants to the UK over the age of 35?
x Research question:What decision making tools could be used to help patients
make an informed choice about whether to take treatment for latent infection
based on the risks and benefits outlined in this thesis?
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x Research question: Should migrants with a chest radiograph classified as
suspected tuberculosis, but negative sputum smears and cultures, be offered
treatment for latent infection without further testing?
x Research question:What is the cost effectiveness of offering latent tuberculosis
infection treatment to migrants with a chest radiograph classified as suspected
tuberculosis and negative sputum smears and cultures?
x Research question:What is the cost-effectiveness of latent tuberculosis
screening and treatment in migrants from countries with a WHO prevalence
between 149-350 per 100,000 population?
7.3.3 Strengthening surveillance and monitoring
This analysis was only possible because of the high quality surveillance data collected
by Public Health England and the pre-entry screening dataset managed by the
International Organisation for Migration. These are both excellent resources supported
by dedicated teams of public health consultants and epidemiologists. A number of
actions from the tuberculosis strategy for England aim to improve the UK surveillance
system further, and some additional specific recommendations can be made on the basis
of the strengths and limitations discussed in the previous chapters.
As the number of countries where pre-entry screening is performed increases, the power
to conduct even more detailed epidemiological analyses will improve. The study to
examine the accuracy of the probabilistic linkage algorithms was conducted in a
relatively small dataset, and through restricting the analysis to non-UK born individuals.
A possible way of increasing the size and accuracy of this analysis would be to use
passport number as a unique identifying variable, or to undertake a series of manual
reviews with follow up of individual cases to check that links were appropriately made,
or not. This would help ensure that on-going linkages remained accurate and free from
bias.
A potential alternative explanation for some of the findings in this thesis are
unmeasured confounding factors in particular these include socio-economic factors for
migrants and HIV. Efforts should therefore be made to collect these data in an
appropriately sensitive manor that met information governance and public health
legislation. Such data would not only provide additional reassurance to the findings of
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the thesis, but it would enable additional health policy and improvement
recommendations to be made accounting for these potential confounding factors.
x Recommendation: Attempts should be made to collect additional socio-
economic and clinical risk factors for migrants screened pre-entry.
x Research question: Are other study designs able to further validate the
accuracy of probabilistic matching in a large dataset that exclusively contains
migrants or non-UK born individuals?
7.4 Conclusion
This thesis has generated new knowledge that improves our understanding of the
epidemiology of tuberculosis in migrants to the UK. The thesis has established the
current state of the published literature around pre-entry screening for tuberculosis, and
undertaken the first comprehensive analysis of the pilot pre-entry screening programme
in migrants to the UK. It has developed and validated new methodologies that will
enable future research into these vulnerable groups both for tuberculosis and other
diseases. The studies presented estimate for the first time the incidence of tuberculosis
in migrants to the UK after screening for active tuberculosis disease and identified the
risk factors for several different tuberculosis outcomes. Areas for further research are
identified, and several of the findings have important public health implications.
Working closely with the tuberculosis section of Public Health England, NHS England,
and the Home Office, these evidence-based recommendations will be acted upon and
implemented in a timely manner.
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Supporting information for chapter 2: Detailed search terms
used in systematic review
1. Migrant$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
2. exp migration/
3. "Transients and Migrants"/
4. Expatriate$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
5. Refugee$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
6. exp Refugees/
7. Departee$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
8. Emigrant$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
9. exp immigrant/
10. Immigrant$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
11. "Emigrants and Immigrants"/
12. Asylum seeker$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer, device trade name, keyword]
13. exp refugee/
14. Asylum.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
15. Foreign-born.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
16. exp foreign worker/
17. exp foreign student/
18. Entrant$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
19. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
20. Pre*entry screening.mp. [mp=title, abstract, subject headings, heading word, drug trade name,
original title, device manufacturer, drug manufacturer, device trade name, keyword]
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21. Pre$entry screening.mp. [mp=title, abstract, subject headings, heading word, drug trade name,
original title, device manufacturer, drug manufacturer, device trade name, keyword]
22. Preentry screening.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer, device trade name, keyword]
23. Pre?entry screening.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer, device trade name, keyword]
24. Pre-entry screening.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer, device trade name, keyword]
25. Pre*entry.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
26. Pre$entry.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
27. Preentry.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
28. Pre*entry.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
29. Pre-entry.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
30. Pre*screening.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
31. Pre$screening.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
32. Prescreening.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
33. Pre?screening.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
34. Pre-screening.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
35. Pre*immigration.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer, device trade name, keyword]
36. pre$immigration.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer, device trade name, keyword]
37. preimmigration.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer, device trade name, keyword]
38. pre?immigration.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer, device trade name, keyword]
39. pre-immigration.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer, device trade name, keyword]
40. oversea$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
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41. Screening.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
42. exp mass screening/
43. Mass Screening.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer, device trade name, keyword]
44. Screen$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
45. 20 or 21 or 22 or 23 or 24 or 25 or 26 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38
or 39 or 40 or 41 or 42 or 43 or 44
46. exp Latent Tuberculosis/
47. exp Tuberculosis/
48. exp Mycobacterium tuberculosis/
49. Tuberculosis.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
50. Tuberculosis, Pulmonary/
51. TB.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword]
52. 46 or 47 or 48 or 49 or 50 or 51
53. 19 and 45 and 52
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APPENDIX 2
Supporting information for chapter 2: Detailed
characteristics of the studies included in review
Study Bollini(88)
Population Screened Migrants
Method of screening X-ray. If compatible with tuberculosis, sputum smear
samples were taken on three consecutive days
Principal case definition One or more positive sample by sputum smear.





Notes Case definition extrapolated from study by Keane, which
reports data from same IOM screening locations. Single







Initially a chest radiograph for active TB. If radiographic abnormalities are
detected, the affected individual is referred, usually to a chest specialist, for
further evaluation, including additional radiographic, microbiologic (e.g.,





The presence of cultures positive forMycobacterium tuberculosis or












Notes Primary aim of the study was to examine “the efficiency and cost-effectiveness
of immigrant applicant screening and of surveillance of newly arrived
immigrants were compared with investigation of close contacts active cases of
TB, and all three methods were com- pared with a policy of passive case








X-ray, clinical examination, history and TST. Three sputum specimens in those
















Notes Data on cases found were calculated from prevalence rates as raw numbers not
provided. Exact criteria for selecting patients for microbiological investigation
not specified “Suspected cases were referred for microbiological examination
of three sputum sample by both acid-fast bacilli and liquid culture for TB".
Screening was conducted for several receiving countries (USA, Canada,
Australia, New Zeland, Denmark and Norway) and exact protocol is therefore
























Notes A positive case was defined on the basis of one or more sputum smear or
culture results. Limitations with culture testing data were acknowledged by
study authors as this was not uniformly performed across all sites for all cases




Adoptees aged between 2.5 months and 12 years, with median age of 4 months.
Method of
screening
























Based on 1991 Technical Instructions for Panel Physicians: X-ray, clinical
examination, and if compatible with tuberculosis, sputum smear samples taken




The principal case definitions for this study were smear-negative and inactive
tuberculosis. Smear-negative tuberculosis was defined as: “if the chest
radiograph was suggestive of active tuberculosis and sputum smears were
negative for acid-fast bacilli on 3 consecutive days”. Inactive tuberculosis was
defined as: “if the chest radiograph was suggestive of tuberculosis that was not
clinically active (e.g., showing fibro- sis, scarring, pleural thickening,
diaphragmatic tenting, or blunting of costophrenic angles)”. For this systematic












Notes No mycobacterial cultures were obtained during the study period and data for







X-ray and physical examination. If compatible with tuberculosis, sputum


















Notes Authors report that denominator data for population screened is approximate.
Three consecutive sputum specimens were obtained in the morning; these
specimens were treated with Kinyoun carbolfuchsin stain and sent to the
laboratory at the Naval Hospital in Portsmouth, Virginia. At this laboratory
the specimens were digested with sodium hydroxide and then inoculated onto












“Participants with 1 or more AFB-positive smear results were designated as
AFB smear positive, and those with 3 AFB-negative smear results were
designated as AFB smear negative. Any participant with at least 1 M
tuberculosis–positive culture result was designated as M tuberculosis culture
positive and was therefore determined to have PTB. Participants with no M
tuberculosis–positive culture results were divided into 4 separate categories:
(1) those with 3 negative culture results were designated as being M
tuberculosis culture negative; (2) those with 3 contaminated culture results
were designated as having contaminated cultures; (3) those with 3 M avium-
intracellulare complex– positive results were designated as being M avium-
intracellulare complex culture positive; and (4) those with at least 1 but fewer
than 3 negative culture results were designated as being M tuberculosis
culture indeterminate (i.e., the 2 additional culture results were some












Notes Cases only reported for individuals over the age of 18 whereas all individuals
over the age of 15 screened by X-ray. Screening was compulsory, but









X-ray, clinical examination, history and TST. Three sputum specimens in




Active pulmonary TB (Symptomatic patient with pulmonary disease and












Notes The primary aim of this study was: “to determine the validity of CXR
screening in detecting radiological findings compatible with active PTB or







X-ray, clinical examination, history. Three sputum specimens in those with




Clinical and, or AFB sputum smear positive cases.
Country of
Origin









Notes The primary aim of this study was to present data from an outbreak of MDR
TB among US-bound Hmong Refugees and the results of enhanced screening
and treatment protocol among this population after initial detection of the
outbreak. Latent TB detected using tuberculin skin tests (TSTs) with








Migrants were screened according to 2009 technical instructions published by
CDC: X-ray, clinical examination, and if compatible with tuberculosis,
sputum smear samples taken on three consecutive days. “Following the
results of chest radiograph applicants were invited to participate in a study of
TST and QFT for which they would be provided the results, but the result of

















Notes The primary aims of this study were to: 1. Compare the sensitivity of
QuantiFERON ®-TB Gold In-Tube Assay (QFT) and TST for culture-
positive pulmonary TB. 2. Compare the age-specific and overall prevalence
of positive TST and QFT among applicants with normal and abnormal CXR.
The study also reports data on 20,100 visa applicants screened over the age of








X-ray, clinical examination and history. Three sputum specimens in those
with findings suggestive of tuberculosis
Case
definition

























Inactive tuberculosis defined by authors as: “radiograph shows evidence of
tuberculosis, it is repeated at a minimum interval of 3 months to confirm
stability of the lesion. In addition, 3 sputum cultures, incubated for 7-8





































Notes Primary focus of study was on subjective and clinical indicators of health
status, not tuberculosis screening, therefore data were extracted from







Corresponding author confirmed that the study used CDC Division of Global
Migration and Quarantine 2007 TB Screening guidance: X-ray, clinical
















Notes Primary aim of study was to provide a health profile of Iraqi refugees
therefore data were extracted from secondary analyses presented in this study.
Latent TB cases were defined as: “Positive TST C 10 mm with normal chest
X-ray, and negative smears and culture”
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APPENDIX 3
Supporting information for chapter 2: Additional Forrest
plots performed as part of the meta-analysis
Figure 39. Forrest plot of yield for principal outcome of active tuberculosis cases found
by each study (case definition varies between studies, sorted by year of
publication).
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Figure 40. Forrest plot of yield for principal outcome of active tuberculosis cases found
by each study (case definition varies between studies, sorted by year of
publication) stratified by prevalence in the country of origin (Freeman-Tukey
transformed data).
223
Figure 41. Forrest plot of yield for principal outcome of active tuberculosis cases found
by each study (case definition varies between studies, sorted by year of
publication) stratified by population screened (Freeman-Tukey transformed
data).
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Figure 42. Forrest plot of yield for principal outcome of active tuberculosis cases found
by each study (case definition varies between studies, sorted by year of
publication) stratified by screening method (Freeman-Tukey transformed
data)
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Figure 43. Forrest plot of yield for principal outcome of active tuberculosis cases found
by each study (case definition varies between studies, sorted by year of
publication) stratified by receiving country (Freeman-Tukey transformed
data).
226
Figure 44. Forrest plot of yield for culture confirmed cases found by each study
(Freeman-Tukey transformed data).
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Figure 45. Forrest plot of yield for culture confirmed cases found by each study,
stratified by prevalence in the country of origin (Freeman-Tukey transformed
data).
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Figure 46. Forrest plot of yield for culture confirmed cases found by each study,
stratified by population screened (Freeman-Tukey transformed data).
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Figure 47. Forrest plot of yield for culture confirmed cases found by each study,
stratified by screening method (Freeman-Tukey transformed data).
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Figure 48. Forrest plot of yield for culture confirmed cases found by each study,
stratified by receiving country (Freeman-Tukey transformed data).
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Figure 49. Forrest plot of yield for AFB confirmed cases found by each study (Freeman-
Tukey transformed data).
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Figure 50. Forrest plot of yield for AFB confirmed cases found by each study, stratified
by prevalence in the country of origin (Freeman-Tukey transformed data).
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Figure 51. Forrest plot of yield for AFB confirmed cases found by each study, stratified
by, population screened (Freeman-Tukey transformed data).
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Figure 52. Forrest plot of yield for AFB confirmed cases found by each study, stratified
by screening method (Freeman-Tukey transformed data).
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Figure 53. Forrest plot of yield for AFB confirmed cases found by each study, stratified
by receiving country (Freeman-Tukey transformed data).
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APPENDIX 4
Supporting information for chapter 3: Consent form for
migrants undergoing screening for the UK per-entry





UCL Research Ethics Committee, c/o The Graduate School, North Cloisters, Wilkins Building
University College London Gower Street London WC1E 6BT
Tel: +44 (0)20 7679 7844 Fax: +44 (0)20 7679 7043
ethics@ucl.ac.uk
www.ucl.ac.uk/gradschool
On completion of the research you must submit a brief report (a maximum of two sides of A4) of your
findings/concluding comments to the Committee, which includes in particular issues relating to the ethical
implications of the research.
With best wishes for the research.
Yours sincerely
Professor John Foreman
Chair of the UCL Research Ethics Committee
Cc: Robert Aldridge Applicant
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APPENDIX 5
Supporting information for chapter 3: sensitivity analysis of
primary outcomes including data on all migrants screened
pre-entry
Table 31. Baseline characteristics of applicants screened for tuberculosis and










All 692232 (100.0%) 75 (69, 82) 58 (52, 63) 52 (47, 58)
Age group
0-15 25555 (3.7%) 27 (13, 57) 27 (13, 57) 8 (2, 31)
16-44 647178 (93.5%) 75 (69, 82) 57 (52, 64) 50 (45, 56)
45-64 15829 (2.3%) 107 (67, 173) 76 (43, 133) 152 (102, 226)
>65 3670 (0.5%) 300 (166, 540) 218 (109, 435) 245 (128, 471)
Sex
Female 242592 (35.0%) 94 (83, 108) 75 (64, 86) 73 (63, 85)
Male 449640 (65.0%) 65 (58, 73) 48 (42, 55) 40 (35, 47)
Family contact with infectious case of
TB
No 688296 (99.8%) 73 (67, 80) 56 (50, 62) 50 (45, 56)
Yes 1604 (0.2%) 1185 (757, 1853) 935 (565, 1548) 686 (380, 1236)
Visa Type
Student 390803 (56.5%) 70 (62, 79) 55 (48, 63) 48 (41, 55)
Settlement and
Dependent 233015 (33.7%) 87 (76, 100) 69 (59, 81) 56 (47, 67)
Work 26823 (3.9%) 78 (51, 120) 37 (20, 69) 0 (0, 0)
Working Holiday
Maker 21043 (3.0%) 52 (29, 94) 29 (13, 63) 29 (13, 63)
Family Reunion 5639 (0.8%) 124 (59, 260) 35 (9, 142) 0 (0, 0)
Other 14909 (2.2%) 40 (18, 90) 34 (14, 81) 34 (14, 81)
CXR
No abnormality 652313 (94.2%) 0 (0, 0) 0 (0, 0) 0 (0, 0)
TB suspected 28552 (4.1%) 1821 (1672, 1983) 1394 (1264, 1537) 1229 (1108, 1364)
Abnormality not
TB 11367 (1.6%) 0 (0, 0) 0 (0, 0)
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WHO prevalence of TB in country of
migration
40-149 39060 (5.6%) 15 (7, 34) 5 (1, 20) 13 (5, 31)
150-349 99114 (14.3%) 181 (156, 209) 153 (131, 180) 168 (145, 196)
350+ 554058 (80.0%) 61 (55, 67) 44 (39, 50) 34 (29, 39)
Year of
examination
2005 994 (0.1%) 0 (0, 0) 0 (0, 0) 0 (0, 0)
2006 31266 (4.5%) 0 (0, 0) 0 (0, 0) 0 (0, 0)
2007 97828 (14.1%) 52 (40, 69) 8 (4, 16) 0 (0, 0)
2008 109604 (15.8%) 67 (53, 84) 48 (37, 63) 0 (0, 0)
2009 132816 (19.2%) 83 (69, 100) 64 (52, 79) 63 (51, 78)
2010 109356 (15.8%) 68 (54, 85) 56 (43, 72) 47 (35, 61)
2011 97455 (14.1%) 87 (71, 108) 82 (66, 102) 33 (23, 46)
2012 62338 (9.0%) 106 (83, 135) 103 (80, 131) 59 (43, 82)
2013 50575 (7.3%) 93 (70, 124) 93 (70, 124) 32 (19, 52)
Country of
screening
Burkina Faso 117 (0.0%) 0 (0, 0) 0 (0, 0) 0 (0, 0)
Bangladesh 180612 (26.1%) 80 (68, 94) 61 (51, 73) 44 (36, 55)
Cambodia 741 (0.1%) 135 (19, 958) 135 (19, 958) 0 (0, 0)
Cote D'Ivoire 1531 (0.2%) 0 (0, 0) 0 (0, 0) 0 (0, 0)
Eritrea 238 (0.0%) 420 (59, 2989) 0 (0, 0) 420 (59, 2989)
Ghana 38644 (5.6%) 16 (7, 35) 5 (1, 21) 13 (5, 31)
Kenya 16868 (2.4%) 119 (77, 184) 77 (45, 133) 77 (45, 133)
Laos 229 (0.0%) 0 (0, 0) 0 (0, 0) 0 (0, 0)
Niger 82 (0.0%) 0 (0, 0) 0 (0, 0) 0 (0, 0)
Pakistan 369194 (53.3%) 49 (42, 57) 35 (29, 42) 27 (22, 33)
Sudan 7596 (1.1%) 26 (7, 105) 13 (2, 93) 0 (0, 0)
Somalia 3282 (0.5%) 274 (143, 526) 122 (46, 324) 213 (102, 447)
Togo 299 (0.0%) 0 (0, 0) 0 (0, 0) 0 (0, 0)
Tanzania 10859 (1.6%) 55 (25, 123) 46 (19, 111) 37 (14, 98)
Thailand 61940 (9.0%) 242 (206, 285) 215 (181, 255) 239 (203, 281)
Sputum culture
testing
Yes 215777 (31.2%) 92 (84, 101) 83 (75, 92) 55 (49, 62)
No 476455 (68.8%) 38 (31, 47) 0 (0, 0) 38 (31, 47)
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Table 32. Multivariable analysis examining risk factors for bacteriologically confirmed
tuberculosis




0-15 0.4 (0.2, 0.8) 0.3 (0.1, 0.6) <0.001
16-44 1.0 1.0
45-64 1.4 (0.9, 2.3) 1.2 (0.7, 1.9) 0.49
>65 4 (2.2, 7.3) 3.3 (1.8, 6.1) <0.001
Sex
Female 1.0 1.0
Male 0.7 (0.6, 0.8) 1.0 (0.9, 1.3) 0.75
Contact with case TB
No 1.0 1.0




Dependents 1.2 (1.0, 1.5) 1.3 (1.1, 1.6) 0.01
Work 1.1 (0.7, 1.7) 1.1 (0.7, 1.8) 0.60
Working Holiday
Maker 0.7 (0.4, 1.4) 1.5 (0.8, 2.8) 0.18
Family Reunion 1.8 (0.8, 3.8) 1.1 (0.5, 2.5) 0.73
Other 0.6 (0.3, 1.3) 0.8 (0.3, 1.8) 0.54
WHO category
40-149 0.1 (0.0, 0.2) 0.1 (0.0, 0.2) <0.001
150-349 1.0 1.0
350+ 0.3 (0.3, 0.4) 0.3 (0.3, 0.4) <0.001
Sputum culture testing
No 1.0 1.0
Yes 2.4 (1.9, 3.1) 2.4 (1.9, 3.0) <0.001
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Figure 54. Crude prevalence of bacteriological and culture confirmed TB diagnosed at
pre-entry screening compared to 2010 WHO country prevalence estimates.
Note: Error bars on bacteriological and culture confirmed tuberculosis estimates are
95%confidence intervals. Error bars on WHO 2010 prevalence country estimates are
highest and lowest prevalence estimate for each country between 2007 and 2013.
Confidence intervals limited to a maximum of 1,000 per 100,000 population.
245
Figure 55. Age and Sex adjusted prevalence of bacteriological and culture confirmed TB
diagnosed at pre-entry screening compared to 2010 WHO country prevalence
estimates.
Note: Error bars on bacteriological and culture confirmed tuberculosis estimates are
95%confidence intervals. Error bars on WHO 2010 prevalence country estimates are
highest and lowest prevalence estimate for each country between 2007 and 2013.
Confidence intervals limited to a maximum of 1,000 per 100,000 population.
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APPENDIX 6
Supporting information for chapter 4: additional details on
how primary outcomes were calculated.





+ve a b a+b
-ve c d c+d
Total a+c b+d a+b+c+d
Sensitivity = a/a+c
Specificity = d/b+d
Positive predictive value= a/a+b
Negative predictive value = d/(c+d)
247
APPENDIX 7
Supporting information for chapter 6: Sensitivity analysis on
cross-sectional study restricted to non-UK migrants arriving
after 2005.
Table 34. Baseline characteristics, univariable and multivariable logistic regression to
examine risk factors for first cases in a cluster of tuberculosis in non-UK born












All 5998 (100%) 623 (10.4%)
Age
0-15 85 (1.4%) 18 (21.2%) 2.3 (1.4, 3.9) 2.2 (1.3, 3.8) <0.001
16-44 5276 (88.0%) 554 (10.5%) 1.0 1.0
45-64 490 (8.2%) 38 (7.8%) 0.8 (0.5, 1.5) 0.7 (0.5, 1.0) 0.09
65+ 146 (2.4%) 13 (8.9%) 0.0 (0.0, 0.0) 0.8 (0.5, 1.5) 0.54
Missing 1 (0.0%) 0 (0.0%)
Sex
Female 2314 (38.6%) 225 (9.7%) 1.0
Male 3683 (61.4%) 398 (10.8%) 1.1 (0.9, 1.3) 1.1 (1.0, 1.4) 0.12
Missing 1 (0.0%) 0 (0.0%)
WHO prevalence
0-39 304 (5.1%) 34 (11.2%) 1.1 (0.8, 1.6) 0.9 (0.6, 1.4) 0.75
40-149 494 (8.2%) 55 (11.1%) 1.1 (0.8, 1.5) 0.9 (0.7, 1.3) 0.60
150-349 3023 (50.4%) 313 (10.4%) 1 (0.9, 1.2) 0.8 (0.7, 1) 0.05
350+ 2099 (35.0%) 212 (10.1%) 1.0 1.0
Not known 78 (1.3%) 9 (11.5%) 1.2 (0.6, 2.4) 1.0 (0.5, 2) 0.95
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BCG vaccinated
No 1102 (18.4%) 105 (9.5%) 1.0 1.0
Yes 3291 (54.9%) 357 (10.8%) 1.2 (0.9, 1.5) 1.2 (0.9, 1.5) 0.14
Missing 1605 (26.8%) 161 (10.0%) 1.1 (0.8, 1.4) 1.1 (0.8, 1.4) 0.57
Social risk factor
No 4701 (78.4%) 488 (10.4%) 1.0 1.0
Yes 357 (6.0%) 37 (10.4%) 1.0 (0.7, 1.4) 1.0 (0.7, 1.4) 0.95
Missing 940 (15.7%) 98 (10.4%) 1.0 (0.8, 1.3) 1.0 (0.8, 1.2) 0.89
Time since entry to UK
0-2 3403 (56.7%) 385 (11.3%) 1.0 1.0
3-5 2025 (33.8%) 218 (10.8%) 0.9 (0.8, 1.1) 0.9 (0.8, 1.1) 0.31
6-10 570 (9.5%) 20 (3.5%) 0.3 (0.2, 0.5) 0.3 (0.2, 0.4) <0.001
Screened pre-entry
No 5273 (87.9%) 566 (10.7%) 1.0 1.0
Yes 725 (12.1%) 57 (7.9%) 0.7 (0.5, 0.9) 0.6 (0.4, 0.8) <0.001
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Table 35. Baseline characteristics, univariable and multivariable logistic regression to
examine risk factors for being a case of tuberculosis reactivation in
reactivation in non-UK born individuals who arrived in the UK after 2005
and were notified as a case of tuberculosis between 2010-2013.







All 5998 (100%) 3158 (52.7%)
Age
0-15 85 (1.4%) 36 (42.4%) 0.7 (0.4, 1.0) 0.7 (0.4, 1.0) 0.06
16-44 5276 (88.0%) 2780 (52.7%) 1.0 1.0
45-64 490 (8.2%) 259 (52.9%) 1.0 (0.8, 1.2) 1.0 (0.8, 1.2) 0.83
65+ 146 (2.4%) 82 (56.2%) 1.2 (0.8, 1.6) 1.1 (0.8, 1.6) 0.45
Missing 1 (0.0%) 1 (100.0%)
Sex
Female 2314 (38.6%) 1246 (53.8%) 1.0
Male 3683 (61.4%) 1912 (51.9%) 0.9 (0.8, 1.0) 0.9 (0.8, 1.0) 0.14
Missing 1 (0.0%) 0 (0.0%)
WHO prevalence
0-39 304 (5.1%) 152 (50.0%) 0.9 (0.7, 1.1) 0.9 (0.7, 1.2) 0.59
40-149 494 (8.2%) 251 (50.8%) 0.9 (0.8, 1.1) 0.9 (0.8, 1.2) 0.59
150-349 3023 (50.4%) 1604 (53.1%) 1.0 (0.9, 1.1) 1.0 (0.9, 1.2) 0.63
350+ 2099 (35.0%) 1112 (53.0%) 1.0 1.0
Not known 78 (1.3%) 39 (50.0%) 0.9 (0.6, 1.4) 0.9 (0.6, 1.5) 0.75
BCG vaccinated
No 1102 (18.4%) 560 (50.8%) 1.0 1.0
Yes 3291 (54.9%) 1725 (52.4%) 1.1 (0.9, 1.2) 1.1 (0.9, 1.2) 0.36
Not known 1605 (26.8%) 873 (54.4%) 1.2 (1.0, 1.3) 1.1 (1.0, 1.3) 0.11
Social risk factor
No 4701 (78.4%) 2463 (52.4%) 1.0 1.0
Yes 357 (6%) 175 (49.0%) 0.9 (0.7, 1.1) 0.9 (0.7, 1.1) 0.36
Not known 940 (15.7%) 520 (55.3%) 1.1 (1.0, 1.3) 1.1 (1.0, 1.3) 0.15
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Time since entry to UK
0-2 3403 (56.7%) 1803 (53.0%) 1.0 1.0
3-5 2025 (33.8%) 1052 (52.0%) 1.0 (0.9, 1.1) 1.0 (0.9, 1.1) 0.52
6-10 570 (9.5%) 303 (53.2%) 1.0 (0.8, 1.2) 1.0 (0.9, 1.2) 0.75
Screened pre-entry
No 5273 (87.9%) 2763 (52.4%) 1.0 1.0
Yes 725 (12.1%) 395 (54.5%) 1.1 (0.9, 1.3) 1.1 (0.9, 1.3) 0.33
